var title_f19_2_19488="Breech extraction3";
var content_f19_2_19488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Delivery of the arms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19488=[""].join("\n");
var outline_f19_2_19488=null;
var title_f19_2_19489="Height velocity response to growth hormone - NCGS";
var content_f19_2_19489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    First-year growth response to daily treatment with growth hormone in prepubertal children with growth hormone deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 463px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Height velocity during the first year of treatment in prepubertal children with IGHD (top) or OGHD (bottom). The x-axis reflects age at the beginning of treatment. The children had not been previously treated with growth hormone, and the pretreatment height velocity is also shown (red line). Height velocity below the -1 SD curve is considered a poor response to growth hormone therapy.",
"    <div class=\"footnotes\">",
"     IGHD: idiopathic growth hormone deficiency; OGHD: organic growth hormone deficiency; HV: height velocity; SD: standard deviation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the National Cooperative Growth Study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008; 93:352. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19489=[""].join("\n");
var outline_f19_2_19489=null;
var title_f19_2_19490="Patient information: Shoulder dystocia (The Basics)";
var content_f19_2_19490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83540\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"          Vaginal delivery (childbirth)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6453\">",
"           Clavicle (collarbone)",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/0/22529\">",
"         Patient information: Maternal injuries from childbirth (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/31/31218\">",
"         Patient information: Newborn appearance (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/33/15890\">",
"         Patient information: When your baby is overdue (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/38/26209\">",
"         Patient information: Postterm pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Shoulder dystocia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/shoulder-dystocia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H281370346\">",
"      <span class=\"h1\">",
"       What is shoulder dystocia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shoulder dystocia is a condition that can happen during a vaginal delivery. In shoulder dystocia, the baby&rsquo;s shoulder gets stuck behind the mother&rsquo;s pelvic bone as the baby moves down the birth canal to the vagina (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59831 \" href=\"UTD.htm?17/40/18051\">",
"       figure 2",
"      </a>",
"      ). This causes the baby to get stuck in the birth canal.",
"     </p>",
"     <p>",
"      Shoulder dystocia is an emergency that needs to be treated quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370396\">",
"      <span class=\"h1\">",
"       Do doctors and midwives know when shoulder dystocia is going to happen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. But they do know that shoulder dystocia is more likely to happen when a baby is much bigger than normal. Women with diabetes and women who are overweight are more likely to have big babies. It&rsquo;s also more likely to happen in women who had a baby with shoulder dystocia before.",
"     </p>",
"     <p>",
"      But most times, shoulder dystocia happens for unknown reasons. Because of this, there is no good way to always prevent it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370411\">",
"      <span class=\"h1\">",
"       What are the symptoms of shoulder dystocia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shoulder dystocia causes no symptoms in the mother. During delivery, the doctor or midwife sees that the baby&rsquo;s shoulders aren&rsquo;t coming out of the vagina as expected after the baby&rsquo;s head comes out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370426\">",
"      <span class=\"h1\">",
"       How is shoulder dystocia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;As soon as your doctor or midwife sees that there is shoulder dystocia, he or she will have you stop pushing for a while. Then he or she will try different things to help deliver the baby. He or she might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Move your thighs onto your belly to make more room for the baby",
"       </li>",
"       <li>",
"        Reach into your vagina to help get the baby unstuck",
"       </li>",
"       <li>",
"        Press on your belly to push down on the baby&rsquo;s shoulders and get them unstuck",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370441\">",
"      <span class=\"h1\">",
"       What problems can happen from shoulder dystocia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Shoulder dystocia can cause problems in both the baby and the mother.",
"     </p>",
"     <p>",
"      The most common problems that can happen in a baby are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A broken collarbone (",
"        <a class=\"graphic graphic_figure graphicRef82791 \" href=\"UTD.htm?6/19/6453\">",
"         figure 3",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Nerve damage &ndash; If the baby&rsquo;s neck gets stretched too much, the nerves around the shoulder can get damaged. This can cause weakness of the arm and trouble moving the arm. Doctors sometimes use the term &ldquo;Erb&rsquo;s palsy&rdquo; for this type of injury.",
"       </li>",
"       <li>",
"        A broken arm",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The most common problem that can happen in the mother is bleeding from tears in the tissues around the vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370482\">",
"      <span class=\"h1\">",
"       What if I had a baby with shoulder dystocia before and am pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or midwife will talk with you about the chances of shoulder dystocia happening again. He or she might recommend that you have a c-section to deliver your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H281370497\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=see_link\">",
"       Patient information: When your baby is overdue (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=see_link\">",
"       Patient information: Maternal injuries from childbirth (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=see_link\">",
"       Patient information: Newborn appearance (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=see_link\">",
"       Patient information: Postterm pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/2/19490?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83540 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19490=[""].join("\n");
var outline_f19_2_19490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370346\">",
"      What is shoulder dystocia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370396\">",
"      Do doctors and midwives know when shoulder dystocia is going to happen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370411\">",
"      What are the symptoms of shoulder dystocia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370426\">",
"      How is shoulder dystocia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370441\">",
"      What problems can happen from shoulder dystocia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370482\">",
"      What if I had a baby with shoulder dystocia before and am pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281370497\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"       Vaginal delivery (childbirth)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6453\">",
"        Clavicle (collarbone)",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=related_link\">",
"      Patient information: Maternal injuries from childbirth (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=related_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/38/26209?source=related_link\">",
"      Patient information: Postterm pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/33/15890?source=related_link\">",
"      Patient information: When your baby is overdue (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19491="Pathologic skin picking";
var content_f19_2_19491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acne excori&eacute;e",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyVRth3HccAHOau2ahlB+YIx4yOc1TtP8AVhtxJUYB44NX4Scpg7Vx34+prykke7tsWFzkJGADnBI7VZjRohsUFmPPPU+vNRH92EVcjdgfNjJ+pqaFiqttJwgB64pNNFRdy1CNqZJcEEcnj8sVI29m2klXPpxxUFn5jOCyAlv4T6VdCeXMMNtQDnPrUWsXEZ1cIMlD1xjrVgtH5g2liPRf5UxWjAyAehA+bAP4U+FSnzcAn3wKl6I1Rbidz0BLhcHcOg9antY2MRyCQD1NRWjDtwD0Oe3rVrewiIVgd3YVLQ1uTRS5IVRggcYGN1RspVd7SfK2flPb1wKiSQuwkJwQMcHmoNzPMN/ToAWzn/69Cj1NCyjsZNqOTkcZ4/M1YXy4x8sjMxPzbh9z1zUMG5RtyjDPXGM//Xq2WWOIPs+uO9Q9zQYyqXJYnDfdHvQ6sZ4owCBgksen0poZV3bhgk/KgOQPxqSOUAK8zknHyg88/Ws7XZdh+BuCgMrp0we/v+FTAMgZpmyox9RTY1VgzPjqCfYdqe86vvG3KBsZ7UlHU0VyNY2YmTBJA+XPHFSxx/MGcEseFyOtTgeYoUsQi/MQe/0p5+UNtRyvp/nvUOPVlJ9CtsYhvmbd93aBTiHwoIXKkdx+dPkHlqx27iMkM3J+tMjByDGQSRlsCpaNErofIke7IZhnqF5puez7kx1J4pSE3MRvJOSTnHFIxAUiQbvYmpcVcYuVI++Dng+tSbSF+bp2wfyqJGdiWjjUqox8x5p7uw2uFwW4bAqHEGiVQ3l7gj47nPpUkTKFXJcv7LkVXJdvvMcAfKppskhjQ5Zmx0A6ClZIhwb0NFyipsbJOeucc/SmeVgDMTn0IGAagspzhmJVT+H8jUpKu/zliW6gvx+nShWepk4uLsEUjB3YSREZwQ5yR/UVbiZpFRozCqg5IbgH2qspSM7kCtnrlcEf41cQCZvniLMBndkDA+nejQxqW6iNKm8qrxyY6qBwp9AQackbSsCikFc8F9xH/wBapUDvGE/dhAdoKAAgelMmjjU5VSWXq24jP4ZqrXMbrZEboxAZ1woP8fCj/CoZtkZJMkZZ8gxdQR7etPl2yyCR2+ZSO7Aj/GmmZdhU7SpHKkAiQeo/xFQ4mqv0KK7MjIYj+8OaSZNrqVG/056j2qdpXdyd5bPUNyfxpk3MbAkqF5Izz9fpUpNI6E7MpTADOBgHkZ7/AE9arOilgCCvHORj/wDXVyRQp+Xfs9xwfwqu6h/uk/iv8j2NB1RZVaLGCkjMpx0GDn3HrURj3J98IRyDgcexq6ys0bEowx97HP8A+oH+dIS0uDIu/aDhiOQvpn09qV7aFXKCBobdWZcfrj6VoWqoV3ozoMZBX+TD/CnJHlPlGUxypOCPpn9KnRML1GwYJGMY9/ajW5E3daEbpHKWNyJRIBzNHzgf7S9GX8jVeRBwJF+cDG5TlT7j0q98uBkY2ncrLzz6YqqxeJiH+QH+I/dP4itIvUx5SEqjJ8xDA/dbocdx7GqjkISoGCexwRViRGz5kbblPOVHJHqah8oCXLDbk+nSumFm0TylGQhuYiQOuM96cLgBd7HgDnnj60y5jZ5RuTGSAGX/AD1qrPasSAJdpzyO/StmrCUOY0ElWRd6jK+3P1p4ygG3OCOmeKx7eOa0mLoCU4yeuBnj+takEollBA25PPp7j61nKV9i1BLcmhXMnXJOcr0pdiqCDwcE9asRqVbnBAJwSOg9KSfJccYI/wA81KZlKJ5ftCFcAAnjn0qypAj3FT2AIbJNVHLknO1QR19qtbEWMCL94pGAAecntXqPXRHix8ySF8DknJJwNx+b/CrVuSkW0FSucbcHk+lVHTygqHnsSRV+Nf3Ck4AzgZOKhpmqsiaNtuCpz9D0FOadSAjH5V6461BLhdsf3jyeD1/xqWJQJFAyu8ZIHGfwqH5GiXUuISyDgqCcheufTFSMQxXBOF5I9DSF0iI3EBgOo7/0qMXKcoGKjsR1/KlcpasspIV2oAeOhqw823Gwje/GDg7R/hVBHCQ7nwGOR65PY81UnmMm4QOySIc5Azj8O9QapG6c7jvJ547AZpLiRw7IFbI6nFULNpI7Ircnc/GWI6n19s1dtZiiK5Bkc8DOTxSexrFWLenqWQNNkZ5PXjpzV5N0j7flVc9c8EVAP9UoAJJPzAdR71PaE4VUZXIGcn2rK5diVFU4ATnjIYdf/r0wqPkwoALcgc1LEcBirKzdSMY60MoYKNx3Y4HTP1pPyLiV4okluAxykY4we/savbESMIgwV5BxjAzUUMa8MylpRxnOARVnAkbjjngUkyxjvEvyjJ3Y24GSDUyScAOwPGRg5xUM8Bih3KhYk8ZPT3p0YI2qAQ5GSOnI60nPUrR6iyKzqxZflxjB70woYo2ZAVwOAD1q/BCxRfNYsSc5GQf/ANVMdB8wBKnsMDpSd0riVToVCCF3sMccKOeKREZhk4C9jTo1BldkDKQAPm5yO1PlDsAHAwOMcD/JqbGlxjeZGMRnqc7uv4U0SYGTjLdccnFQzTCNM7X9VQEA59MU+EtIUbhSeOeuKnVlW6smt1BLFflT/a6U8FUcgYVv0qLgoQrs2ehIxmkfiIsVJHTBI5rPYm1yaSRUUK8bMAfv9gKWPCuHAGMcZ5FRGU+Uh3AH+6RkZqMuyAl12u3UkjJ96ViVDoazzsFABIJHBUcn8ab5qbgjEnI4wd2Py/rWZHPGDsklY4weOVFSuU2n5UUjGHOVBod2Z+xs7M1dyMpO0OwGGBOCfamZj2DYMK3ZjtJ/Gs9JiV8zymeMEe5z7GnGRg7mK4m8luTCSCB78ChtrQzdJ9zRWQOwRss6jK4B4A+nUVVuGRFbCkAn7yncg9elEIYErI8bIfm+/wAk9yMd6a+0NvQAMDmOSNv0we3tTRKjZjBJIUdsoyrjKNz+OOvtURl3AAI/XO0MGA+makbbvOSpkzuGeDn6GmTAxkoyN83zbWXqeOQen/6qhm0UkysfvFT5ikc7SOtRA/N+73MPUHn8qsOqSKA6oyddrE8+4IOQf6+1RhVjPOSwxiQ4z/ganSxvGTvaxG6HIIU4HUZ6d8+1WIwigbiGHXkdfrQ4AZdjtkcFWGCPx709flVQ5ONxwe3rg98U7dgctLCOnlEH5Gi4yrH7v074J6HsfXpUvATMYcEehHI+vT/GghSNoXA6gZzj/wCtTwDEFyNv9x0PT8+3tQYakAUMhkj2ewxwfw7VAS3mARIwVuTEwzyP89a0I0EgbauJj1VRwfcf4VDHCScMWVAclcfd/DqR9KcXqNSRWeGSFWMXCt8w/wBr2b/Paq/ltLBJ57AsMlX7Eeh9P/r1tCB0AbeqBuQy/Mue3Tsehqq6lpN6Kqsx428jJ6A+v4Vsm1sKM0zBiwGG9A8bcMCOUz3Hr70+9i+z/NKm0Hg8Zyf8+la8tsvmLIh5PIKnnI6g1m6ujyWzIhKPGPMiGchl7r9TxyfWqU2yuZdNivbiZklaDynKgt5bryw9qi0hTeSyrHvUISFB64/xq5NGWsozCCso7Acqfb2NTaJZi2TzHVwTx97OSepFDaFd7jpB5Y25Cke2f1qNgWBz948HI6irkwUlwuCCPXjGf51XcZiwSfcUK5LZ5Gp2jLcLnkMM1YsULNJ82GznOOvuKpK6/fY4YdPerMEiDdvGd/3SOc/4V60u1zwoXLzkELkjdwMdiPr+tKhVwigsyjOWPH41GmWjkG392B8v1qW1bcw3fKMZJPb6UrXN0yw5/erNGW4HAHTPcVYtpBNkANuHIOemKgml3bgpXtj3q1E6wRkkMcdzzzWbiaJiOXkZmOVxzz0PviqMm5CZHc5z1B6/Srz87iQTxuOBzWNqkhEgAbKKpHP3c1LZrBXJL292soVs7s5Abiq8F7ITx/qmGFbGOfrWMk5iuH81X2Hjjqv1HStWK3jitwqONhbJZM4PuQelJ+R0KFtzoNMuZHtFDh92duRg8CtSCMyS5OUH8Jz6etZunIDDBvZmd8suDxWpaL9pdWkVlIyFK8ZPvisZSvoUlbU19P8AnIJB+c5GT29auRqhViyhHbADdxVG2Z2G0qzY43HuatRN5bbJGGB2PH4VLdtBpak6x7F4bkHnBz+NSmQRgBkDPjJGevvmlEjYfjJAzuIHHtVdAzTIzIG3DlT0H40tkWldj0jPDydO4yTg4qzaqdwDrycEY/lT4siLIPKnkZxirUsYPlk4UdanV7A5cuhHOu1CqEEdSPSoo98YLIN3Hfgn2qwkIbEiA4HOOmTTniKOVAAXb3GTT2I50lYchXySzqSzDoOcCoJWEigbduVxjvU20xL5abQSME9vpVN59hZHDeYoPJ7HNTIUFd3Q1FOHjiYJu67j19qryyLGgI3HHGMd/rWg8IiRS/DP824nuPSqEqwshMTLk+vUe4qW2dFOSk7oySry3ztNKYUjHbk5PTHtTjKIomMcTyMG5Unk+3/6qWXcwmRYy5I4dzj2OP0qC5LYCk7VRM7lY59uPXNGjWp2b6GsbppFztZVHBB7e2KI9s7nLsW7L2FZgjkhiM0rSuzr8qpyyfhWhAVjCGRXHGA2c846GokkmZuKS90f5jKrI4IVcHapGfw9aYJVAKrg5zkt2+nvVxbNWUbUUkdHJJxn2qGK2xbnfhiSR0yPTpSt1ZkqkCEFRIpTcpbo6/KP1/rT2lKKoVpS+fmOMj8KX+z/AC38vCsSOctnb+VIsZifcmMdC2SR+A9KeqLcoPrceN7ghZDE3TDHH50qSMsYDRpweNvB+mRQ8aMrHO0n728cH6GoiIwGMkMisQPLeNwVOOoYf4YNQ4kOzWxZDFmOyNWI4KkEPn/Pf2pCZpMkuGyOh4P/AOuq7zSFkExmx0RmA+Uem7/HmpkO6Mu6JLyAR0bHrUvuhcrWtiTy3C4YbC33XJ4b25pxh8uMAHcp++gGGT3wece475qP7SiIw8kCNhzG5yPw700vuhQCRyPQ4PHse49qNyHGQSARkj7y5FLjcg+Ujd14zn/CmBWjlAdDnGfvYOD3HbFETkDCsdp4BOP1NLlNPQWGFo027yy54DenpmpNhUn5eOMr2pTk8nkYpUDqT8u5MZ4oSJbfUeibgCv3R19qd90Lt3AH+EjimBtv3e/K8fpTiwKkqcHIypp3sQ9RVGZBgnJHHOMH0B6fnUrmSUukzYYckbPnT3296iiZSSu0E7flOM5//X/PFXUEDxK7BlcjCt1wR/Ce/wDnmqRhUdt0QLbXEB+Qh1JPRsqT9a0E0yK5iDuhU/x4GGBHU7e4z6VPHFayW7RKBBMMbGUny2B7EdQffp6VbhBCKswIlQ4LH72O5HateVdThqYhvVaHOXNhLb3KsH81chhMmCD6/SpZo8vtEYEsZ3Mj9cduK27G3iU8EFQdrDPKe5HpUMkEbXJeUiKQExbscH/Zz7envS5RxxTbSZjwwMtwP3R8oHKEclT3X6U7UShgHkIFcHBUDGOM5qe1mZDIrBT1UZ+7u7Z9qoXkgMe+Nh8x3DsaXQ6I3lLUpiIhGZSOTznsfT6VGAjo534YH+IjDD0+tIJAQPnPPTHABqCTKueTn09B61cWbPc8jRUe2aSbcWHbsB600FI5MoThRn5c8+/1psxZIQQy4P39xI/SkdlVU3fLkBiM84/z/OvWep5EC6kykA/MvQ9cirEWe5XGPlB781nWJ3rlwMg9AOn0rSiH70htrE8+2PWldm1rblsSbTwCGPJz61JZ7pCAQNo5PJLH8KgjjDMoEgKZwdhqznZNIqKMHgkclvfFRJ62NI2sSzbPMCNuJY5OO34VFPbCUHACjqABT5oAZQDLkjAJzng1aARYRld204VmHWsrrY0TscvPpoaTlGTB6Y6fWtGx09VjjZ2DnI6ZGfYjvWuYIZAzOg3e3G6n2sZyXBGAQAp6Vk49zpjUZPAuyBnKrHIOQpHBA7f/AFq0LH/Uq64XIJAIqrt3LHzjvj+H8DU4ZwqopPykZB7fj2pAtTRgIEkSuv3j1AwDTp51jk3zbAm7OMnNSMmYo4g7bwCwJ6HiqoRXG1yD/cUjPNQnd6lxikaCFpNkifdZTwT796mtX43MmCvy4zwPpUUYaS2RA3zqvH+GauQKDsTaoI6gevv60N22LeiJI9pBOACPvD1FWfvocLkY4+uKpsRjzIgAcHv1p8UhzHtO7KksORxUqXQzlG60La4jLEA4GOBzUj8qwbdtJ4Pb6VWTcZSxJIHPHUe/1qeGRnty24mJuNuMDnvRcxkrakKBgqkgMo/HpUWoxK8iyRbvvZPHb3q4FSJRHGqgDB3f7XpVeQyK53IFYjI56UWVi4SfNdDoyY5Qkn7zcOQedtVJbVFlLRxs6j5NwXBB9fzqV1KxEuWyTt6cNUuBLtVg46Bhng8evvQyk+V8yKDWx8sp5SHn171A1is1wHeM7c7Ww3XHYetagi85l2g5GSwY/pVhIYtoMzOGxkBcYK59e1ZuK6FfWHHc5/yXRgVQqofgqOgz1+v+FWYkRHkkusoi+nJb8OlaNxD5m50yYAdqjGAPX3/Gi4t/KhSXY0krN8xAB3L04HT8qVmN4hMie1UqGtJNsQBA3vtd/wDe9MU6WNRhY5yrngDaQGGKuW6QpIywwqAoDKZ13H8uxx0NEwARdzb5GB2KGO7HqM9qpxOf2ruUFjVEaPyVLLgHGTn8R0/rUM8U0K7mjlVSeM5Ax257itKMmRg0RWMBSpiDnH4k9fx/CoL2GW4QKrl26KI5SwB7HB6GpkmaRq66mVKUbAYyJKDld4yPpj+tLs5BLIjddvSrUVrcBla4LtLGTuBHzcdSe54oCJLKCqIY25+bjJ9qlOx0qoumxSmMiqy73eKQYZTjOffqPxp5QKoZVP04OP8A61S3EQ83cE3KDhh2H503AiwBjbjIHc0ty1JNEBbhtyb8ADkdD7VHD5JjbamG/hdGAHuGB6/UVckBAU8EZ6jtVWZJZZQ7KhXOGxwfypqFmUrS3HIA2MfL3Azwee3pmpzt3EgN83ZucVGsJ2t12n7pBzmiPeoxLyM8cVEnbcTLEW3JDY9Tn6Y/OiV/LAJPT2pUIAwSCp6GmhdwHf1x/MUtWtDNb6j4juUKc7T054z7U7PIVsOOgyOo780y2Xyk2ghlHzDH9PellbMYIK8cEnND0Jtd6Dlg8twVZtgP4r6f/qq9BjfkYJI2upGVcf3h6Ef4+1V4S00JXAV06Fhgken54qSHeiBs5XOUOOhFaRSOep7ysXoImg8lkVJEB2mOTqB6L69P8O9W0RxK3lyg27HhWIBiOfXuPrz69qhaT7Up3BUEigEpn5X65X0z+FW40j+Scuu5hhwB8rn1wfWtE+h5lRPruTNF80joSkxXBXIAcex/HvWcLgm1mhuEMgZgCSPmVh/XBGPX3xWg00SoPnLRE/IT1C/3W9v1rJ1OVlkJDMyHAJyMlfQ+47EetN6E0oyk7NFd2X7MycF2GVfHBx0/OsO6uVl5ORg4I/z6VfuLkfZ1jbPy7nUgYznt+FYc7B/mHBPXHY9qg9WnCyuyaQhSCMHBGQp+U9/1/nUEjB5B6AcDH8zVcykHBIIXt2yO1Pcjyy2ec8HvVxQ2eSSgohzIpJHHzcj3qqJnOPNySRheev1/nVW5laPEZdSowcnnioWuT5sYBJUgDnp6dK9ZRujzacOjOgtm/eY3cqPur93Hv71qfMVTZkvjHB6fWuU+2tG+Ac9io4//AFVdsNT2A+YuSzZIJ6CpTaOtUZNXOkiZRJgt8y9vep7ZmA+ZQQvPTJHtVO2kMo3hsA/dGOtXIXJfG0EZy3PI+vv7VknfUjlsWhlYyVABLE884+lTIX8tAzZUtg46mo3QB1JwufmXBzkZ4p0DbJXLjHPygcDFQ9S0i20SbVwzMWyD/hVtUVcLswPugEcfhUKDzQmTh2+7+FOeYEJg7QGxkjrUsaJzFsIR1wPvDn17U5wqkMoZXb7jrx+FR5c7SRkdT1OKuACYpEMEdSSMc+3pWbZ0Qui1a5J3nDDAyO+feplTbvLqu08g9x6GoIsI26QdeODnPHpVw5a1MiFCU9fT0FRI0XcZbv5gKlQrZ71dtkYr5oOCMZ59PSqG7920mGXkOCqjPp35xVoT7gpjc+oYd/aoe5T12HyLlt+7JJwd3PXtSR7+CpZSex/z1pZzGY1QjJLFhn+VWBFtmCGMhCMgnt7GlbqLmsrElvIgOGYgnjcBn8KlidHuFQghAcenFQRIPMdtqgDnHXdzT3SHz1eJi3fJqkzCSVy6zCTy9pUxKcHA6c96iQQSTsZckNnlRznscU2O4RIpM7U427FHLep9/pTN4l2MXEYP3WPH5gUNJmUYvUsJCGZWmO+UnGAOFH9aa8KmRgoYIpIyrZJx/epUk810eQIgOSABk5/u570xFdVlYRhwrDZznB9DjvQwV09SO2hb7WqrL5YBLOR0x2FWZhFHbpIExufCqMkKPpSRpGiAFVMjctxypz09x70+WMrEGYIjOfuk9fc+lApT5pK5FGYpMrbxcgkOu4498A1es4Gh+ZDGAVIeM5JA9R6VTjC2c2bYBgF3FueW7iprPaGe5LpCzqAWYEhR6d/1pJGdVtrTYmVQzF3aTbgiMA5OB2bPSqVvFu1JHLEpCpHfAJH97uau3bSGEMvlgSMVEgBycckhcY/P1osoZxEzIZJA2XXHHy9O3BP61aS2M1NpMlaCGabyrmRVk2FkXacycZ7Dj8apJAXdRGrJIPmCjgAgd8f0q4skcqu7I/zAZZlwQ2O/PIPNEUXloGicNKo8uXAIxnpk+9FkzOM5RRUIt7h2MzyCd8BWQtncPeqZDq+SoZum9cD8QOlXpEFxctcQXEY2r8yM53tjjJHT9agbbMGjYyBwu4SAd89x6VEo9jphNrUiP78t5gDSkZDJxn2JFVJY2EZ+YDb9/AAK+1aKIBJJG4CSjkEHh+P61LOi/ZsypkDkyqMN/wDrH9anl6mircr0MLylWInl+M5Lc49vUVGIlCoGAYsOGHH41elBUErGrpnOcYz74HT8KgGSBiRDGx4LHG33/wD1VLSOuM7q5EMr0AIYEE9jSH5XCnOD8wPUAUreZHw7ZAPLYBCk9+O1RCdG3rLtyTgOP8PTvn60tNjRXZIxUtjKn3BwD7ilGQoKqduefSsi7eRiDCyI4bLL13fQfrV3T2kkZjIy49B2NZJ62NZU+WPNcuK/OM8Dp2qaLbzuyBxyOfoRVC5Do+4r16kdqntH3Extlc8gHgg0J3eplOHu3RpQjB3Jn+gqWIF3OwZyMlcYJ7fnVZAUOCODznPFaEZjELnrJwRjqR7e9Xc4arsV1Hk7hz5YIKlRjA9aLi7MshDZH+2CeCP6Uye4aMrGyqdwIyB1BqJvudCTjIIqOboOMOrQ+S5fZjbkKc9efxqCW6+QhWUqCB8w+6f8D0qq9wdpYZxnYT6GqskoKnIw+NhGfvD/ABrWNzdUooLuQuHADD5s7T1U+1Y8s4WCQ7iu0/Qn3NLNcNg5bLAY9Tj3rPkuPMLmQAAjBOK2jC5WiRbjmWXHzEMRlST6etPjnXbjsR61nxLiU5PXkf8A66svvj5AOCduT6/571qoNGMmmeKX0xeILgfKfmz1qCJssC3Q+nakuSv2hhgkd+1LACQNhPvXrJJI8+D94ulPmODx0/z7VLGWifOMkjgj+nrSfIIvkwMDnJ5/GpLZBPtUgpj06/8A1qxlbc9OnUVrG7pdw6qArqE44PJ6D8/8K21mjZA/LSDuQQPqKxLYJGETEfzDANahbaqsgAHTI5x6VzJczMJ2voa2VlRM4IVdq08DPOcDjkEdKzPOwQFIUrg4z0Pr+NX7dwyCSZdoJzgf1pepCVtjSiBBBX5lzn5jULvHGzmMZG4jb12/UVEgk+YLyOhAOARUfKMWk8tx/CPf1rNmsFcuRM8ZU+btYY3Akcfh6VoxK5O5UDnPA6HHrms+FMRsxCb3xnHzD9a1dPt3VGY/OV65+76dRWelrnQiwgyA0bSYAG5T1H+NWnkBifqOh2twaYpVsM23cAAAeCw9R71MUBRkyNxwd+O9Q7jvcI5gUU9+4xnd7VWuASq+W7Ll+gA5PvU0UAjnYK3GB939eKkYBGbbjGQPofepb6GkbIlR8xLuywQ9O+fWrdtIJ7go7bOM/PwD/h6VDEBGgycuT0/+v3qYSBTkoDuGclcYFJXMp67CpbusskjbyGbPsvsPepo0cusjxuI2JK896pCfLbA5Ic7gB6+3vVsOisN4D7jjcD/nmqv2MpKSHXaiAbUwXbBBXkn8RUUCCSYFoj8ylQQPQ8mpriZY4y7NGGUcL3J96S3uoy26M4x2C42k9sf4daG7shOXLsTW5xI0TIvyYIBOMegNWipeCTyPLJkKhI8ZCY/i9cjsahjCzpM0W55PvHnBwO/PBqNH3P5igBk5Jxy2PT1FNOxhJKTZYhkXzo1dFJ3E7QvIx2+tMkIuLpZ5tzSbSmWHOByOBUqNGzQZKeZnnABLY7H1PSlt5GIaRpkWOQF5AVIwfp0FJPqzO9newRvsUeXEJN43OZTjavcge1TafGTCdk0ESDduLpkMD0HvVVpImikMhCxOC/mBcKfr6U9rSZHhCRCCLYSfPIJfv8o7ZBqk77kyWlrj3tY0jYQP5kGOPlLZP8TY6j0quXmW7iMhkabkrAZflIx/CAcdOcduatWcW2EeUJUkdSP3cZBY+uc5OOnSgQTeUsiQiQg4WXdu5zyPU80NX1RMZpe63f8AAWyijluZJV8zzpwCTnnA9PXH6VbjgfypiGWMeqruLN6nJyfWkgtryXMkpQDlVc8gA+nHAyOakhSJkuiEaYIyszn7yAdwc9D6+lUlfcxqT10f6lBkLPJFGspaMB2laIIFB+nY0bGEavGG+U7flXJz179vfpV66nVkEkJt5kLAqDuUr9Rj5vxplt5UaTxyTKl0z5WM5JbjoOMAfU0mtSlUdrtf1/XkZc4Z5XClgeGZG5VvUe9TWZMzR7xuYnYHPQD3qQTBo5ZHd/MLDY3oPcHt75/Cs+ZHiheRX2OSS4BBx9D6VGx0RfMuXYkltWgklQzkyIfl4+6fb2qjcKS27yNr9G2jH1yP61K0zXOFuJYmJAIlQcMP9pe3tj1qwru0qzSnfIBhmD5PH168VNk9jeEpR1kZKq8ULSK+2KQlVwOD7exqncqC7xlV46FRjn6VsyJvjlLAhzhlYLgkZ6/SskWfJbOWzwwPPFZz10O2hUTu2U5UhKrv+YY5wOQe34Vcsm2QqD97oMdaYlv+8LAZ2dc8E/Ud6sLEE+ZcFF5IFQorc6JyTViygDsRwBjBBFOFuqurbPmXgcdqjhYbztOO3HarYK45xluSATV2Vzjm2thXXAynGOo9qkDjYdhHy9R6e9VUZ1kI3FkP3RipCxUH1xmodjOUXsJP8zLkHjn8arXZCnKNwQMDuPX8Kkeb7oY4JI/CsnVLtBG0ZzuIBX1B/wAf/r0Qjc1hGxBLceXMxJXJ4PHBrNnvlMZwxRh8w9DWZqF/uVXz84ONw9Kzo7ws6jkqx7jgGu+nSS1ZU5XNG5kLFSwIYfMD/OoY5CJWLAbG6hvfrUUzCRQAVA9fSkQMpAbPGM5GBW8bXMlqadqGdoxn5OgP8q0fKUxFWzu6Hnk/X/Gs61k/ucFRge9aQZS24jLDAI55FU5K5jKLbPBGhDyEhgMdSe1IiMowf04/GrckDNym4LjB4709LdlQZySD0rq51Y5oW3HW0OAHzu5wV29OK2LSFSAUXHQkAe/Sq1tF+7UfMNwzk/xVpWgUIN6r0xgdK5pyuzVTsrE2xnOQccZAJ6CrwQs6qW4HJAGMVQs0DMR2Udxz+FXVlGQGU5OANw5qF3C+uhZIkELFSpTOMY5xVuObA2vnYODxiqUKkoSFBBOBkngj0/Ora7PLG1B8vIBB4X/GpbSNEiwxdpVJUFQen+FJKPLlJhRSjdFAwc9/wpbVY3KNkfMAMZ61O8ZMw8sr8p5APt1rJ66m0XZ2LNmBu2rJuGeSe2PQ1pW5AX7OoIOcsVPB/wAaz4c+YSo5bjB7VcXhB32jOTyCaXTU0tqW2RxN82GixwpPf29PWpnG6GLJUOnXPVv8/wAqi8yPZC2Y+Iwu4cYqxaMGt8yqAq5DYOST6Vk7mi0HmQSEYb5WORtxz7/nUy/PFlDhcY5GQBVWMiCEMrASHKgn+Ee1SOSo2qX3DnngNxUMrfYsxcxso8sMg3EHq307VEtydsm3OT1G3IHvUG/CgS544wTkD3JqKOYBlViQT1JyRntSuVybtly2u2VtyhnhyQoHdv6fhVp3YLsSNoz98Z5XHrWfFulSRFJY53E8gg9Oa0IVAV8qxkB4B9Mf0oTMqiV7ocfMkQFpUOBuG84YHp+Pt7VZO8nbtXGeD03e/wBarWhaWFkC73PO6Q4w3rn/AAqzGUaOHeF467gRtPoO5FVvsc8/d0JreV0uFmT9597KE7c+uPQ8UyOT7Oj/ACKYpBlVJwyc8/8A66UqZXZGEalduCBwxHQ9enJpA8TxKMrHtO0EJ6d6epjZPoW5kBkDSxFDjO4cs+Om70z+NSxym5ToAighlc9j+Bx9KguD+6UoolRiroqfuzkeg/p3p9qm6RWjIIJ3KrAoDjr6nPt1qvQxlbluyeGBVWaKcZXyxsRWypB/vDnj605JGITP+pQcTDnjuDjt3prmRhI9i/2cI+JS6bCcjJ46sD0q1Z3Ad0LoLoEOspBJaJf7wPQ54GO1Va+jOaTa97crqdw/0WVRGTkOgxvyOue4NV7JFWeR1nZgcHypH2ZwOoPfH51K+5Vlk0+PEcY/dxNGHX/gXIP5e1X3iVVjR1kzPHu2k7lfjhTjnGeM9hSjHXQJVOVWBAUknCzIH+UOMF2XGCFwejHrnP0p8QjWC5hVkGR5jQlSUBznJGMgn0HGeeOlMlluoLeFoolss5DR8EEgf3hg4HY+mMUR3HnTiK3UmZgWJ8odMgcEkc+p5rWLadkczTkrseVaSJHuZIlJj2Dfx19PTp1xUUFt5V3umgMS7SCVJy/HG5T6fX86nuYLaOeIzxsGQDgKvyj+JTg8gnHT60oZVlJuVZrdUXyth/1eOgP8s0nGzBSdtNmUzkXEjuW8uJdmCuSM9yPT61SdoMSpJP5EciLGUYbxkdTj0/LipvNW3uNjs224+Z3hKsqnqBzzjryOnoahszLbySSyPI8DPlCygZ9d65PI657HpWZ0xTaIbPyZ0lNvHkoX3xpwQB7UuxWCsFKPIvykEYY5wPzPFVbAotw/mP5ZP3Ah3Fj/AJ70xvmjlRgYShO5cZPvkfgMmoujscJJ2TLcjFbQwzxSrLE52tzkA4ypHf1H1rOf96mcAMDjHUE/40+WaSNlxKxaULkZyDz0IPSnCQI8mARvPK9QR2PqcetJtG1NOHzIHj3KokwCBjpgkU2JdqfMMYH51aVMpvRhhfu+/tTbuMyqrJx3bFJpWubKd3Yrqdu3IweOverBPoMjr0qKYA+XjBIxTmG05GcEdMd6i7RTs7MQvtwVwPTFEzMpOOhH41Ap3OcE+xFNun8tMtgAe9Zt3KUdUQ30wiXzCRwcE9vxrh9W1HdJu3/KDgHpgeh/z2q74m1lolmgG4hhzg4Hsf55rkPPWVWCnC5/L39q7KNNWuxyvFEtzMTuyV5OOP606B/nX7uM88dDUGwsAvBz1wTz6ZNWbdNuTxyOOp5rqtpoZPzLUO9udxVifvY5q4FZk3MPmB6Y71BEGbyyVAbjcMc/lV8oAjOinceRk9P8KahfUlysQQXARXUSIhHK/wCFP/tiONgshBB6HPP5/riuc1eeeJRtUqV98YFYUuovG3z/ADjPQ/z9+tdMKCteRlJt7CQEYOdpUk9s80kxVG8wcR/dOOATinEmIIoJwPXgCmX9qZEXDnfjlWPGM8D+tJeZ50d9C5bsWVSQTkc8EVbR2TARc5OcccnvmszT2kACuT5g4OOc1owuSQgz064x/kVlLsb7Fq0ZupxyeTnn8KtjzBgnG4d+pqKMbQQuCAMFhyKs2SjzBkckgDIx1GOtTazsWtS6gAjEe5dmMEnuP6UuNke0K4LDHTOM9j70wx5kmUEMFPJx0qWNmdVySVUZAwRj8e+ai3U1i+hajMaptUZcDGAakiIyzcliABz0qNMKEVIwZT1OMZqaNAWzkBScADj61N9DRLUtQlSUV3KrnB57etJNcbWZsAqx+6DwM9s0iLGpx1YA4yeB61DL8jeUgADccZJzWUlrc6qavoaQbfEny8AcbTn6VoQBvIKltpTBAC9/X6is2ybK4OVbO0DIxWlGzCcrO5AQ7c5zzWV0W0V7jep3MPMPd+35Vag3LGpVlAHOSc5+ntTTs8zaSzIVPOenagPt+ZiQmABj0PtUv3dy730Ir0yG33xr8wOTg4qos/nxPGEhfapKhjscnOcZ5784q9cyt9nmAyRkEZOMheazoI0mZZGRxIMBiM/KfpjOelS+5pBXWpqQTM0f7x8vKuSzv849j6/WtOydGnTzGZvlGXGcAeg9DWYIleRpGy2cNyDwfXNaAcuSOhwCcnd19PWiPmc9WKexYjkXduLOmOh65Hdc9z/hVrfHMmImDKCT84JI7f56Yqkjt13IVYHKc5U/Tp+tSl5XjXDEnozZ+ZjjkkY5qr2OSUbvQlgmkh86EIXSQgENwVI6YPb+tSLgLhihIO5mEmC47gAdKprLGCApzyBx0z9e1aBRY96KrCSTOxyThT6nH3qtIzqq3QVUUyeYHQpJwSSCY8d/b60hgeSF5FfY8bfNscZJPTB9DiooJGH7tYQFRunQg545qSfzY5GIdoyWEg9z6g+3NO6toZtST3JLe8YjzQ0dzIoG5GPI9APcdcc1cuEmkgh8gYZ2y7KuJHHqc9cevf8ASsawkK37xOpYjcrgDGc8lunJGegrRiluItiiWQxldynHyhPTvxjt2NOOpjVg4u8SwoW2hs5hDIAW3uYwrEKRwcDk/ofyq+VMMm77YUtWRpGBYHc/97PXgcAdaq25VIt0YM0Skv8AKMSAf3T7HtUd9aNqWnbI3YEPuaNxlSB+PUZ/Oq2OVrmaux1vNK1issV6b6wH3p8BmyW+6B39+4rREk1raKjiN4twURu+1sHOQQQePx/Ks7Q0RLcwSXXKtlVkcAoPXjqSf/11YupVsIY5WnV97BEJDTBSQTj/AHeD9Ka01IqpKXL5knn2mm3f2Z7iM+YMxwOpG/JO1EJ4PQ8deKQXTm5mNqoW3yPlUbgCR1x2z6VXuvs0gjXz49incduNqkd+fpwanlDKt4Y5FaNdrpIflBGOTu7nnvkGm9tBcqVm/wARfLiihkmESTKqgKxwuMdvY1TlkMklvbXKhJnztcNlRjoDkdDSWtyFaVnGWX5mZ8/ex3x25Gag+3xXEZlVWJwwESA7lYe3PGOnr2qHY2VN3tYzpHVLlBGdpL4ff8wX/d4yOvP8h305pPLvtsiM0wjzuXkq3Y+44+vNRoizrHd2nRgNyMAGU9z7g8frUl4x8uJCjK46dQ230x6D+tTbQ6JPmaS+fcyTDmSWeNT5TcYbsQf8aLiNyQZdylMA7Mce4Hp7fWrF3+4uRzv2Nhx03A9xT7qNGclR8nXnt/hWaWh1KezKyEAcHHcZ6E1MrDyjjBD8gkcg1C3OdpK7ezdxTmk2hMckdcd/rTY3q7lWQ5RhjkU187VO4ev6VZnViR6FeD7elVJCB8u7g9QOMVEjeGtiPG0g4IBPUCs/VrlY7eVncbcfMCccfjWjIv8ACcZOa4jx7f8A2WGVY2AypGPXIqIx5pJI6YK5w+p373N4zRuCOcf401XZCVUHcMHj096ybdiGyx6f5zWvEiuuwbgQRn0/E/nXpOPJoErM0opN0Mbd2wODyP8APNXomyq8njj2xVCzUlFf5tmMEdz9PpWoiKJHAxnoc9//AK9VTd9znasy1bAbucAHKlfTvV+M+ZCcYGehAzVOFAxH4AVYiZxJGYxhiMdMEev4VqpWehm1zDdT07z7R2H+sHKg9CPSvPda0yUTO0akqOox+teu20eHXP3X/n6Uk2iwTrLkAvnI44INausnGxlGLhK7PIJXDMoCnIHQY49zT8l41C5Y4/H2FUVkIJbGVXIx6/X1q5C5O7K7gTle2KU9TzoqyHyOQ6xBRgnLMDyf/r1ftxwScFsAY/8Ar/T9apr+8lbjAPXnnipovkAycNncfeoRrE0bcMSMEnB4x/T1q5azMW8zADKfu7fX3rNWVvPGCFAGNwNTRTH7xIx065A+vvUt3WhtA0N5kSTaTk8ZyRU4+RI8MMqAOec/UVRa4+zwhl3MCBxwT9PampcKjAsOS2N2evNRKy3ZtFN7Guk+5d2GfJwAe3rUkEnzBVG3GTgnpms+G6UF9kIVAeQOfxFT2lxJHdb4lHbnIzntwaxlJdzeETVS4xEWLb4xgA8Ej8KlU7UG4AsTnNZ7XDkliMsTztbj68U+0meZipVdoxzjOTnrWV0bJNG0gGI0kKqQP4hnj0qaIYUjBA7Z7GqlsQGGCAFOcr7+tWYZWabIDEkkZbtWbtuaalpDiVXjUYPbPBomhaVlAULznhs/hTwMohMZdgflAO38RxU8bbVAXAb1Bzmpk9AXkV7mHaFWRvkUZ3k9D6YojtlWJdrckdA3T6VL05+RSeBx9400fKdvLMR/d6ehqUkXzO1kSQAhVj+cjG4E9Pz9aD1KxH5gcADv6/Soy7K3zKS33SwHAqxC6xvlhuLDqPSm3YiV1qSRHJUyAqNvJxwT9anIZ5Nh+8OFAPb2qokzxbo1GU5ZQRz1/mBU0Q27VQ55JBJAb8/6VRjJdSwYRGmRuyeQDjJH9easxxsZyNzHOAjN/UVRmkAVScK2cDgnv2HanrMVkClAT93AOM/jVX6GUoSa8y60p+0qBkoX2BVJVie3Pek3kXCT7XYxMQx2ng+o9/qO1Z886lY8sQFblRzgd+eualt18+IvIwVeV8zJx7f56+1O5k6dleRYV/KuYZ2/eovzBicllyfTp6Yq1ZMUMaljGoy4Kjbn2Ptjj3qvbQhcwu3mEYZRsJU+vP8ACe+O4qeBQZvlh3yMhUFyNpPfBzkAelWtNzGpZ6FkXDI7yuNxmABVcxrnscHg/wCTxUks32WKC43y7WGxZQAQoP8AAfQnHfrVAvCgtYbosoSTeXKls9tw7g44+lWoJI1jna52spLEhVypOfl6nG7GOn6dKfNe5zTja11/wTV08BLbdHMGAVmVQVDop6EE9MH6/rSKoeBRcu0xX+DAViMdSw6569Kxbq6vrcxJbySrbzghCfmjJB5XPUN3I9Ku2lyDCytB5V3Eysr/AClpVLchSvp05pr3jGVJr3k7+m4Wttts3DTrmRs5ZRtYfUcE/hjjjFTX6L9muIbhv3igMN4O0L6j2I7eoqe5kRo5Cs8hkwUMTDyiiE5IK8nd0xntmqF7bfaLRV3hnMu2AYw4jznYT1PpggeopSVrpChJuScihLIr24nt3uJ0VVZoTGQqEcb8n9Tz24oRTLLDtQxzOoeVOQQpzjn8Dx2q7HP59wYjDOoAzyvB/wBnGev86hhKT3M1zESViIUhsg7uoUN6nsaz3dzrvZWehctwitGqy5eTIaXbjZx0AHb1xSTMTaIA/wC+iB2sy/fHcipLAKJPNwd2Pkzg4+v5/qao30rRskqq/k5wFPO0e1PpoYwXNOzE+SaaA4AZzzu6A+hqu7mMFFGOSoBPv3q3cwiF1d2MiF8Er3HqKquBIvmcYJIBFQ1odUGnr0KQlIIz0B69/XJp4bdGjI2X3cilLKUBI3E56GmFf3cbJ0QcnHPWkpdDrWvQdKwZAWHPOcVTZWVj1x1z2qy8gIBxtyOcVXmyCiIfc/8A1qzm+ppTVtCGYHaeTx3715R8RbphqBRWIA+8PQ46CvWbj5V+X8zXi/xEb/icEYPQnrmtcIr1UdMXZXOdtnIYd8/rWxauSvzcAAYx78jH5VgwEfnwa2IzmPK4BI6jOK9Cqioq6Nq3cEcjOOMdM1diblvmwowCCaxI5GznqOoxyfpWjbymU5bk54AHINYRdtGZuHU3LR8k4JP+yOntWjZoVzgjA5xnt2rLstpUOSQM5DH1rShfaoI4PUgDqRVuWhmlqacLbVO5sru49q17dhlsjO0ckdue1YUcg8wDf8p6j1rTgZkYtkFeQeOxrF1NLDcLnz85dXy2cgZGT39atWjEjeBnnGSe3Sq0UhkViU3AYxjk4q3aqSoQHCk+uOPSvTmjwlLSxo2zYG5sr/Fj39asZUuQDk+uOPpVaGRnfPG0cgYx7VMysEV48YB5ZutZbFxZNbMS4GAfY9OO3FSmQ+ZzwgqFAY0YttVvvL7jPJ/Opt7xqilTySR3wfXNRK5tFim5aTq20DKsw7+uKqLI8p8uXkHJULjPtj2pJY0G4ljkgnaf4qW1LeZmTlVABA+tYyOymi1ayjjcxOB93OBW7CkgiViQq5x1zg1ghE3hnQqyDqp6fT8K37MblVlyxAGRnB/LuelZLXU20J5iYI1eNS4OdwIxz9BU1sBJGqk4JHX7vFWGPmgq2FXGC0fT6Ae9LAqyOAFb2ATIzSaZaaJYmlRDkFWXIAA5FXbFgOWctJkBgTzVR1kjkU5kWUkja3GBTrd3jlXKsjE8seSffNZy0NIrqaducllyRknOM5HT0qZQ4VXaPLdVYdcepqnbTKyjy9+RkHA6++fSrsbFoG+UkHp2JqHdlWsPc+aMBflT7xzjn1NIhKfecnB4I6Y71AJY4ZijbsFRjAPJ9uxwasRSnHmRgYdRnAwPpg9KLWJd1sOYMzMygbT90Zz9cZqLzfLH3WI7ttz3qO9mXfg7lwvGRnJI9PWq0AcEecQpXCtHKx6Y67uhPbHX8KmW+haS6mqkrHIIB/iwP5n86SUvyyEbWX5ht7jvn/Cq8LHeqbSCODhjkZ/p2q3GsSyKjq2zG44Xn+fT3q1qjOSSd0SRMygsTtyMP0b8R/nNEzAJ5YVSo6kt0z3prAB/MbcxBy3UE+lNaXYWI4Vjgg+/eldozUU2ULu8KbisgJ3fOQFPAHcenPUVNp9ziUCaIPa5w3ylyq/89Ao7/wBKzb8bdQ3jChWwMjnb78//AFqkllOZFTBCkHer8fn/AEppvqdUqUZQt3Opt1by/nRkO7LL13A9CCfb15p6vIsDeajvMSSkpIwB2IP86ybKYG2Ylw23GASQQPUL6etX4p1nt0Q7lY7im3nJ9Me/tVbnmVKTjuSNGzeQyyurKuW3P1HXAz0/lVi0gljYu1upmcENEExuj67mVT+b45qvFLF9nMc6yu0qcZ4K49D29wMVDeTs6wsqNhOjDc+0eo2nJHsc89qrRGDjKeiLUcjbppLeMrbk+Uy5ykw7Hd0wOnY0wTPa24SPhi2drgFlQnqO55/A1Wku/LKZbz4yCFYbdufU4GWxzgjmpZlt57m2uV2rGIwqqGJDvnt/dbp7dae+qK5LfHHQ6EMWuIL7yFdGwk0okyzAdjnnPoDyOlOu7by7t0Mcs8MpzAysGYDHOD0B6Ej61hI6x3c17J9sghVRE0i9I39+3GM5xkgVo+c0yznTrtb+7lj2PCygqT0MhYnC5OcDNWlzI4JwcJL+vx6Fm2tp5oJ43uMk8NIp3iE/3sdc+vtSRxNaokEXlF3TO6FiRIByOv6H0qpZ6HfxWk02pxi0u1xFDI8pRWfrl8fw9R9fSluPObUN6lt8UexBGDtLAc7QewA4xwamcXFaoLqU3FSuvwuWBK0K3LmTABCQpj5jn+JvYenvVSzDTgxOCsn8P4moLUO8ricOr7QxlT5gFHI5q9JcMkc0SsU3MGfeRkYHzY+oxzWfQ2cXB8qV2yt56uUkBDDbt+U8A/3qilD7o0ThWJPzDAz3qureXFMD/eJx0x9Kt3jP9lQzgqcYUfzpX0OhLkZmJHsMW1y29ctxyhB6f1/GpTgMu3IJGCBUcsjRtsVlOABlTweKhUsSGbGRnnuKi/Y6lFtXZdkQ5Rc4XGOKrTKRtPdTzjrT1kaQjrlhkc4p04LMSQeeDUsUdHZlWX5hk5zivG/iZbtHqm7BI29ex6V7MsZA68gVxHxD0o3dnJKApZQB6/lWuHny1E2dMdU0eNwOc4rVsnYnG4+oPpWZeW8trcMjqVcHBB7VYtJOx6n1NetUjzK6JoSs+SRuO/AdSVY4Byeo9x2qxZybJcjO0dumKz2LkZH3h2Haprc4IIVgq9cde/f/ADmuNrQ6pRSOrsX8tCvHbB9P8Kvhv3anOSx6549hXNW9w2M5BBOOB7VrC4DpyAGIzjHHFZcyaszmas7mpBKQUYswbHJ46VqQXgYFWPTjkYrmWuUjBfLZxkgHJArNm8QJZXDAuXUjAI69OtQotuyD2iOCgk2Qog79QD61fiyRH044AJ71hRODKvOMCtG3YHlySUXbxXuzR85F3Rr9QFicgnqOnP1/pVmFmfy43B3JyTnIxWdA7s3JBQ9M+vpVqCRjudyGDN0/SudtGy2NEZkHGCc/kB2qfHmgqOG6Zqqp3rldpXpgjlqmhfD4G0LjJx1/OpvrZmkXoTtaCJWZ0ZtuNxLYxn/PSp0jRS0mVUYyQozmmMxZPKBUD72etTBjLIFdlAAxkisZwTeptCbQyyVJgSPkJ5Bx2HStO2hVQ2CRxwM8flWakLLIZVwQoIxjrWgsxVYsIh+p7+9Y2todSlfVF+Fy7vvYjbwfmyDUq4xucsWY9Cx6VRLlCVCFjJjj/wDV+f4Vag2ylVVRgnJJOce9T1NkupbYt2VCeg5zkmrMZVSqOZG2jAG/aP8A69UJswMrKgZ8everUX7xyZMnABJYcA+grKRupFtEIQJt2qMc93/DtVsM3cqVU87GyD/hVPftUckbjtwvpVmFF8pfkTkcAHpWTvcq4SqkhfGTsGFGflXnsOwp9rE0ShGBY4IBJAyPc+lLCQ/mKRtDnb83HHoKkjhJc/N8zcAsen0FFluDdlYrXNuHD4Yk9Mbs7fpSxJJJbOqY2LtA5BxjsO5FTiPc0kS4x3KjB47/AFp0Sh5FwihwBk9AR6Giw2/dEhThcgnPfOBj29qtxMqjazEsB8vy5yPSoTEWDnPLY5PTPrUh+QpjbgL36g/WjVGUnzEhtykjZXeWOCR2H93nj8KriMySFiAgjGNuCdx7Zp8zhyHVzvJwVPf3qJZw8hKt9MA5p+ooRkUL22bzQOCjdcHOR2x6H+lIhkgu1U7ZMgHzOufp/LFXriU85Occ7R1Ge9VS++TJXbj7pzyfY1UYX2OmLbWpOs2ZXXzMBg2VLZ/L29q0bF457No9ivbqyO2TysgHYjBA9ge1YVxOqzrIjKXAzlARjqNpyOorQ0m6kAuIo/NjjOGzFLs2v688dMfXFaqLRhXpc0LpG7Ixu7RjOVEqEr9qDbdins/AByOh5zTGWASeX92Dywc78Mvbdg9QfUVTivBc747jeHJCDI6/XHHvVrU5Z7ea0gf5o0/eRhQNue4OeMeqmplY8/klCXL+BX2xDEERBIBChFzuUc/mM5z0pL1pVto4JPKmhGF/fNu8tv4WQDkHqMng9+1SyXMoviBCkIKA7Y2AYqR26cHsOBxiiGcRRzGxVwJEKzb02AnOeDyVPfg4NTpYppu11/XqVNRmuBaJJNLJdxg/ZwJD+8j9GAGMY+7ls5yKtW5WcBzcrKSFV7dlCbgBxu7A9PrxTWuomsZV8+3ebaMLNDuK4PTdjgkcg8jrkUyeKNrdPMs1LD7qxtiM8fK317kU+ZrUIxveNra/1vY0bm4nKNHLdXk6KARbzkhEboAh/i9DVS5N4JY33StsITK8BT2UVVtJriT5QWIHRQCQfxratbl4w0UjDfzvYoMg8dD/AHvelKXM7kSg6GyTZGBcJFaNHJGodtzR9DzztYdsenamSWqBWuNzs0kgEfPb0OferkVqmoX7z6rL5cWdzujAMWP3RjnOe9Z8gEj7YlbBY8HkgfXv9amWxnTld8qevUfGmZGBbI+uR+FJelnj+ZtxPyrk9O2TToVSMqXVvL5XA659qikOSuMkn26UjZK8rlFY2jkjzjay7gQM8Zxz71NEmWyeVJIHrVqNAqbtgz+eTQ42YGOOvWkauo5aDGwgj24wvA4of5m5AOe/+NRLJ5kpAPQdPWpthUkNgY71PmJ6DGQZ4JyOMCq19bR3CFSDt569auHuSDn2odNz8de2e1Q0NTseW+KPBnm5ltYlBI6AYwe+f6V59daVdWpLPEwHrjpX0m9uJMApuGc5I71Q1Hw/b3AbzI4yVHJ28n6+x/zmuuniZwWuqNVWhL4lqfP9sxOUbIIHbtWlBEJAGADAkcdK9HvfBMREkiJ8yrwc5xgdfp7Vgr4fuLcsuOEJIOev09qJYlNXSOuMlJWTMmC2KqzEYGNwJzU9zEdpVSMBun/1/etmLTplAUKd+37oGTj29qT7CxVSwAC4JznHX+Vc3tG2Zyj1ZgyW7sjhSxJ5z3H41Ru9IDyM5JYMvv2HB/PNdYbVkZgFwvt0HfJNJFZFo3YLlj3x1zWsKso7GUqa3PEUIJIP/wBer8LYPyHBIwD26df0rK7Dk1ZiYgcHGOcn+VfSyjc+Wpz1NmGRmxgtjgjB5xircEu1DnHzP/3ycd6y7CZmcgvkAZz3q8Apj2IOThhk8n6VzSVmdiakjXgf90oDk9PYj8KtGQkJsPXGTnoM1k2heeeNcbQp3MvTA/pWm7ZkCKdvPJ7/AIGudqzNL20RcQB2MZYjqd2P0qa3CxgIAGLAZJzgmqEDP5zKTkHB6/zp73myQnopH5Y7GsnJXsbwi2bSEFUUMDg/Nipw3y5UAvkZPqKy7K5V2XcGAI3bjWmgLIGQq3HTORU3UtjSOg4sJYnRWOAvXnIz6HtVqwV0jAfl2wMj0qBUMjjDAMgyMHgirUZWRTubkZAyOfcVi1qdKloWLuRjEERQRuDZ6H06/wBKnglAKDseDx+pNVJcqqgp+9PT0B9vwqq1yznb5haIj53B4U88H3461ElqaR1WhrrJ5kxRADtb7+e2MHB6VqwY8v8A1YO0Z49KyUmeeJSu0kAZzgA4HQ1qWj70+Vtg4PJ6D2qHuaapFiFNjKq/MM44GS2f5VIwYOw3L8pxu/w9aYh8s9QueMA8/wD6qkcxux+THP3VJwPrSDW9xQ/zNsJY54J4H1PrTZQxjZVIXHLNSO6gogVRnjA7ZqQn7wGMHrg4JosO42NhsVJH545B6/8A16W6XfFJKpIC4Q57t6Co7lThZEUBRwGI5+tVri4Voljc9W6g8c/5/Clcai27oaZDHgyKxjZivoGPpmrCyLI5QnDAZIxgf56Cs9XVSvmbdxJYc8H3q4rwtN5kRRSy52gHkegppo2kguZkZAWUPszjGM/Q1lWs6PdSQ7WdhlwChJXAy3P0rRvpiYkUrkydN3G30rMtBtvUkRgCCdwJwGHue3er5rOxrSj7jYoSeKdyAJIGBK7mPHf8PpVuxeBZomljcxYIII+6cccd+amZ3RdjKh9iSSajjdt4JVDgYGT0PTP19q11Wo5NzjZov2ZWfUk87KRFQrED7g9eOv1FbFzdGGQwxyOyrjEmMkjpzxz9awtPi2xOxiBjY/M6Nh0HoB0xnnOO9adtiNlAVWA5bofyIrKT7Hm14q9+3QuajZs0UEkc8eS/ywxPuZOOuR0HtUNxbXMzkW8KMAoJ2x+n86tMI0OQuwN82R8vP07VLJObd5XIQFwOVBA6d6Td9jkU5RslqUI4WWEF41Csfk3Jnr2B9PrViS1iYbTH8mcDHCj2/wDr0jzS74jcuxUDCqTtz/n3pblkciRk3H7oJb5R+FTfQG5Npv8AAUW4EX7qPZzgFuCR7EVFEwM25grMPl2kHp6570t3cSxph8bsfMncDt+dQ2zM7LJIpMQ+VSRwD/T6VOrdhxT5W5FqUE+WqP8AMO/Yk9cflTYI5ollZtvByxPUc0l1EqE4BBZc5Xnjtj2p1tIyR4UAEMCMnp7CnK7Yre7oVo3aaQnlBjKKPX/Gp1kKjaFB4HJ+tLLG0RwcEnglT3qR0EWUkKk55OevepuU2mIo6Y6AYx/So5z8u0rwDwT1pwfAG3YCOQcZFVy7GQrtGSeR6U9BwTvcjtFCuSe4Pf8ASrjDPcjjtVeaM7kKAZ75/lVhh8mQe35VCY6j5rMYgBbbjOB9MUrEYO0AnFNT7uMgd/wqXBBzU7ieg6Abl6c5q0yqw56lQMVXiYljj1HtU3VW5+UAYq1tYwnuRumS2VPHUY6g1RuLWNpFCqu0rhuOD6fjWrLt3rtHD8cUk8YRuOVI798UOIQqtGOtrEY5F2qxDccZqrc2qJHIUXDOeffnn8K0o0KckjJ4571SuWLJ/tAnGehqJOx1wbkzLurdYmfaPmJGCp9+59Kj8pULeWG3Mu09xnOefetCSAnCsilQ4O31981DNEFJ/iAYkFTyKi6sbLofLQVSOhzUqEhBjvznvSBGVVY8qQcU9kwxwRjsRX2LPkoaO5LC7eZuQ4I5rTR9zJJjPOOv+frWXAuCGHfsKvICuMElT1wf8isZq52UpWRo2beTJI2Vb2xnPPGB7davFwixoduPvA56d8D/AA96zEIDcN8vqOvFaUYPlKWzg+vbNc0t7M2sTvKPLUYC7xnB6n1zmpXXzlyzYbsR2qojyNF2K9+M8dqtwK0caujbuOOevr/+usKi6o6KbtoFqzRTqGGSCevpXRW9xuCIcKzDCjHT3rDiJKMG+6RtIUcn6Vc0+YiYNkFR09z6YrB7nRe5uIAeI32YGBkce+asBWMaL8rEcA571USQgMoC7m4HGeakMpigPmclTyU/pRy2Gmw1Gdo0I+UhiCMryPU/Sk0u5E0LebtaPpgjGeeg/Gqd1MroVX78q7VJzlPw96TTy8SMjcEkEFh1HTA9B3z71D7nTDVWOihjLRrHtSPD5DZ4/wB0gfzrTtiAQpwDjI4x9PyrHiVn8sAtw2Qu3qe/41fhuREwVcNnnOMkmspO70NEtDQjc53N8oBIz0zT45BuK5ORyM/41U3s0jOoznnCjODT4pN+Rv6dTjr7U0UkW/mILKw3YBA4FSR3C7grkbsHI9PrVezIYLkrjvjp+OelTtFncDlcc5I6n3qGxNq9mV5yNrMrtkd8c/8A6qpTTbZ1TcfmYRmNRnJPYZ71JeSlJFWHIlXBLA9R/tVRvSwLKuPOKbmKjt9P6ioszeEborE7Z3QygBAVwp4DeoPc9OelXhKEMCyHcGzsdgQAe49s1n7oZjkyfIVCp1yW+nf8asJGyXyzDJCkK0ZOMe3BpJmzjc1SRgyr5TAnbkHODjJBGeDVGWBUlV4QWOPusCcjuPSrdgouXjmmChhkjGB346fjV5MeaQuwDnAC45H9au5gpuDaKcieYAqblZRwTyB/WnRQTy8SyAsvzbd3B+mfzq9hMcFRn1FJFI0bAsufQEZ//VVOV9yPaO1oj7WLLOrMEYDIZuKktFEZDbCM8MMdTQZkyGZ2VWGMhcnFESqCrK7ttO75h29vSobuznbetzVicF0e3cxgDB4z29T1qM3JD7lkbIOMMOKkjJkIiTytx6kNjP8ATNRSmNXKuFYqcBjyRjtVXtsccbXsL5sO12+V2IxuA+774NQyTRkZZUZl5AP8XuPQ1Az71OdwjB4JUA0kqxecgAVCRhiwwD7nPFHMaxhFaMm86JXV7l920j7nOOP1NLvllgRA21c7wo7e/wBarvFG822NnkBOV+Xqe1LKDB5iu+CPlIzkE1Ck0i3CN13JEmLK3z56AKM07zWwW3AAe2Sx9BVCRyz7l5CYLbRgZp1u7g4fkjnJH8qhyLdNGkjlzmQkc9h0pHZS24du/wDWkXaIweS2PSmMCz/MMZGOtUndGKSuVortbi4aOMEjpnHX/PrWjHEAm8nLg84/pUVrCka/KqqSecd6fcZihLL1POcdaFKyCbTdohLKvmgL+ODTmYbmJyfx61ThBMm5sD29BU07fKADnis3LS4OCukOUksxGOnJFP8AMC/fwfp0qtESPcfSidm2nGMj0pXDku7Gjnay7QQCMg04oU4/hGR+NQ2zs1vuZvmC9/SrQ2PsXqM8+9aLuc0tHYDlZFbIyTgcelIWMjbeAFyKWVWBOT269iKhlXYpx65x7+lVexEVcY0iorpFgnIPtnuaqyxFCWIAX35796mwDGC3YEHNMdt7IHPLEKMDpUO1jojpsRxMju6EdF/Wq7xqyKOxJz9KmMSI8k+Rgrx6ZzSTDKdeTwcehHes+U2i1uj5SAJjGMYxg881GAdpG3ofm4/zig8ZU4w3U1OojAfIJyOMdPrX2Ddj5oIRlQRwck4HNW4fvHduUgbtwqrEBsc7sYXkHvQrncXHB6Dms5I3g9LGnFkjc4JYjkZ5zVxZRsIcFscdcVm2z4wmMsRnPt6VIrMkZ2gcj155rCULm8feNeA7Ao5yxHJ+nP4VYhT5gDwAD+FZ6EGOLa4z2Hr9TWhvZQH34JGMKK5po2i7MtBFG07TkfebPXpirVnA0UiFR1OevT0/PpVS3Z2lQErgYJAGfzq+JFc4jbg+/K56Vnypm0ZNF9WUxiRGPAJ2nsKbFhwhZmK5+XPOT6VGrGILuTIwcc8j/wDVSTNvmjYqpUdAOP8AJqJM3gMu5QHAR/lYk5GeO3FWtLkZGyvzYGBmo5bbzcmVAxbk+n/6hViOA7VjUEjABbGO38qxlF30OqMo2L9vcERh5G+6SF2fdrTs2ZQgCAbxzuH+eRWXbRJAGzkkD5AT09v51tWoRkPQDj5j2/CpemhfMlqiWIMm8ttYnqc/kfeniE4VXPmAnOQQf/1mmxSo8ZjDAYPJI/WrMbrHyxwAOn/1qW6BNor+RLDdLiQGDZhlVTw31q3O6qmB1P8ACOtRIwdXcAksehHH5+tSjZGhjyxJ4b1Y1HLqXfuZvlsWjEjtjOVIHI+tElsVdWYk5PLHsex4q3LGjPk/IX644IFLOCP4TvHC5PT60WNVN9DkbhJIrnf852NjGzJ6/wA61tOBkfDRYbqvzDr3wccfQ/hWnHp0TNiY85yzHksakFolsCIlGM7iue9Z2u9TWVVPQbaoYUIcHAYnA6kdqugoHZkY7G6D/GmRFECggtGDzg4NPhUI43A454NVtqzmk9bkibQgLbSeev8AWnblLAFDu7ck1IFCldxBHPUc4+lOVVwAQGJ4UjvTRg5EDqzSBdm7AwQB17ZOe9WbdRnbJI+08HcMkfhUioBEMgE5zlhyv40iKCNu0buuc/ypW1M3K6sTSTqIPKWTMYPA24I+v41HgzsWLgHpyMVNCBhcqhIHR/8AOMVEhjhfKoD6DGfxpmKaW25CiySNtj27shQx4A/Oo5vN+0Sx3MgeVGO9sltxHbPf69KtyyykZiLqyksCo4/+tVcxtySw+bnnJP50rWNYt3uxI4Q7AW8R3Htv79+TTZUX5ApPq5IwF9gO/f2onhmjjZm2iMHOSaz5ZNzEnhQd2c9frUtvY1hDmd0y1JcNFiCKQFAwZgBwT2J+npT7cNJ+8Y8FuveqEahmUuG2vye3HtWmqCUqw2Rg9EXgAdhSlvqVOKjsWogM9SB6Y6mgFt43bSfXHU0FyAqrjaDnOKjUyM4D+nHHvVXSRzLXUniba2Gxn+ftT53LKBwD6dagJPmBQT/P8TTt46sMAj060m+xFtbjANgGT+Oc9+tJI25hjrSzyY2ZPXjgZqFXALZC896jQ1ir6seGBAzzgZyRU0abmaRxkY496q7sY68ckAVYR9yAgkrtyMetCQpqy0LS7sgA/LjkjtirVvhPLBKgtkkemaq25ICqRxt5z2pZZGR5AN2SOBWidtWcko30LLIXlL5+XA7dB9Kjk3DK5y2QePT1pI5ZJAuQcArn1qR8FgAQ244yD1A/z0pvUlXWjKc7ANJ0HXPbJ96VosRgsfnXLgnqDUkiAyE453dCO1OCuGLs2BjFSaOWmhVCbbMBs7j8vHORn0qor733cbdn9athi0hOSVXJ6d6jhiIPy8q3UCk1c2g+Xc+TtuTt24PGTjk/hU2zeg+UADgjpipEDFFPc8Hjn86QEqckfIxxzzX1LZ4EUIg/euNhIYAYPSoV4dkA47ZHJq2By5QgnA6d/pTXXdmT5cZJz7fShSvoOK6goK9Op5B6EY7VYW48wrx948nuf84xVdgMfKDknHPrTW3eYBlhggDtUPU6Yu7NWOTZJyAduSGHof6VZjYKFwCVTnGOOvWs6Fgc5I+7kHFWoHJDMgALDsa55I6Io1LS42yMy4O45A9P/rVchlO4EDC8g4/zzWNZvzydozjkVqwkAqCfmbnPXA9cVzyWppsacBJQyAJtxxnpVuBn3oSMnPAxxmqtnteMhnUdgSQOauoxXBBU9yRjn1qGuqNIy6Fhk/dsWVsn+LHHXkVZiyFBX5cDOMcVXSRF37DnnKg85FTJKMAkcggkAcfhUNrqaxuSwW5A3S8senuK0U3FTldy8dsnFZ/2lmfJHQcdcmpImTG92bB5ILVk0tzoinbU1IYxvUfNknJwMAirYkyY2dV2rk8d2+tUYpgx3EANwVIxVlWXYPMOCBzmp3Ra7EkmcnacEHJBPGT7VMC7MvygKOmB/Wq6S5O+Pado7dxVzKCNH3Dcfek1YpleQAThwzjccH3/AApshkTlly2OPX3q0cNGWKFQBgYwTxVdwWTeAApPIPXAqGy4vuRiTkBjjIJBbp+lSpcIUDblXcOdvX61nyR/MJchWHABP3l9fapnkATaAwIJK5/lU7Grgi7CUZt44XqoPc1MYzIoEo/XtWXCriSMbjjO4r3/AP11sQneqmPt2JovfRmNVcr0JYwEGMDHoDzUkwGzaqAY559Krs6kjdu8wE7uOBUpP7vfxu9jk0/I5nvqEX3ep4HUd6Z5wyVjBwehPB+lIpyDwAemKgkCojkK4HPQcE1DdtS1DUvpIrId5OfYDinBizhIySx7k7fxPpWZZ8xguAG6HGeKsxFXchmQ/XJH/wCuhNsmVNRehcQln2EiIdDzkfjTJkU7j5oAwCCwPPtjn9aSUxyQkeYqlAS2Fzkf59aqGTELbHUDHA9TWiTW5nGLetyK6mYKUyQCcn3rOLSxyYQqQ2cj0+tWnRt+1WLyMRgLUMnDYYbSDkL71luehTSitC1ar5gHm7iw6k9gKvQSKrAE98cVUgj3MVU8Dr3B471aSIgkk5wKSu2c9RrqWfM3fL0XPO6iNRhTklie9Vgp8znOOhHpVsMQgX07U76HPJW2GMcMMdD25pA248fnTFYoAD96ncIucksDUdR2sNlb159APSqjPuOM4GQMYqedt3cdOQO1U5GB3AMAevWhuxtBaFh32YHbOevNWopAj4GAjHrisxGDFcvyBjj0qSKQYZGIIwMEdP8A9dMU43NmKUvNhR83AQY6VLPgybHO5c4zk84rKhnMMqMrHe4KqfT3NTh23qAxwowB3GepP+e1Umcs6bvoaCljGSf+WnXB7e1Sgsu2QgZIyV9KhW5TcFjBB9u/oKsQFmj2kgrkjcRVo5pXW46OANBHyQ7NzQyEq/ZRhetNjlDFGDYGSAMck461I1/BGhbgYYdeMn+tFk9TJ899CP8As9vNRCCCTk/lxUc7Q2ir5hyxJOD1A/8A1iqt3r6RIXHViSPYehrl9T1Vp2GJG4yOTUya+yddLDVaj9/RHzrasdqpt+bGQfXFBlGVUE/IcHOO9Q7iY0IGB6g9/XNP8wDlcAscj/A19S0eDFlrBK+m7G4emKcAobCqQFOQSc47H9aitpcq7MRjBA9B36UpkXf8ucZz/wDWqLGy1HwHJB2jGNuT/n/Oak8vkEryBjnoR/Smx5Ul3XIBye38qsxbCM57cHHSs5M2johqBhuCr0HOeaarBMlcA/lVpisagsQUbkge1VinyBgQfmHPpUX7nRCVy5b5k4APl9Tk55rRsWDAsYwDnaCT0PpWZbSBWXbw4754xWjbAMzAAs+ecDtmuepoaNmlBJ84CjOefp/nmtCOUIpHG4AjPr9fb6VlQMFd2By3U9j9anhLTng8KTwvGD2HNZJW3NFqaHmHdt445znoP8a0bVJChwvHI+v1zWbHGA+GwWxgAnNaVsxAEYyV53DHf3qGjVOyHuwjcEKQCduQcge1CbQxkyVAOWBPf6USuVGxNo/DHPpUan5CVUllBGR6d6ya1OiErov210qOF3KM8gM3U49KtOzPAVYEZPHYVirGV2SqcMDkMRxj09q1oJRKB8xypz1FTsbJdUTWG+OQK3EeMsR39610KvlRk7snOKx45SSxYqQDyD/Orvm+XEWyWC+h5PtUadBstpIuBtG7HQgYzQGJYRsqksSc56Uzf12DknGcd6fKnlJhQVHcnn+dJoYn2ZeScH1PahkfKxhlEYOdoAPPenAPtGcZ+nBFPUoB8y4I4GOtNrQfMxY41jUK3PruOR+lSSgxuCnTpxTZXKtsdCDwME/5xVRpysmwqWHXI6KKj1FGLky3uWQY5yKfBPgHIDccDtVBJhJIcNlRyT2x7mpDIBzH0z3FTLuN0+jLW4KcnHHOCab5yliWzjHcfpUCP/fGVI5wcn2pPmUBjE5hByx6fh+dF7ByW3JGuIzGfl2j2yaz7l907/Z5cAjOG4Gf85onlJWTGQV569Kx1lkin3buWPAxkn61S2OmjST1Ni0ubiRissjlByFVxjPbirkOJCUGduc44rJiDOygLxjJZW7/AE/OtWyBC/MrFhwM/wAqp7CrRUdUTFCDyDz0xxxTo7WP5mxtPYCrQiAIA69MZ60r7UUquM9MY4H+NZ6bnE6j2RHBGqEkNu56EY/yKsEbpPkUKmB0FV1V9mQOc5C9vrU8bFULPwCPl46/jSM5K+pKIwMMBjB6Z5J+tL8qMGPzbTgLng1Gs4yCCQfSklfey9QD15pOWmhm4tvUAD8znoTwAKjkYOOSMDqB1olXdlMnpyQcUxtqKFDZI6fSkjWK1I3Pzgc5brkdKo3EgEfBAAB3Hpx7+3apZ5GTySSQMnJrB1K9EDEEkIxz0x/nPWm1c0RbW5/dEqSSSPbAq45Mlmrc7mJCjt14NcdbXztOUO7k5z7e1dHHLiOLcMLwfr6fjSa1H6m0TiFSx5BGCBzn/wDXU8ch5wM47Zx+prOSUeSQSDwSD6+1SR3axwKGI3EZ5HJp8rIlqae4I6kdSAvvWil15VttduDxtXrj/GuWn1OOIDGCexzisi88QDYdvf396taLQzeH9pudRe6ssZf5sYXb9PpXPahravGFicnsRnOPWuTvdSknkJZ8YOMdyarGWWQEANkjnPT86FB7s6YUox6G7c6qXDYb/gR7/hVVb0rGvzjI64H5VlbZZAFAJxzgmrUOnzSHLnGSe+RVKBsm9keT2ky7WWXlW4z3z2pGG0jBJA96pxNj+lXInKhRn5c59q+qkrHwVOV0WbQhCcg43cf1q2pVpAVTrxjufcVTDk7SoIwcggc1YhbzQqsOc447dqxkup1Rd9CfafmDA7cDA3fzqWF+yg4X5Tk8k0yeLbEpUqWxwR61Lbxjyg7ADPUH1Hb61k9VqbxsSNh1IA2jkYX1p0aklfkGSMY75xUdvh1YnJGew/z2qSTEckbNgRknAJ/Ss2mbx3GKWWTGCuOT9P8APpVgTPG6ZUDBJ2j+vrSzQK5SVs+YRkLwABVdoi2w5OFxgiodmbRs2a0TEEylMBxjB4rTtXwAI/ucckDNYqFhCqKPmY8c8461p2bFHBZ/ugdPpWGzLNVwTCDHgNuwD6n/ABqSIPgqx3OTy3+NVo5cjfjGB3Pf/CrEczb2Q5dSDyB29f6VM7JmtO5ZAVFDY35wAfT/ADz+dNB8tAPvIfmYZ68dqfGFQIrj8QelOeJGkOxgWx+vrWcjeLtoPtR5sbgnZGDldv5gGtC3VFhJVct0xVCJhG+0BT0yf8K04ipl3q2DjGPQ9qytZGqfYlt0RV3kYOeTx/Kp4t4kYt/q+obAOPwqNVjiT7owTy3p9KmQAgsOcZ6jr6VOg7lmHGwgADOMqeM1NwZCNwU4xg85rPWUKGcqUJzlcZI96YlwFJcqBwACe9JlJGonUAYJI5AHQ1MNqRqW7kAAHiqEVzt+8Mg9j1A9an8wsNyuDzk0h8rHSFj0UnnOO9VRCZFYDp3Hb64q2m12LEsV/IAU1nWNwRgkDHtUtlxbWiKqw4xuQgntjH0471aZAY+nPqD6+lKXXJIyc8c0qnGQpB4qRyk2QOr9CACw9fekSLy2ILHGeefyqWWPGWUHAGSfWmHc6ABeCORt6UWKUrmbqcqQwMw+cgD5DzxWTaRvOsrQW8jxofmbfhVPbJJwvXvWtNaebnJJB9ev4UkemjerEl2UYXzR5m0egJ6D6VUWm9Tp5+WPuPUZp8EsZPklWY8Eqdwb2HrXS2yeUuJclyM9M49vb6VUtItqYALDp+H+RV6JSw5XI6YAqJJLY469Vy3HoFYHqTnHP9KdGQW6DPQU8xqyjEYzx93j86aDtY4zgjqB1qdjkuOQAlgq7jwOegqO5LZA5Yr681MhC4Ge+RUUzpsbOR64NDegop3uR+WQcE5J5I7VIWIGFA9M45pifN8pJ2j1pSygcAc9OKXQrVuwg4AOOPeoZ8lTz9c8YolZSvdtxHHHFU7iYbHbJx90DsfeqSLiupQ1m5CWrBcccDn0rkdauvtDKFJU5Hfp9PbJqfxFqQL+V93BIwO/+fSudS5kmjXbwwJZyxyABxWtOnfUe5v2i4kMh44wCfarxv1KckHJx97Ga5F7y4LKArHcDnk/5Oas2sM83GTjPY03Sa1ZoqbOol1pFTarH6H0/pWdPq000m1c9ePf8KsWWikp58xyuRjnAIPp60+GwSO8L42L1PYhfT60chcILcoMs8sZJB+QZ9hU0GmySoWbOPXoa6G2s/8AQVVgvmSvvIzjCjpVyyt1cgr91SVyei/48UKDbKukrnMHSAp2lTzxwePepItNZQF2jHPP8q6qK1UxvNtAXOFAqVtMYTDgnPXnIolBi9tFaHOR2YUcqMjJyTU0MAQgbQc+vetMwgO4UEYbA56mq91GY5htHAOCMkCqUbMp1ND5kU46VZik+lVakQj1r6lq5+c05NM0EIeHbgbgeKsJJuJD4JwCR9KoIc9DkkVPA2WTufc1i4ndBmzbuHLAKM9eO/8Ah60AOWBGNpOc9Ac96zraVhLlHY/3fUmtJFBUsFI5zjFYTXKdcNVcm2GNt2BlOCBUowVw+0Dr69RVcsy7gMdcEgc/SnxS5Tn+I9T0rFm0SyzHykbCE9efftUZT/VoowOjex+lSxOQAp5X1x3qVkLKrnaXAx7Gpsa3sJACWYlU3EZQ81JbyhAZNoHODjipIcOCVJCkZ/H0qNRsLOQQh7YrB67m0ZGnasxiKvtK4+VgentWhHujIYYIwOT6Y6EVnWrgx8EnAzyematxNhFjDDzM5PrWZqmaJkwwWLDFuoAzipM7W4LbiOD6VWgOwfe7Z2tzu/wqZHJUNheR2Gce9J36mqXYtRsCflPHQ47jvxUtsziQMOT04Pb3qnCyIf3WOQOlW4lZ3yAAinnPb6VnKPY0TsWZbkgDsB15xVmK4OV6M2OSTkVmLxO2TkZAOTk1PGwIIU7c8bf5VFi9C60yqQMEJ0AJ/lUeUDkocE9d3B5/l9Kzp5mCOD8yjnPoPpVOW/ZcEEhnB69x/WplddDohG+x0+/gYC59+p/wq1A5BIcY6ng56965my1Haf3rgtggluc/WtmN0DB2wTjoOcVK1L9kzVTaI8Id2e54xVWRw77RgHqee1SRMu0v0Q89P51FJEXYvyc56Dik43YoJJ3HJOBwV4B2luhzSNcpu+cbfw71Gm9E24BAzznvUCRszk4+bjk9cen0qXfZGiSeppxTbSGxtI5yeMfhT97PvOTkn5j6mq1urMoLFd3baMZ9qXI5EYZuOq96cfMycVccFywA/j7kY/KpxCQdoHzHuetORxgg844PtUpZ2ccDkdaTdyHJhbxqpChgzjrxVtXC9fm74zxVa3VI9xJIBPLdzUm/ORGOMgZak7GMldkjsRgk8+mM00FmOMg+9RmRi/cn2PANDTbOrH8KhPUlRY52bdjjaOnOBUBb58nB5496DNjJBAJPSiEK7biTnP4ZptGiVlcm37UwcKSP0qCYsFI3AAdTTZ5SJkVAD1LHHH401nZm3HIUHufWpQ4xtqRySggKNoAOCT2FYGq3jQ+YBzkkIO5wP0rSuJ/LS4fHC5A5zjvWKLOS5aJ2Zju7MecVpDUUmczdwSTXZJ3F3IHJ4FWU0woi5BOePXP0rtbbQvLkVugXHOO+OtSy6cwgXAG5icADPH+NbKWlgUkji4tKEybUQu2T249q6PTtI8lWwrE7QWy2BnHTPetG1sXt1ACqWYdQO3tU0w8iMhFycABQe/Y+laKSKlNvQcQjRRqcOAoXAHA9h9Kgls1JjO3cOpx0IpLcsibCB5p4PzfnV+Vum0bgMAD3qWxKTjsVwp81mkXLbcBen1ohxGrKRgL8xIPXPanSRjcoZ+n3iB+dMBwk0u0DsAO3NHMUtVqWVYBo1IHytnBJqw8+/aGwCxI69BWS9ztjDNn5j064HTn2qSO4DJuJAGcDd2Hv70rq4nTvqXSEMqcA4Y57k/5FUbrayFmILs2c+w/yKkWfMR2jPOCeeBnrVdVADO3AySM9z60+o1HufLlFFFfVH50SxPzjoDVrcccfnVENgVNE+OpNRJHTSn0ZdgYq4IA4960Iplc4BGffrmsxSGB557YqeJwFxkYPH0rCcbnfTnc1xJ5ke0qGz057+9JuZXCDBHJUjnHtUFvLwqEj5upIxj3qZQpjyp3A9D396wasdcWXFclsghunAPP4/wCeasLIC2HwPc9vpWfHMx4fccc5q1DtQYZsjGR2H0rGRoki6AY2ZoTggc84z/8AWqYBXt2LbPf61DEVJKlx6ggY+nWp4jjIbAwRxj0rFvU0ixsD7JApxgZA56+3vWhHMoUAseRwc8Htj2qhGEcfKWwOp9P/ANVT7VCbc8kjax/z0rOWhvGVy9DPlB5iAgDCkHnNOMsgJQEsp4O09OeoFV2LJF8o+XJDbcH8amtpFxGwAX1yf8/lUO7NYyW6NSE7Y2CEZIw2RwPSr0OEjKlgueM+pFZKz5fAGCv904IP1qR55AqNu3Zx0GelTsrMpXkXpnGxnGC3Y+v1psayOh3yKCQWC/d/ziq0lwJAQFOFBIXHT/69RLOSp25Ltzkk1Ks9EbRHXUp3l8/Jjhh39qoshnlQDBA6Ag/nmpZGDKVXIYfxZyc96r2UvkyMzMREeAwJA+hpWV9DqpFqK3Zm/dkcclTgHFbGl3KiQI7gjPHzc/h61lW0gaVsYZWY89MenNT265dSoj3q2cdyOfyrN26HfJe6dpA2YsKF+XpzzTzjBKgDPXHes62nJRF4DDgHrVxZUYAFsAdTu6+1M8+SsPdSylh0PQDkcd6hMKohCqpIGSB/hUpnVPv5TA4J6VTnud7g7dwYHBPSk0ONyWLAiADL6DPT3NTMyrGHDcYxn2rLFwGy3KleM9f/ANdEcg6N36E55/Gs5SL5b7m2kiEAjaFxg98U8yrnk4J7n/CseHA2hfu/xKetW4nccgNnnqOKz5nsS6SRdMm/hiA3cZpxGxRlhweOP60xcnaXLZ9MgUZYYx698UOxlYf5rBCvy4x+Zpjy44XGc9feo5HG0nOe/ApkKMOSc59alNbIahpcJDwSzLgHBPv/AI1ahYBV24AHIHSqkuC2QBgcYxS7wCRtGPfrRoinHmRbZlyVCkFsdO1U53WKLeABg9G7mj7QhTIY788YyeKoancBEjyf3aAu2TyT2FVEzdkivfP5zRW6dW7g9Pf8a2NHtl3FuMJwecAeg/PP1rEtY2M5lf7xXGCcYz2rqbDaLZQgClhnOap6GUtjQijRlJPb17n2FNeMDB2jIGfp3oR2WPHfByTzTOjZB/HtVc3Q57O41mGXKgZzyarSICRhRu/vAVM2S3OMewqMqeT3A/OpUjaKIPLjjwI1AJ6npxUcjKpJYAnpyOgpk27B2k5PfsB60x8L1JJ9jR7Q3UUVZLkmf7w2gZABpxukxhhx1AzSGNdzYAz2XvUE8RKMq5yevPT3pqo7aF2SGzyi56gFS3PbHrUwaNgEQEJnsM9PaqxijVMYzkYx3b/69Byoy2BwTgetPndhqSJpJDGoCY2578D8/WsrW9WjsLZpJ5MAHgZwWP8AntWb4l8S22lwsmUknYAhM84I69P88V5Hrmt3GpXBZ3wgPyqp4Fd2Gwk62r0Rx43MqWFjrq+xj0UUV9GfBhQPTNFFAIsxyDvVhZMYK/QiqCtgVYR8jA71nKJ2Uqho27jnnPHTOMVcjYgsd4I9PT8KyVOO+KsRz8gHn69KwlG56NOd9GacLDlTkEnqB/KrErAZUHaeKz0kMm4EgHtj0pwlbGCSOOtYSgdcO5oWsjGZQxJ9RjocVpxzEhUIGQOOP0rCjl4wcDA9f881oQzjq+SBxwORWE4tO6NWjSR1XkBcEkkdBVhGXdkZwDkcd/SsyKQAkLnDHjuPp+NW4tqAqGxgYPfI9K55opWNB337Qjgrx8o7HqKUJ2ZthzkDt/n3qMsDGXU89OeadGmU8wsGOcBgfb+VRytmkWizEzhsEEc9emO+anj3tuO7aDj5feqYmPykEjdyWHQn6mplYyD5TwVJxk9Kn3djRXLIdFkJX5VbqwGMenFPhA27icgcHPGRVU8jcBnnBz0qdGLKAz4B756ge9Rrc3i9BssWN20AsTnJHIH/ANftTI4kk+acbsHkA9SKndQoLErg85PGRUrhpRknLY6f560rGkZNMqxQxYIA3Dr82ck/hV+2tecofu5KAH9aEtm+QKVCg/eOcA+tXI32oECEDsB29qTSZv7d7Eqy5UFiEIPGD29fap47htpywwFyQOcg1VO0SK5BznJ7+vNOyRuEf3uvPFZq5PMmWFZpiQPm/i5P+PSlVy0eQvy9Cu7tnn/GoY1Yc7shurZyCfQf4U2KQZYv0Hc9KTv1KT6EzFARvYIvYAevtUBbdkHOzoMDj8fWmXtyFYg8nGcDtVRb/cUVThB2UVMjRHQ2iqyqAAwHGCDk/wCFWXYoHVDyeuD/AFrK0+/LR7AyufciryS45Z0GfXv+FJ67ENO+pbV+CAMH1HOKWRzhc4zz82c1HE2c8jLdR3+lSArv67sdcVLjdCsAA2gNkjoOealQYUHhV9D+lQzXCpkgE4H9KLdjIhdgQP8AaqbXE07CSyhWKqMnGeTVOSKQjcxzu5AAxVt4yxAXA3H5vU+9RTSpDHlcZx0J6UW11C9kRygpboASuTgHP8qy70efcRrlfLBwo7fWrF1cGRA7YwvrwGI/pUellZphKwz8vCg/erVbanO9WacqLBAJVPQ49zUum3bzA5LbT0qQ26zph2J747UDybaHYowcdvWs+5WmxdE/y8YHrgZqOa7AYKNoPbGP1qm1wgAAz04BOPzqjNcgZd32hupzSvcFA03uhuClhk+vTNNN2rDCt1HGe/8A9euO13X1sImVSC5BAH/1/risvw5qN5qFyZpywgPO4nGf881oqU5R5+g3FI9CE5kKqg4PUnpimysmCu5cjrkdKofawsZ3bRzx2/T/AAqrPe4cjPbA54/Ad/as9O4zUefy0IOBnB9zVWSdRjPb045rGnvcEnOOy5PWqkt5JKcJgcnv0FXFX2IcraGw97HGHy3C8Z689+K5DxP4tFoDFb7fMH8Wfunscev6HrVpo5XGdxORznpXmni3cNRYZ+XPFejgcNGrO0jgx2LlQpuUUUdUv5byZ2kdmLHcST1NUKKK+ijFRVkfI1KkqsnKW4UUUUzMKKKKACnITRRSKjuWI2JHNTD7tFFYyPRpbFq2OCD3BFOZyVXpzz0oorF7ndB6IkQnGav2jbxzjK9DRRWVTY61sWrEnzByeTirKyMJAB37/hRRXLM1L9pIxVQT/EAffmrsPz5DAYAz6daKKy6Ercqbily6r9wsPlPQcVZLspCqSvzdRRRWMtzsjsWUkcqrFs47Hp1oErNIQcfKAaKKlMZZRjKG3HGMHj19f88VJAxZgGORnj29xRRUybvYtFyCZmRs4xtBxjinyuyum0kfjRRTBbkLTyGUruIAzjFPa5kEKkY5OOnT3ooqGXDcbLM8QUIcZHNQTuyFmDE9DgnjOaKKk2W5TluJNgBOc9z1pYmYyFCxKgE0UU5FrYsWjuNm1iNxOcdvp6VchuJPPCkhgOmRRRWEtzRbGzazO5wxHTPStGDlXB7Hg0UUnuS+pPtUFeB6UMO3TIycd6KKp7mDZWnkZEUZyC3eqVwcKoHGTRRUg9ipOPlI9zVq0zG/ynlupooraXwmMNzWEh8jPB/DrWLfXEiSJtbGaKKxRrEaJ2KcgHg9RUW5nAdmJYDj24oopAc9d2kNxdlplDEHoRxWnBiMbEACqABxRRVybaSFDV6izOwRiDjBxWfcTMOODweTRRWcNyWyCFd7EsTwRir9tEmxCVBJfnNFFdKMY7ktxGoOBxyQfevKfHIA1BcADOTx+HFFFehlv8Q87Nf4DOYooor3z5Q//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Excoriated papules with erosions and multiple hyperpigmented macules in a 25-year-old young woman who had developed acne papules a few years before. Chronic picking of papules resulted in erosions, scarring, and postinflammatory hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19491=[""].join("\n");
var outline_f19_2_19491=null;
var title_f19_2_19492="Primary ciliary dyskinesia CT";
var content_f19_2_19492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54505%7EPULM%2F70358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54505%7EPULM%2F70358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ciliary dyskinesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAUsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzH4fXGgaRNqcV1PYXCreRiOW6hISa3G8O2NpPIKnbkZOMkgEHlfCX2FfF0Mlw9tDaZly0yKygbGwMMCATwASCASDg4xXqlrbwNNJbTPZG+jW3SS7S3tWEikzb5NjceWCVB6EhVJxnFY/iTTbO78IRw2YsBIYYZ4psRRgbLdmlRSBuZiVYnP8AEVX3oA5NYNGj8V2Go3Vxp5tZ9Sc3NpBGWigiWRcHoAykE4AHQV1creGZtRiiaHQEjWOPzpFaJWXEj/MCYyjNtKllAGTgDgEVQhhsF+FrSNDbPI1o37zyowY5Rcd3xvLlSMKDgKCe9eVOxyaAJL1IvtUvlHcm47TjGRmoNox0pTSGgBNozS7RS44BPeigA2DNOjjLEKgyfSpLaCSd9qDjufSty1tkt1AUZJ6mgCraacoXdONxPQelX1UKMKMAdAKfxQBQAgAOc1IMdO1Nxk+1OAFACYppFPowPWgBoGeKXHFOAFKBxQBGVpe9Lg5NLg0ANI4pOnan7aYRQADpRnilA4pQuDQAzoOKd6d6XFKBxQAlLj1xRine1AFO4sYpMsg2v19jWXPC8L4dcemOldCB3pHiSVCkgBU0Ac3g9COlLjmrd7ZtbsSuWj9fSq3agBMUoo7UEcUAOQ/NzXsfh4+Gx4c0qO5XSz5ghM80pi8xH+0DcuM7zlNxJOFwAB6142KlRj60AekeKX0OXUELJYQMtkBtgCuGk87AJMJCBzHyeoHTGcGt3Xb7wrb6hZ+fY2E0CTSrF9mMfzpujKPIIyBtx5gCk7sAFs858hjBZhjJq6tnKy5Cn8qAOi1SXQft1xKiJIn9qO3lQqVY22eAr52AHkAbcj1xxXZ6ZqPhmWeCSytNNt4zBErQ3BjBQCWXeSZA+TjZkfeIIwQBivKmtJYxyOPXFRgENQB0WmG10fxNbRtdWdxaTrEs1x5SyLEr7WfAcEbl5GcHvWfrWqJqGqXF0tnBbLI2RFAm1FAGBgfh+dZjKTnPNOUHH3aAOi8deHhGlvdaVY+XHDaebetErpGD5zRhgHJbaTtA9euBnAteK9E0uy8ERXENqiXghtJRLHvJIkjy28liuS2SAAMADPWuot9C028Mdxf2yyCZYI5x5l3hw0ko2qruHLZRB83yjBNeOa9dXCXM+nC5neyt5nWKJpCyqAx6DpQBks7HjJxTaAcHI69jSZoAXtSUtGKADvVizgNxLtHAAyTTLWBriUIn4n0roLa3SBdqDHr70AOt4UiTaowKkNKB9KMGgAzQP1o70ZoAWlHWkANPC0AJjvSDOakC5HSjZ7UANB5pR0NOCUuzigCMEUueaXbzShRxxQAxqQjFSY5o2E0AMHQUVJt4oEZJ4GTQBEO9OHNTi2kxymPrxSGFk+8pH1oAhcBXwGDD1Gf60Ej8akKH0pNuOMCgBFOVz2pyYxShcClVfQcUAMYBwQeR6Gse+tGgfco/dk8H09q3AuOgpzRq6lWUFT1BoA5bFPVcnGKu6hZeQ+6Mfuz79DVaLG4ZoA2PF2gf8I7r9zpvni48nb+827d2VDdM+9ZKJ9K9b+IvgbxDrHi6+vNP0uaa2l2bJFZQGwijjJ9q8qkjMMzRuMOpKkehFAGv4ShSXxDpiOqsrXMQIIyCNwr7qXw/pALf8SrT+v8Az7J/hXw74LAPibSRjrdxf+hivvZZEyevX0oA8x+N+lWFt8N9Tkt7C0ik3RANHCqkfvF7gV8jzLiQjFfYfx5kQ/DTURzzJD/6MFfIEwG8mgCD14oGMUpwKVVyM80AZB13VVuXmGpXgmZdjSCdtxX0JznFZLEsSScmuh8XaGuh3sUK/bsPHvxeWv2d+pHA3HI465rn8UANPWkxTqOMnvQAmKfGhkcKvJPAowD0Fa2k2u1fNccnpQBZs7UW0QA5Y8k1aC0oFOwQe+KAG4NG3IOak2/WnBTQBCFNPCegzWro+j3Wq3S29jBJNKx4VFyf8+/SvT/D/wAMre3CS67Puc8/Z7cg49mfp+AH40AeRQ2csrKEQkk4HvXVaT4B1y/TfHYTJGf45sRL+bYz+ANe26bp1lpa7dPs7e1wMF1XLke7Hmr6h5WJyzn35oA8ls/hReHm61Czh45CsXI/IYrRi+FNoM+dqzH/AHIP8TXqUWnzEc4X2qdNNX+KQ/gKAPMU+F2jKPnvr1j7Ioof4XaMR8t9eL9UU16j/ZyY++34U02B52txxnJoA8kn+FVsebbVV+k1u38w1ULn4V6irYguNLkH+1I6H8iK9n+yBXUS52noRUhsI+gdgcemaAPDB8MNZz93S/8AwINSx/C7VT/rZdKj+szn+Qr2mSxKAHcpXpzxT009f42yR/dFAHk1r8KocKbzVIlbusMLN+pIrVt/hvocQw82oTdiAVjB/IE/rXpiWUQ7H86j+yLIxMYAj9TyaAOBXwB4aUc6fO2P71w/9KcfAvhoqQLCVR7XLn+dd39iQnq3BxnpStZIe5B96APOLn4ceHZl/di8gJPVXDY/MVg6h8KR8zabqcb+izqUJ/HkV69JY85Dds8iq8tpIp4BYf7NAHztrvhHVtGY/bLSTyx0lQbkP4jisTyWFfUKb1G0Hg9V6g/hWBrXg/SNWVn8lrG6b/ltbDAJ906H8MUAfPZQinBcV2ninwXqei5kmQXFtnC3UIyp9mHVT9fzrkTGefagCvJGroVYZB9awLq3NtMVPTsfUV0u2q19bC4hK8bhyDQBi/aJSuDI2PrTAMnqaAu04OcjrSoM9qAOi8DjPirRhn/l8h/9DFfd47/WvhHwRkeK9FPcXkP/AKGK+5RM/PC0AcJ8ezj4b3vvNF/6HXyPOfnOK+r/AI8zM3w6vAQMedF0/wB6vk6XljQBCTRuzySc0uKQdKAOi8UaNNffZoJJrK3ktJYbOS1to22wPM0hILMxJYbefQnHauA1O0ax1C5tWYOYZGjLAcHBIz+lerx2vii1uYpLqfR0kaFI99wVcO4ZhCTgEGQdVb+7jJxnPlOpLOt9cLd7vtAkYSbuu7POffNAFMigD8KcVxQBQBZtLQyTqr4243HB7VvKoAAAwBVLSIdsRkPVun0rQAoAAtSIuTSKPartjamaQfK5HQBRksewHvQBHDbu54HA79hXoPg74eSapDHeam8lrYNyuBiSb/dB6D/aP4A103gjwGlr5d5rkKyXQw0NkRlIvd/Vvb8/b0600+SaTMmXkIzgngAep9BQBz/h/QrXSLQ22k2/lK2PMlZsvJjP3m4/IVspYDb8zc9a2ljtIFxIxmb+7H8qj8ep7dhUyJaTMN9uIxkcrIwP6mgDD8iCLBI59Cad9rjjB2ITk9cYFaGo6cI4fMIITOAcg5/yKzdsUcbfLuJ96AF+3g/8sj9N3/1q0bJXni3suwHkc5NZjtHuKhVCjHKjB/X8q1IdRgfCrE0a9huBA/GgCZrb5cq/ze9UJ55IZDG0Jz2w3WtH7SgVjn/OKo3NzC7BpDuIGBgZoASKTzAQy7Wz0zn8ae8qRqC7BSeQO9VXuQ2PKDL6g9KheFiQz8sT1zQAy6uTOANuxRzjOfxp9veMm1CN4+vNRtC4B+76/WiJJAQRtAJx70AbKgMmQOPWmRqom8tMRgcAkdcelRBpIlG11OPUVFJcSpyIlAHcgmgDWS2ix1Ln3NQS+WmcxYUd1NZ0d/IcbMKemKhutfs7Un7bdQQHoVlkC4+maAJ9QZrbYVyyEcZ6j8arrePg/uTx71ian440FYsyanbZjOVCEtn8hXPv8TNODlUt7txnghVIP60Ad7vikIMkTJnqRVkWUbDKsxB6d65XR/HWhX7Ii3X2eQ8bZ12An69P1rtdIkikeQ4EgKbkHY/lQBnS2jx7gAHRhhlxkMPQjvXmXjD4eQzxz3uhB1uNzSPaEggjr8nH6V7QGtmOJA0fuhyPyqrqGnbR50DKyk/LIp4z6H0NAHyVNC0blXVlI4INRFea9t+Ivg1dVil1DToQmoxjdNEowJh3YD1/nXjEqbCQRgjjBoA5/VLXypfMUfK5yfY1TUV0V1CJrdkxyRwfeuf2kNjvmgDoPBC58W6IP+nyEf8Aj619vKQM4x1r4h8E8eLdF/6/Yf8A0MV9nY60AcT8eXA+Htz05niHX3NfKr/eNfT/AMcx/wAUDP6+fH/M18vuPmPNAEZ96AKXHNGTQBdsPHd5YadFbQQxho5VcyN824Bmbbgg/wB7r7VyuqXhvtRubsqEM8rSFR0GTnH61Vo70AKTnGalt4/MkVB1JqLb71qaRDl2k9OBQBpxoAoUDAHFShKFU5xV62t8ugKl5HICIB1J6f8A6qAEsrRpnUBWOWwAoyWPoB3Ne3fD3wa2kSC+1BVGosmI4cAi1U45J/v/AMsmn+AvBo0Z47u9Il1VlGBtG219QPVvft0HrXolnaslu7ojNEn35McA57n1oASCIQrgDJ7t3qxBdm3Lo0SyK64K8568dKjUFyQmeP4iOKljQRg47+o5NAD/ADYCvNlJuzkgz4H8qDelG/dWECkHrJIz/wBRSAcetJgZ6UAV3M9w5a4cn0A4A+g7U1rSPacAhh3zVraKdx9KAM17VgrYAYnvnFVGQgk5ORW7tGc/lgVG0ajOceh44NAGPzjnB+tSIhatIQRnPy4P0605YVCn8hx1oAhjiUKM44pJGyAFz09KlZAXxzjvUioOpIyfSgCsIuMvk+3PWk8tj92M9e/Aq5twO1IevGQDQBCIGZQHkIHTavSj7NEikgsDjruPNTkgAe3QU1h69hQBVMWDuIDY9v61xHiXwXba1NLdNcPDdyH72A2fqOK7zAwfTPp3qORQSvTA9RQB86eKfCmpaMWNxF51svS4jBx+PpXNxFtx25GO+cYr6nlhV0ZMcHggjjFeYeMvh3FPHNd6MRBL1NsRhXP+yex68fyoA8wScquxwCe56Gur8J+KdT0W4hfTrndGGBFtISVJz2Hb8K5UQAM6y5jZPlO/j5vTHapIYwG+YjCjccjIoA+hdO8daRqA8vVIbjSLzPziVd0RPsRyB+FdpYwTx3IMTRS28g5KSAo6/XNfK66peIirNM1xFtwBIc4X0B6iu58B+L/sDLZ3DF7MnADdUz0/CgD2W+t43lfyJASjEJIO+DXi/wAUPCYilbV7GMJFI22eMcCOQ9/ZT69jXsVjPHOm6I8HnH+FJf2cV1DIkiLJG6FJI2GRIp6g0AfKDoVYq3BBwRWHqkPl3G4fdfn8a9G8d6A2iavLEu4xOd0bEfeQ/dP16g+49xXF6lB5tsxGcp8w4oAPBPHi3RPT7ZD/AOhivsj7Qgzwfyr448FqT4u0QD/n9h/9DFfX4HB60AcP8cZVfwHMBnPnx9fxr5kkPzmvpL43ceB5B63Ef9a+bJB8xoASjHvSY4o/OgDmKAaAKcFINAAuM10GnJstk4wTyawo03Mq45JxXSxKAoHpQBZgXfIq8jJxXqvwr8PiSVtdu04RilordC3d/wDgPQe/0rz3wzpk2qavbWluP3kjhQfT3+gHP4V9F6bZxWsMFnari3gQRxj2Hf6nrQBu6Lp4uHaS4YiCPmTBwWz0XPv/ACrW1K8/4lpi4gSYBIIhxhQwJbHpxgHvn2qta3Vlb6QEnZ2cMxaAceYeMZbsMAD86xILmfUb6W4uNjEn5WQjbgcYHsBwMUAasShIwoHT2p/TkYFRr06U8Hk5P6YoAd69jQOAetGe56UdxigBBjIzTxyO+KbwAOf504fnQAoGevJxQOv+FH8+tOAyef1oATAPbkdDUcrtGMgdeM1MB+nOKOuB/IUAVkHOSOcc1OB06+1Jtwf604L8voaAEPHpjrULfeAI69KklYD3NVwCXJzk/hxQBKvKgnrQcc4GaRT8oK8DtSk5H+FADSPr1qJuDkev1qbBOc//AFqa/uen0oAgZe5warTxBx6EVbYdB6dM1C4yCM9e1AHlPxN8L/O2sWWAzY8+InGSBjcvvjqPxrzgH90Djjt6k19Da1AlxbMjgFWGMGvJNe8KXmnBrjaptCcxhWB47kjtQBzssIgcETRzHA3Kh+63pz1/CmsCsrAKykHp6U4xqsjF92z2IBqe4XzLmVhEY23nKg5x7UAej/DPxJJv/su+lPmr/qd33iO6mvbLSwiuLGDyZCLp4xIFONrZ7e1fJVrK8Fwk1s7LKjBlYdQa+j/hzry+I9EjMbqmpW3VMgZ7sn49R9SKAMT4j6D/AGto1wqpm6tw00Jxzjqy/wBa+fZUBYg9DX1x4hj8u6lcDJV/Mwe4bkg/nivmrx3pa6T4ju4EyIWfzIz6q3I/QigDkfCS+X4x0hehW+hH/kQV9WGeTsxr5c0JAnjbSD2a8gP/AI+K+nSy9mX86AOJ+NErN4JkDkn/AEiP+Rr52f7xr6F+MzKfBUmGB/0iPv8AWvnojLGgBtAPtQQOecmlHSgDnQgHanimj+dPFAE1mu66jB9c10ES1iabg3IwOgrobOPzHAH/AOqgD0/4PaYwlutRIGxEMCEjq7EHj6KD/wB9V63bpsXJzkj6Vg+FNMGmaJp9ltw6xiSX/fbk/kMD8K1dZv003TLu9cArBGzgZ6kdB+fFAHD/ABC8Uw7Z9HsvMMisFnlU4AHdR688Gux8CWa2fh+0Rd3KbzkY5PPSvA3uC83nGRvOcs8jHuc5/nX0Z4bmFxpFpMg+/Ep4HXgUAao6dMj3pQRketNx2xTl49MdOKAH8Y5z1pc+nT2pmeDjnpSg5z7elACgc8k496cMYOCD6YppOcHNOHTv+NADu/elAGevWmZPTHPpTlYc0APB+X15pcfXPrTR0OBk9OtB6DcB70ADgE85qPzVUhOregFEj7eAOf5VAwz97JIoAHIZySST+dOUZOOe1VnbLlEJyKnUt/dyT2NADs+/GKXP1qMsfYfjT19SD0oAd6ZqOQ8jk1NtGARjmq8pAYn+RoACBnPtVaVgH71ZB/dn9K5Pxnri6Rp7yqc3Eg2xLn+LHX6CgDN8X+KrOwmaygYveJ1OPkU4zgmuPtbh9WhdtSvkic5wJBwP8PrXN3135s6s3zOfmLn+In1pzpL5qFAXVyMZGcn0+tAF64s47eIzCW3uAjqpAHJHUGtDR9PbXrTUpP3QdAZmwuGZznofoP1rF1LzrG4aKVHWVCcq4GCDxnH4VLcPbjw/AiXRW9aViyLkAxDgA49/WgCoUjiUhHlIbqWUAY9M55rZ8H68+g61FdKWNqxCTIP4k9fqM5rn23qVdgQe2RUhd5uZeRjrjGfSgD6jnd5lfzWZ3bgs3WvKfi7pYmsrTUYx88JMEn6kH+f5V6dplyLuwtp1x++iWT8wD/WsHxtZfadC1SDZuPlGdQO5X5sfkG/OgD5402P/AIqvQ3/6e4l/8fWvocjk18/2aeV4k0bvtvYSD6jcMH+Ve8G4PPyj86AOQ+L/APyJrf8AXwn8mrwVjya92+Lchbwe2VwPtEfP4NXhe0k9KAI6Afan7D6UBT6UAc0G9TxTtwqHPbPFKh5oA09JOZ2/3a7/AMDaeL/xDp8DjKyTAMPVRy36A1wWhANctuzjb0A61698HoDP4jmuGHy29s5UehJCgfqaAPZbb95Oz4JLHOPqa5b4xGfT9AS1mGHuJlyA2flGT/MCu38Oxf6csjY8uBDM3/ARx+pFea/HXUFddFsyQZRC07rjkbmbb+hNAHla4d1VhtwcZP8A9avozwgETQbJIpBLGIVCuOjcV82KqhFZXIbPIIr3L4Q35uvD4hYjfCxUY9KAO/xx356Uc5OBnjgClUcetLjjsD6UAO5759hQep/nQB6mk6EdMUABbkfWnbiM/wA6aPTIoA4zk/ligB27rzyO3anK4Ofao2x6ioJpljUkkZ9BQBf4UZByahuLhUGIyGc9vSvLfH3js6c62mnMr3JPznnCVxVn8RtftXZ3mgmUnkSxDH6YNAHvynknOSevaiaQKgcn5QO56V47D8Vr3YFfTbTd67nA/Knr8SrqWVBe2cHksORCWBA/EkH9KAPU2bEplVgQ3Ydqu23Kgjr6Vl+G5rTU9BN/FcK1vkgMflZSDzkGtSzhZbUT7sxtzkdh60AI7Zk68VIhA45J7VSSZWYMSAD+RqyXCNHk9eKALqDjOCT1qpMf3hAzkfzq9EMSoGPDHHNZd3LHBJK0rBQpIOaAFMgERLHAwck9BXhXjfWBqeuSvz9miBji9x3P4n9K6H4geOojbS6do0uZH+WSZRjA7hf8a83jliYKkgYhv7vGPz60AX5bWIQrNJMA5UYjxkngflSR3TIUkEjo0TDyUA6Y7k54qFmhS5kMxd04AGev+AqKRxK33VXHQLnGPagCbEs0UlxcytIS+Czcsx70IbeLe6zSLcoPkIUYLZHA79M8moDG6oJFRgh6cHBpsygKgPBwc/nQBZAe5uFGcyysOWOASe5qxdRyw3ckFwT50R2sDyARVO4Ee7ELO6bQCXUA5xz07VMjmWXMm6RiAMk8k44oA+mPANp9s8C6VOrsbhrf5QTwdhxt+vGadeBZJo0bBVwUI9jwf51m/A28+0eDYVLFjYXjoQOcK4BH65rX1WMxTOufuSsB+DUAfNCJ9n8RafbSZ32+oxxg+wkxg/lXsx+8a8r8WWptviNIqfdXVY24/wBpww/nXo7O4z8zfnQBw3i3REF9qd+9m09u/lbEV2y8hkj3Yxn72XUdeVbAyKzbSws7bxZrWn3GlWkdrDMZMTo5dYy4VETLDAJdfmOcDnnGDrfESxtF0YTrHb21xJdJvuSmG5DEliASf1rmfC2jW2ozzJPHLqCEqpvYGlEcWex/d9e/zYXA60Adfc+H9PieV/7Ji8+38xXRLWUiRQ8YHlR5y5+YqHOATkngZrzDxHaw2viDUre3TZDFcyIi5zhQxAGfpXow8M2pupJjDcIkaEJH5lyJCBIqklTEH4DDAUEE55GK83161isdb1C1hZmigneNCxySAxAz70Aef8Z9qFpARzSg80Aa/h8M9+qowUsCM5xXufwbRd+syrgrsiUH6sf8K8F0iTy76FsdDXvvwZAW01kDpmE/q1AHsGgo0k80Q482Lbk+7pmvEPjJeJd+OJyhKxIkcaH0UDg/lXstldPaPIUAJeEpk9s968B+I86y+MtR3bvLV1RsdeFAOPyoAwbu6kupGkmO5yeXCgE4+lerfBQlrO/bgKGUfjXkCK0rrGh5Y8ZOPzr0D4e+IYbG7h02IgQAFmc9ZJDjJ+mOBQB7upBHGTTxWbZXSuilSOauo4b8PWgCYdOelIc8jHtTQwwMZxQWBOPyoAPocD2FGeOoGaieQZ9ulUr/AFCO3gaSVljRepJ4oAtT3Cxq3Pua8t8d+OEjElnpkgaQ5V5h2+lZXjXxvJe77TTnK254ZwcFv/rV55MX2l8EgEKT2yc4/kaANDTLA6xPP5l0RccEKwyXGeSD64qXS4UfVVtmt7K4XfsIlkK55xgYIyfwzVG2ka1Mci5VT3YZBI9KVre4hZbzyN9uzE5cZUj0J9+lAGzcaNYDU7mO/wBWgszE+0RJE0pIBxjIGAe1Z1zs+0MI2DR7vkIXH44qSa/jvobdJYVUxL5aSIcYXOQCDnIGTz15rf8ABfhmXXLyGedNlhE3zvjHmHOdg9fc9h+FAHqvwusltvBi297HE7XErXIWRQdoIAGAfYZrq5r61sNE1FpHXybeBn+meMD161Qs4FiClUG0dOOlU/FVn9v02a0iynnxsJNvfIIH9aAPPJPiTbxXnlmxkW3Xod2WPPcVtWHj3T76SOGIOGJyqtwT7V4vdSjzJLeZDHJCSmR13Z5zV7SbKG6lhg+0eVc+Q4CuMKW5wN3ryOMUAe/3Xi20htYJG3h0yxGOcYHb8f1ryH4ieLtS1O8YWvnW1gx2bcbWLY5yffk1b0jXLTUh/YmqYjYfuoJHy3lv0Iz3Hpmp00LWorhrW9jtLy3JDo7ABZAo43FQSrbSVBPJIHWgDzGASykuVIAOSfarIlQlGVNpB55611Y8B3d4jSaZHLBAJdqx37CJnznBVjww6elZE/h29skMd4YoplfBhDguxz2xx+tAEEKPdBMqoUZGQOtbmi2EDyxxNJHFJKhbaW+cRgcke57D2qrFHMIIUtIkleT5CxU8DuFzjPUkmtu9jS1017gfZxdmERorgAQnGCwb1PQDn9KAH6RFLJA0N7bGENdDBdT8yEdPccDkVzniCzew1BkmTG45jTbt+T+HI9cV0WlukOiCCXV7QWqKTIqyYnErEEquexxyRxWhqFgLnw0FvITFOuFsyWBKJzn3I927mgDzxyWYkgA9TgYFWY0BgaUsOGCgA85Izn6cVFNA9tKqyqSAe/GRSRKS2QDjr+FAHtPwEvjbR6kXYiHzFDqD1BU//WrvdQdpIGkfhnctx2ya81+CaH7LqsmMqHQfjg16Nd4NmpHbFAHhvxEwnxJTHAbULZm9/lXmuxNxGT1PX0rhviU4PxWt19Lm3z7fcrriOc0Ac38UZ0bwuqqTk3Kdv9lq8ljneMEI7KG4ODjNeo/EsD/hG0H/AE8r/wCgtXlHegC2b6cMGE0m4DAO45AquZCSSTzTDSUAcyOtKDknpR+NC8HigCzZvtnjbIGGBr374LShv7XiLAs0SsPwb/7KvnxDjFe1fA26B1gRbhmW0lU/UFT/AOymgD3HGURv9mvC/EUVqfiHdpqZ2WbXn71s4whx6fWvc4MtbqB2OK8M+KMBh8YXu4YEio4/FAP5g0AY2uixt7+6j0aQvZ8Isp7+uPbPH0rEtZXhmDxsQy8gjrV+OzmOnyTI0ZG7aYt43nI67e4+lZgBUkuM44x6UAeqeEPHCqoj1CUR7F+8xwG9q7/TvF2nXKZNzFkDs4r5vVjs4z6ClWd0/iKkUAfVEWs2ciZFxFj/AHhUNxrtjDkvdwgDnlhxXzTFql4qqqXEgA6ANTbya6k5mldyRnls0Ae4618QNLtEbybiOZ+yowOfyrzXxH4uvNaxGx8qAEnYp6/WuPTKZ3A7qu3MCRxW7faEeSRNzoAf3Xpk9Dkc8UAOtlkurlIoEMs0h2qg5yT0qyohtrgpqfmyQQuQbeOTBZxxjPIHTqM1nRu0bExsVPTcpxx0P6Vp6PPcQhmRkWBDktMMojdAw44b0I5oAdqDq9sXmjVbh2BWNW+WCMcBcev154yck1UtImlcBRn1GcZFW7topbOzSO3jjEW7fPvLNOxOcn2AAAGOPxrS8JaJJresJbx7kjB3zSKPuIOuPfPAoAl8K+Er7W5UKr5FmH2POSAB6gD+I/y717hp2mwaVb21taowt4VwmO3PJPqT1z71v6L4ft7a3iEyJHHGgEVunG1QB19PX1rcWC3CKq21t7/L19s5zQBziABAVOV9R3qtMcEuT9M1tarpbi3a4sCwAGWj5OB6j17VzWpFYLdp2YsEQuST2Az/AEoA+fdVga91/XJY4pGL3Mjr5Ue//lpzwOg96n8mRYYrXbGtw8o8u6jB3Bv7nHT16ZzVKf8AdIs4fE8gY7skHqQQCPUHv60y9LR6LYx2fFxI0jMSeQMgYHboOaAKxtrp72YSBvODMHJ4wR1zXdp4vvbPTbO0urhJm8tXMgUFto4C56ls9fpXL6iL3NjFuMF3LCFk2yZEuRwxPfIwOp6VHppi1DSyYEb7ZZoN6sch1LfeU9sFsEH60AdGniPW9UvwILezuLl0+WRoVkdEP8PPAHtiqs4vLq4gtboYwhCCIDOQc7mBI9+fwrOmlubPUgYEjitUAJ5HzEDHzHrnPb8vWrGg38en3kN1eSBTId7HaWYdRng/p3oA6CDwsI7I3N9qanzXCokKF5ORk7h2X8TVmbTNB/slY7/UnjRTvLBhuc/TofYUnhi8uhp0N9IktysM5t1O0s0yccr1zjnmsh9K8m5u7TVrd/IkYus6sFdAD1Cnr6YoAsQW3gyyuEnl1O8vzkbYTCAv/AvatHxRrNg+I5I7lV38Sw8oDgdcnJz6cViWnhu3gkE8UNxeKB8qXMbQoG9CRnP0Bq9LO1mjMdQu3u3yiW8MRAiP/Ajz+ANAGTrenmKWUbg0atlyvGD2IB5/CsRldWw4xkcEdCK6AmVreVJmaNXbMgeRXdj1yeMjrXVfDmz07VJbjT7+2jmiEfmoG5KkHnn8aAOx+FelNp3haN502yXbmcg9duML+gz+NdRermNI16s3SpowFVR0XoB7f5FVr6VYXEkjfLCjSsfYDNAHzh43u1uvis8sZBVb+NV98Mo/pXam7fJyq9a8mt7k3Xi22nbrJeK5/Fwa9Rz1oA5/4iXBk8PKpCj/AEheR/utXmPevR/iEf8AiQxjt9oX/wBBavOO9AElwixTOiSpMinAkQEK3uMgH8wKjzR2ooA5nA5pBjOBUzJgHmo1C5Oc0AOTrXovwYvltvGOnK7EK0uz/voFf5kV52ox0rW8O3rafqttcqcNE4cc+hzQB9hwkpCy5+439a8u+NenlZ9P1ALw6mB2HTIOR+hP5V6hayx3SrPCwaG5jWZGB4IODVbxD4cfxLo11YrHu+TerDGY3HKnHf8ADtQB82280ltIk9uSJo2Dq2M4I6VFDaXM/m+VGzFE3uB2XI5/UVoXVpeaTfTWs6+TOh2upII9f8DmtJL60t9NkYJLFcFBlUlJS4O4cMOwHX8KAOd3Rm2KONkiHKED7xJGQarsgxkE7vT+tPI8xxkgbj1btVnUoYLa4Mdrc/aYwo/eqhUE45AB54PGaAGtavFZW90CjRTMUGGBIK4zkduorditlvNFSQm1e8k3QxRo5MhAIbLL2PUA9+npUmmzaj4ghj06KCFrW1i3+XHH83H8WByzHNRanoEWnwyNeXsNrc7Q0dqx3SEkZw2M7Oo64oA56WKVH8uZXRl/hYYNWrKCWaQQwAs02FCqMk+1QxgSLI7SLvGAFPLNz2rTu9HubHTzdXBjQpcG3KLIC4YDPIB4oAq3MDQ3EiOjxHPCOMHHbitezuH1HQxogEcbtcpKkm0DPBBDH24OfY+1ZtnZ3WqXEnlAyOsbSsXcLwoyTkkZNNs5ngMjIdrlSu4HBAIwaANXUrmFT9ls12wQ7oUyoOV4+fPqxBJ9uOle1fBLQI7XTEu5UBlnX7S2f7o4jX6c7vxrxq0iufEF3p8C7Gupm8psABjj+Nvwz+Rr6f8ACFokWk3IRQIspAg9FUf4EflQBpuzNKeTk853d6cVZY12lwx6niiNDt6biMZy386kRnIwevIyMZz/AJ4oAjErK4XcVHauG+IcJsrDVGgGzzLWSRAP4cqcj8813bryDjA69fb/AOvXO+OYVuI4oZAD5ls6j3yWAoA+Ybm4uL6S3WSYful/dsRjaNx9PfNXL6OO8tE06S6txc2bytG0asSyEZIcjvkcfXmnztHLpamBLeFolaLDuokfkNnGc9dw/KsRXMMyzKHjlX+JTjP40AdDGdObQ9MlmnE17ZTNC8TvtzGw+U+wVv51k6HjS0vn1HzYklUIyIvzsu75sZ4HOOT71SRXnv3dot42MpC+m3GffHWtTSxax6mllqc4UsAhMmDEuQPvEHp7gjGBQAqXljcXVmltbeWwkCoJGEgxkY3ZHNTn99cSbLK3uFikIhkxtAJOdvUAj0HNX4fDdtd+JI1srq1WGGRA0cL53AH70bE4fPB65G7pVHxRoGpHVpDCqvaliIRvVMeo2k5HNAGxc/aE0yN9VnvVaUYDxMN0QVfu7SR8o54GORnnNQ6tqL/2TDcWFzPclCQbmUfvASMc9ccdK19MtZLfTY7iVYv7XtLXckGQTNtHp3wuM49KwLLxnrlxeK0hilt2IDwCFFTb3A44/OgDmLi5ur6YNcTTXEh4XexY/hW3fzypFFZC4lluydsnOFjPQrnv2z2HNbtxqcNlqdxJpcv9nkH5ZVt4nJB9wMj6+1Z16bcTGW5VHvXcmQxscc87ue5zQAxGtbe3S1uJzLFGDzFGVcMeoyeNuR/+quv+DlrPqHjFjFhIhbuZHx8qLxXG3UVstsHjkDSO/wB0sGIXHUnGPwr3v4M6B/ZXhc3d4giuNRcOxbGRAoyM+mSc0AblxAIruaIkusbFBnvjvXCfFLVRp3hHVZNwWWdRaRjoTu+8P++c13eozKWnm+6HJYA+5zivn74764st7Z6RBJn7KDJPg8eY3b6gfzoA8x0o51qy/wCu6f8AoQr0o9Ogry/S326tZu3QTIT/AN9CvRxewjru/KgDI8bH/iUxY/57D+Rrhh1rtfGE8cukoFySJgeR7GuL7UAOGWOBgfXio8U40YoA56Q89OKYDyaRjzyaQHnigCVBkYqWI4biqoY54qVCeCaAPqH4O60upeDbeFnBudOfyXB67Dyp/mPwr1bQHT7W0ROPtCYVuhDg7lI/UfiK+Uvglrqab4sFvcNiG+jNvknAVyQVP5jH419L2MjbSC2Cp+UjqPf65oA5H4y+EG1C2/t7TYf38PyXcSjp33Aenf8AMdhXhkySyHAJYg8D+gr7HEwuIvtZi81JB5d5COmD/EB6dx714J8WfAp0W+ub3T8G0BDyIOMKx4dfY55HY+3QA4TStD+2R3AmmSK5R0ijiPLMzHGSOyjue1Y08JSR0JBZSQcHI49DVmV3DNJvYyMTkk8k1FayCO4jLRrKgYEoxIDc9DjmgC1oWoXGj6lFd2r7ZF5BPSqur38+o3jXN02+d8b2xjcfU1b1i7e/vRMYo4QVCLFGm1UxxgCpNU0mawmCXVu0B8kS5mPMmTjjHv2oApQaVcvpEuprtFrFMsRYkZLEZwP896t6nfS35EkkSRRvI0mEGFLkAMf0H51Xsbh4I3gl3tav9+POBnsw9x60+/tWgdQHV4WUNG6nO5T/ACPqDQBBDkbip+bHp/nFXrrTLiyMH2pfL81BKhDBg6noRg06003fp7XHnR7/ADRGkR+84xyR244qfTLK5v7+Kwgy8kh8tFP8Pf8AADkn8aAO/wDg7oXnSXOqybWWImCP2JA3H/vkgfia950FdmlWwIwHkkc4HpwB+lcZo2mQaBokGn2v8I+Z+7MfvMfr/wDWrt/DVrJNpKkuRibMXPtyPx/pQBpGHZAzllKkfMc4/Hn0qCwPn5UfNk8MO3oD7cdar+Jp5EkSzT5YwodsfxZPGfasiGeS2lSWJyJF6H+lAHSTwAEAZLZx0wB14/MfrXP+Mo9t3ZiTgCJj78Ma7DTnS+tEuZI9rgnO3pkeleeatdHU9Sed5AFZsIrfwL2GKAPnLxzYPpfie8j2YjZjLFn+6xyPyOR+FZVmzfaElkXzyT9w9yeBXrPxa8MS3lsmqWYaSa2TZIncxgk5A9iT+B9q8kh3yGGFBl2+Veeck0Aaumrq2l+IvtWo+ZDFZ4kkaRcIU6YA75zjAov7G01tJdU0xnjDSESQuoyuADkY7Y5/A1U0eSMXRj1DfJb3aGKf5vmUZBzz3BAP4VZS0i0y4ksYZ1uBI6pFMn3Crgjccjjhu3vQBoeHrOCOe3Esgd4ZPNiIyN+0E4Gcd8c+1cpcS3WoagTIZJrhzjHJJ9gK15JNttG0bRJc2zASSO+5m56KOhHHb1pbiZfOku7OJY1cgLKnVSwPA9Oh+lAEmi3Lw2c0EqsLm3YSRNISPKA64568jg8cHiodSm+3PG8B2SkbZE9cfxCo57ghdqIV8xeT/e9xT0twYyRw7puUk4Bx1H1xQBuiyiazYRy/bItvlxyt8qq2CeB16msgMr3a+dHkFQrc4JwuM/XitjwI8DTXkOoXTW9oYhKcNt+YMO/b0qGw06fxJ4gli0+JVEsjOT1WJCep9hn8aANf4deGn1/WgXRmsrcgyDGA7fwp+Pf2r6Kv3Fvax2URHyqofA7DnH4nn8qw/DOk2fhnSraK1jzcFcxoT8wz1lf3PYen6WLiYopkclmJySe5oAxfE+rQ6TYXN7cH9xaIZGH95v4V/E4FfK7+f4g1uZ5Li3jmndpWe4lCLknPU/XpXo/xy8T+Zcpods3EbCW6IP3nI4X8Ac/U+1eXaHZXGpalFDaqryA7sM4XgHnkkUAM+yy2WuC2uFCzQ3HluAQQGDYPSuxH61zfiN8eMtSYHB+3SEf9/DWmLqXGA/H0FAFjWbKe9tYoLSGSa4kkAWONSzMcHoBWJ/wjes+fLENKvjLCokkTyGyinoSMcDiug0vVVsdQt7i7/eQRlyYypIYlGABwQcEkDgjirmo6ppWpWP2eK6l0yGErNDEkDN5Y2tmMEHkhiSGJ5Dfw9KAOJsNKvdRlaOwtJ7mRV3FYoy5A6ZwO1VpYHikaORCrqdrKwwQfQ13ula7p89zqJupZFMsNuIXvV81Q8YA+YIvzAfwgjBwN2ec8p4gvY77XdRu4t3lz3Eki7uDgsSM0AcCenQ0i8HigggnNAznI60AO7nIOaevUdfrUfNOUEigC3bSmKRWUkEHIr6j+F/iweItFjklfN9bgR3A/vej/AI/zr5VXIxW94U1y60DV4L6yfEkZ5U9GHdT6g0AfadjdNBIHi2kYIZT0ZfQ1c1a3ivtLSS2QzPCCjQMm5vLPYjHIBPX0Ncb4W1231jSoL+xfdBMOhxlT3U+hH/166MFJo/lJzkdD0NAHj/jX4fNtkv8Aw9GXQ8vaL1H+56/T8q8zuLWazuDHcQywyofmR1KsPqDX1NcRh3AkBznhgR+tZ2q6BYatEI9RtYrnjCs64YfRhyPzoA+ZZhkknOSf/wBdLOZJIY2d2bYNgDHOB/hXtGr/AAo0+UFtNu57Z85CyjzE+nY/zrlbz4ZavFIQs1lIvY+YVP5EUAcPNcCaxtojEoliyvmL1YZyM/meaigDB2GDyMGvSdO+Dvia7AZYIEj/AL8khVceuSK67Q/grbQnfrutKxH/ACxsV3E+248UAeP6aL25C2sEUs5UZSNI97epwBz9a9c8B+FpNKt3vLuHF/MOQBnyV/u59Txn8q9T0rw1oXhjSJRpmnxW8rgBJJ/nkf3OazRHwRn5e5zQBFY6XPcr5kh8uEfxtk7uewHX+XvXXaPcpE6WtsshiTsV5bPViR39AKqWMEs9jZps3JHGVLHhcZPU+g/xqtqNyDELWwYrCeJJBxv+n+zQBvX8Nrqsa7yBOnAkiO8r7EDt1/pVG00DZLvvmDxA4CRZJfPrwNorCt2NnNHcW5bevP3uv/1vWug8SatHPZ29tbuQ1yFdsf3Sen1yD+VAGvBPFDZ7LSICNSVARt2D16+vNcpregvd3ElzpxjZJPmMR+Ug/wCyehz1qqqeVMs1sfLlHR1yDXRW0w1DLKuJ1GGRTwR/exigDh7m3uEi8rZnGQVOc9eleSeLPBNzYXsmo6VbSG2kzviSPc0JPXAx93+Ve8avGBeHgeYVHmDphuf/AKxqgy7gQ3bnjrQB8w3r2rTo9uG+VcMoULn6fXrVGOV0ZYlGVDb8tyV+le/eJPA+kawzTTQG3uW5M9v8pP8AvDof88159qvwy1S1lZrKS3u4f4CW8tj9QeP1oA5m6gUL5sVu7kqkjBlO1iBlsfmDVKVxIg8mBIzuUJCgJHfj1PWuhfw14pt5NxsrvcEMalSHCqeoGCQBUEPhPXROskWmXQ2sCgbAwfqSKAKtzp0RllVJnBX5vLbGImK5xnuDjiq+j3UlgzsgVum5GHBHqPQ+/vXXQfD7XdRuGuL5rW2aT5nZ2yR/wFRj9a7TQvhppNjtkv2kv5f7rDbHn/dHX8TQB5VpOh6prMqrpljO8bHbuAPlpznBfoPx5r3Hw5oNr4esktbNC0rHMkjD5pG9T6AdhW5DFHBEkMMaKijCIgwAPYDoKCEgDsxwSck+tAEufLJdu/3m9a57xNrVvpOmXOp3xIt4Bwvd27KPc1bu7lfLlnncRW8KF5Hboqjkmvmj4l+LZPEusOYiU06AlLePnp/eI9T3oA5rXNRk1PVby9mAElxM8zBegLEk4/OnaBaXV/qcMdlbTXDqwdliQuQoIycDtWXnJxWv4Wsrq+1q1js7aWdlkV3WNCxChhkkDtzQBN4kYHxhqJ6f6bJ/6Ga0VdcfeBrJ8Rn/AIqbUCTk/bJP/QzSqelAHU+G7lLfxHpE7XCQJHdI7yF9gVR15+mRXXf2jazbYn1owbVAunXUMuw2fLufb++7jGOMgcYzXCeDp0t/FGlzvOtukc4ZpGfYAB1+btxx+Ndjc6tpAvNP+2XJuLiNzmY3YkMZ8lRmR9v7znjIx0x2oApeHtRskv8AVZLK6gilMduYdhFksm0DepO7hc4LYOWxxjORxPiGWGfXtRltiDA9xI0ZUYBUscYHau48O6nYJqOqy2N1bxSE2zQiMiySUKMOpJbIXJBYA5bHGM5HC69Lbza3qEluMwPO7IU4BUscYGOOKAOC/nQvNBoXrigBwxinqCRzUY4PvUqEY96AFA55p6H60zBNLQB6B8MPGkvhjU/LmAk064ZVnQ9QP76+4yfr0r6csbmN4obq1lSe2mXckichga+J42Ixg816n8IviB/YFw+navJK+kTDoOTC+R8w9uuQKAPpiN1lB2nj09Kad0RLffTvxyKoWskclvHc2cq3FvIAySxnII/CtG2nVwN2AffpQA7buUHHBwelOtz5V1HNsDNGwZd3IzUigAHgUAAdAKANh9XiuObiyjdv+uhFMGpSKpW0it7ZemY05H0JrMXqM5Jp6n5TxgDv60AK253LOWYnqSck/jRj/ex7U5WIJH6Ck64z296AFILRGPc2wtkrk4z9P600L0OeOn+eKd/DnmgEgYU8k9jQAwgDjJ29KrxRBZ2zkbVGPXqTVlyCW3Yz0+p/z/OlEe0IT1IwSexoAFAxknPelQ7WBVirDupwRSDIU7cDPfFHfls80ANKjoeSck01lBBBz7GpCcL6cc0EDJ/rQBWKDA49a0tGNhbzb7i2DSj7snJH4rnFU3XABGKdHnIz9KAOjMSXgxbx2EueRhFyB6YOCKb/AGWY8yTQafCg4y0S8fjWFngHOR79qHJYDcST70ALq/2X7ZutQiptCloxhWb2FVjgEAck9hT5CNwyCfwqvPcJCCP4j7UAPdljyzE5NZtzMGSSeeVYraMFnkc4VQKbLKpie5uZFhtohueRzgACvAPij8RJ9cup9P05zFpUTFFC9ZsH7x+vpQBL8VfiENaB0rSCyaYjZZ+hnI7n29vxryt3LUSvuPXNREmgB2e5rW8OJJPrdisKO2JkLBATgbhk1j1seFbq4tNcsmtp5YS0yIxjcrlSwyDjtQA/xHIqa9qamNWY3jsH5yMM3HXGDkduw6c5pref7H61Y8S8eJNTyMgXUnH/AAI1m4546UAdR4PaG8123jnihfiQxxzMAjyhGManOBgvtGDwehrtNMtrfyymv2+n2t9cyPFLD9lQFlWFSuNuBEctkkAEnHuDwvgmwg1DXoYbwBoAksrKzlFOyNnwWHIB28kdq63WNIsLGyW5t9JW9e7wuIJpGjgPlg5jI5OSSRuzwpHPJoATRLES+Ir+LSLGwmsokiklkVDeiNMDKxhh8zMTjGMgjqACa4fVfLOp3flQtbx+a22FusYycKfp0rpotHsYPEeo2EsN2USyklhDyqGVxCZAzFMgjjgA+me4rjWzk8UAcyaSjmlxjt1FAC55pVNMzzQDQBMDQDUQJ7U7oeaAJFPOalR8cg1XDc8inK2TxQB23g7xxq/hu4T7LeTfZgctAWLIf+Anivf/AA18QdN1qxSa8je2/hM8QLR59Gxyp9jXycrcVq6D4h1LRJjLpl3LblvvhW+Vh7jofxoA+zrOdbmMSaddRXcf+w4OPrVhbiUDMsLZB/hr5q0H4iNOx+22cBuOP3sDG3kz65Tg/lXa2PxHCbQdQ1SD2mijuFH4/KTQB7El7ET8xKkdsVYjuoWB2yAY9RivLrX4jRvgHUtMl56TW8sR/EgEVrW3ji3mwGi0mbP/ADzvlU/kwBoA78Tx9nz64NN89QxAJP4VyCeKLVwM6TKw6/u54nH/AKFUq+IbQdNI1D8l/wDiqAOrEyEHk9elNknAAzIgA6jPWuWbxLbdtGvQM92Qf+zVG3imMKSmjS59DNCP60AdN9o3uBG+R6KpJP40rSFU2kS5HOec/nXFX/jHVtoGnaTBGnTfLMJCPwUj+dUrPxd4qXm4s7GYE9lZMj67v6UAeiR3ZIIOxv0NLHOw5lVgO2F6VyNl4uv5VYajoLsext51k4+hwatDxHZFszaXqsAxyfIJA/75NAHVJKH5BB/GpA3HOB+NcmPFGhbdslzdQk8/PC4x+lJ/wkmg7c/2lIf+2b//ABNAHWEnH3lH40jSKpGXA+p/+vXJt4i0WQgRy30w9I7d2z+lDa5aA/udJ1WYHqWi2A/99EUAdQ91Co+aXP0ph1JWyFUyZ7heRXHXPi2K3/5cbG297u+jB/IZNYWofERVyP7WtIwOiWNq0zf99PhaAPRZTcPlnIiQfeZmwK5fXfF+kaNbyus631wgyQrYRT7t0/LJryvxH8Q7YOx+zTXsuBhr6ctnj/nmuFH5mvPfEPirUNbCxXUiJbIcpBCgRAfXA6n3NAGv428d6r4huZVmu5BalsrDGSsYx6D+tcWz7jknmoy5J4pueTQA8mkyaQdelKSaAHqfWrlhfXVhN5tlcz20pG3fDIUOPTI+lUQaeDQB33hizsNT0ad7yxlnvma4ka6likZWCxh8CQOArcMeVbllzxWlb6Jp8fijUrb+xUbTomhlkknll22sJXLAbSCzkkBevIxg544PRby7juI7WCW8ME0iiSC3lKGXnG0deT0HB+leowWNob9y+vazZziS2t5/LuvtB8xjKfK3gLzhRg4IDFhz1ABTsPDuj2OnaXqmLuZrlpElt1YMYwYiRlUYOQcgkDHynB7bkkjgtE1MxLciB7GCeNLO4lhRoTKqMjKxY5IZgMkgehzxRu/C50jTtP1ttTuo4pbry90ULeZHgjLBsgZ6455x9cZuqXGr2virUrGx1O/Z2ujamRrggy4Yqm9s4/OgCbxM50OS0fSxLo+pvGwuYLW4k/dqWyqsSchsdVzxxkA5FcaTk89a9X1XwtJO8R13UNRv3jgU/vbhYh5jSurbGlONo2DHdsg8CvMdQtvst/cW+JF8qRkxIu1hg45HODQByNKO9FFADe59jQnWiigBy0MTkUUUAIPvGpB1oooAUdKCaKKAJFYggg4NdNo88ssH7xy2DgE+lFFAGnGMjmpYCS+CcjrRRQBIAM9BRnn8qKKAA8D8aH+4PcUUUAR4G4cClYDYOBRRQAvTJHBp0FzPDgwzyxnPVHI/lRRQBcTXdWjUBNUvgOf+W7f41ZXX9XNszf2pe7lIwRO3qPf3oooAgk1rVJhiXUr5wexuHP8AWqs80shzJI7n1Zif50UUAQZxVfUJGitneM7WHQ0UUAcnJI7uWdizHqTUeTRRQAgPJp69TRRQA4dKCaKKADNSJ1oooAu6dcS2uoWtxbuUmhlWRGH8LAgg/nWzda/qU0iMZ0Qq8cgEUKRjcm7acKAMjc350UUAQpq+oGRC91K4Eok2SHehPHVTwfujgjHAq1qGvaldrqKTXAKX0sctwqxogkdc7W4AwfmPTrnmiigCbS9cv7dFhWWN4ViEYjmhSVcBy44YEZDMxz15NYt5cS3V3NcXDl5pXLux/iJOSaKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution computed tomography of a 26-year-old man with primary ciliary dyskinesia demonstrating extensive bilateral bronchiectasis. At 10 years of age he underwent a lobectomy of his left lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sten-Erik Bergstr&ouml;m, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ciliary dyskinesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a 26-year-old man with primary ciliary dyskinesia demonstrates extensive bilateral bronchiectasis. The patient underwent underwent a lobectomy of his left lower lobe at 10 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sten-Erik Bergstr&ouml;m, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19492=[""].join("\n");
var outline_f19_2_19492=null;
var title_f19_2_19493="Pustular psoriasis 2";
var content_f19_2_19493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 28-year-old woman developed fever, widespread erythema, and pustules at 34 weeks gestation during her first pregnancy. She was hospitalized for several months, and the eruption resolved within the first month after delivery of a normal full term infant. A skin biopsy showed changes typical of pustular psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19493=[""].join("\n");
var outline_f19_2_19493=null;
var title_f19_2_19494="Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients";
var content_f19_2_19494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19494/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19494/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/2/19494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal meningoencephalitis is the most frequently encountered manifestation of cryptococcosis. The term \"meningoencephalitis\" is more appropriate than \"meningitis\" since histopathological examination has demonstrated that the brain parenchyma is almost always involved.",
"   </p>",
"   <p>",
"    Cryptococcal meningoencephalitis is an important opportunistic infection in immunosuppressed patients. Issues related to patients with HIV are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients will be reviewed here. Other issues related to cryptococcal infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. neoformans causes infection following inhalation through the respiratory tract. The organism disseminates hematogenously and has a propensity to localize to the central nervous system (CNS). The basis for the tropism for the CNS is uncertain, but a number of hypotheses have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CSF is a favorable growth medium for the organism as it lacks the factors present in serum that inhibit cryptococcal growth [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/1\">",
"       1",
"      </a>",
"      ]. In the serum, the organism activates the alternative complement pathway, but complement activity in the CSF is very low [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dopamine levels in the CNS may promote cryptococcal virulence by serving as a substrate for melanin production by the organism [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"       \"Microbiology and epidemiology of cryptococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Production of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      by the organism may contribute to brain edema and inhibit phagocyte function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inflammatory response in the brain is generally milder than that seen in bacterial meningoencephalitis. The inflammatory cell infiltrate is predominantly comprised of mononuclear cells with occasional polymorphonuclear leukocytes. In general, involvement of the brain is diffuse, but localized infection (ie, cryptococcoma) can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with cryptococcal meningitis are immunocompromised. The most common forms of immunosuppression other than HIV include glucocorticoid therapy, solid organ transplantation, cancer (particularly hematologic malignancy), and other conditions such as sarcoidosis and hepatic failure. In a multicenter retrospective study of 157 cases of CNS cryptococcosis in HIV-negative patients, 30 percent had no apparent underlying condition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other issues related to epidemiology of cryptococcal infection are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical presentation of cryptococcal meningoencephalitis in HIV seronegative patients is variable. Some patients have symptoms for up to several months prior to diagnosis, whereas others present with an acute illness of only a few days. Most patients present with signs and symptoms of subacute meningoencephalitis; fever is observed in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Typically, headache, lethargy, personality changes, and memory loss develop over 2 to 4 weeks. Patients may also present with disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among solid organ transplant recipients, cryptococcal infection occurs in an average of 2.8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The median time to disease onset is 21 months after transplantation; 68 percent of cases occur &gt;1 year after transplantation. Central nervous system involvement and disseminated infection have been documented in 52 to 61 percent of patients with cryptococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Approximately 25 percent of transplant recipients with C. neoformans disease have fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of cryptococcal meningoencephalitis can be challenging because of the subacute onset of symptoms and nonspecific presentation. The disease should be suspected in any immunocompromised patient with fever, headache, and signs or symptoms referable to the CNS. C. neoformans should also be considered in immunocompetent individuals presenting with subacute to chronic meningitis. A lumbar puncture is necessary to definitively diagnose cryptococcal meningoencephalitis, although this procedure should be delayed in the setting of focal neurologic signs, papilledema, or impaired mentation pending the results of radiographic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture with measurement of the opening pressure and careful evaluation of the cerebrospinal fluid (CSF) with India ink",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cryptococcal antigen testing should suggest the diagnosis in most cases. Culture nearly always establishes the diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The opening pressure may be markedly elevated. Almost 70 percent of AIDS patients with cryptococcal meningoencephalitis have opening pressures &gt;200 mmH20 on the initial lumbar puncture [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/6\">",
"       6",
"      </a>",
"      ]. Increased intracranial pressure is observed less frequently in non-HIV-infected patients.",
"     </li>",
"     <li>",
"      Examination of the CSF with India ink demonstrates encapsulated yeast forms in approximately 75 percent of HIV-infected patients and in 50 percent of non-HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Gram stain is usually not sufficient since the organisms stain poorly and can be confused with host cells (",
"      <a class=\"graphic graphic_picture graphicRef58455 graphicRef63752 graphicRef75483 \" href=\"UTD.htm?18/51/19251\">",
"       picture 1A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cell counts of the CSF are characteristically low in HIV-associated infection (0 to 50",
"      <span class=\"nowrap\">",
"       cells/mm3),",
"      </span>",
"      and higher in non-HIV cases (20 to 200",
"      <span class=\"nowrap\">",
"       cells/mm3).",
"      </span>",
"      Mononuclear cells predominate in both HIV-infected and noninfected patients (50 to 80 percent).",
"     </li>",
"     <li>",
"      Low glucose levels and elevated protein levels are frequently observed. Inflammatory cell counts have a lymphocytic predominance. Some patients present with normal CSF protein and glucose values [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of cryptococcal meningoencephalitis is established by culturing the organism from the CSF. Cultures are positive in about 90 percent of non-AIDS patients. C. neoformans usually takes three to five days to grow in the laboratory. At least 3 to 5 mL of CSF should be used for culture; the yield may be increased by culturing more than 15 mL of CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryptococcal antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) cryptococcal antigen testing is an important adjunct to CSF culture for establishing the diagnosis of cryptococcal meningoencephalitis. Results of the antigen test can be obtained from most laboratories very soon after the lumbar puncture is performed. A positive antigen test suggests the presence of cryptococcal infection before the cultures results are complete. The antigen test is very sensitive and specific in the CSF. In a study of four latex agglutination test assays and one enzyme linked immunoassay, all performed well, with sensitivities ranging from 93 to 100 percent and specificities of 93 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum cryptococcal antigen testing in patients without HIV infection cannot be used to rule out cryptococcal meningoencephalitis, as the sensitivity is lower than in HIV-infected patients. Among organ transplant recipients, patients with CNS or disseminated cryptococcosis are more likely to have a positive serum cryptococcal antigen result than patients with pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Cryptococcal antigen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cryptococcal antigen can be quantified by evaluating serial dilutions of CSF or serum. The height of the antigen titer generally correlates with the burden of organisms. However, serial measurement of antigen titers is not a reliable indicator of response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=see_link&amp;anchor=H2294041#H2294041\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\", section on 'Repeat lumbar puncture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    False positive serum cryptococcal antigen tests can occur in the setting of infections due to the fungus Trichosporon asahii (formerly T. beigelii) or the bacterial genera Stomatococcus or Capnocytophaga [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. False positive CSF cryptococcal antigen results have been reported rarely following exposure of samples to disinfectants or soap, or after samples were placed into an anaerobic transport vial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. False negative serum cryptococcal antigen tests can occur with samples that contain a large amount of antigen (the prozone phenomenon) if the laboratory is using a latex agglutination assay and doesn&rsquo;t pretreat the sample with pronase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/15\">",
"     15",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extraneural cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cryptococcal meningoencephalitis is occasionally made by recovering C. neoformans from an extraneural site before CNS disease is suspected. This is especially true in patients with HIV infection who have a high likelihood of extraneural disease involving the respiratory tract, urinary tract or bloodstream at the same time as CNS infection. As an example, blood cultures have been positive for cryptococci in approximately two-thirds of HIV-associated cases of meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, lumbar puncture should be considered for patients with positive serum cryptococcal antigen or extraneural culture to rule out CNS involvement. Immunocompetent individuals with only pulmonary involvement who have no CNS signs or symptoms may not require a lumbar puncture prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging of the brain with computed tomography (CT) or magnetic resonance imaging (MRI) prior to lumbar puncture is important in the setting of focal neurologic signs, papilledema or impaired mentation. MRI is more effective than CT for identifying CNS cryptococcal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic images frequently show no abnormality or cerebral atrophy without obstruction or other pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/23\">",
"     23",
"    </a>",
"    ]. Less commonly, hydrocephalus may be seen. Mass lesions are seen in about 10 percent of patients with CNS cryptococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some brain lesions persist radiographically for long periods",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    develop surrounding edema during effective antifungal therapy, presumably because of an immunological response associated with control of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19494/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptococcal meningoencephalitis is the most frequently encountered manifestation of cryptococcosis. The term \"meningoencephalitis\" is more appropriate than \"meningitis\" since histopathological examination has demonstrated that the brain parenchyma is almost always involved. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. neoformans causes infection following inhalation through the respiratory tract. The organism disseminates hematogenously and has a propensity to localize to the central nervous system. The inflammatory response in the brain is generally milder than that seen in bacterial meningoencephalitis. The inflammatory cell infiltrate is predominantly comprised of mononuclear cells with occasional polymorphonuclear leukocytes. In general involvement of the brain is diffuse, but localized infection (ie, cryptococcoma) can also occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with cryptococcal meningitis are immunocompromised. The most common forms of immunosuppression other than HIV include glucocorticoid therapy, solid organ transplantation, cancer (particularly hematologic malignancy), and other conditions such as sarcoidosis and hepatic failure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical presentation is variable. Some patients have symptoms for up to several months prior to diagnosis, whereas others present with an acute illness of only a few days. Fever is observed in approximately 50 percent of cases. Typically headache, lethargy, personality changes, and memory loss develop over two to four weeks. Patients may also present with disseminated disease (eg, &gt;1 noncontiguous site). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A lumbar puncture is necessary for diagnosis of cryptococcal meningoencephalitis. The opening pressure should be measured, along with India ink evaluation, cryptococcal antigen testing, fungal culture, and routine spinal fluid studies. The diagnosis is established definitively by culturing the organism from the spinal fluid. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cerebrospinal fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum cryptococcal antigen testing is useful for evaluation of patients without HIV infection, although a negative result cannot be used to rule out cryptococcal meningoencephalitis. The height of the antigen titer generally correlates with the burden of organisms, although serial measurement of antigen titers is not a reliable indicator of response to therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cryptococcal antigen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic imaging of the brain with computed tomography (CT) or magnetic resonance imaging (MRI) prior to lumbar puncture is important in the setting of focal neurologic signs, papilledema, or impaired mentation. Radiographic images frequently show no abnormality or cerebral atrophy without obstruction or other pathology. Less commonly, hydrocephalus may be seen. Mass lesions are seen in about 10 percent of patients with CNS cryptococcal infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/1\">",
"      Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Infect Dis 1966; 116:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/2\">",
"      Diamond RD, May JE, Kane MA, et al. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974; 112:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/3\">",
"      Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986; 51:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/4\">",
"      Wong B, Perfect JR, Beggs S, Wright KA. Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun 1990; 58:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/5\">",
"      Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     Cox, GM, Perfect, JR. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. In: Topley and Wilson's Microbiology and Microbial Infections, 9th ed, Ajello, Edward (Ed), Arnold Press, London 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/7\">",
"      Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/8\">",
"      Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/9\">",
"      Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992; 24:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/10\">",
"      Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/11\">",
"      Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/12\">",
"      Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/13\">",
"      Shaunak S, Schell WA, Perfect JR. Cryptococcal meningitis with normal cerebrospinal fluid. J Infect Dis 1989; 160:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/14\">",
"      Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/15\">",
"      Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/16\">",
"      Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/17\">",
"      McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/18\">",
"      Westerink MA, Amsterdam D, Petell RJ, et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/19\">",
"      Blevins LB, Fenn J, Segal H, et al. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 1995; 33:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/20\">",
"      Boom WH, Piper DJ, Ruoff KL, Ferraro MJ. New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol 1985; 22:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/21\">",
"      Wilson DA, Sholtis M, Parshall S, et al. False-positive cryptococcal antigen test associated with use of BBL Port-a-Cul transport vials. J Clin Microbiol 2011; 49:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/22\">",
"      Charlier C, Dromer F, L&eacute;v&ecirc;que C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008; 3:e1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/23\">",
"      Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/24\">",
"      Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000; 31:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19494/abstract/25\">",
"      Einsiedel L, Gordon DL, Dyer JR. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin Infect Dis 2004; 39:e78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2447 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19494=[""].join("\n");
var outline_f19_2_19494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryptococcal antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extraneural cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2447|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/12/44238\" title=\"picture 1A\">",
"      Cryptococcus neoformans in CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/63/9213\" title=\"picture 1B\">",
"      C neoformans india ink",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/15/17663\" title=\"picture 1C\">",
"      C neoformans Sabourauds agar",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19495="Trifluoperazine: Drug information";
var content_f19_2_19495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trifluoperazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/39/41588?source=see_link\">",
"    see \"Trifluoperazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/15/31990?source=see_link\">",
"    see \"Trifluoperazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trifluoperazine&reg;;",
"     </li>",
"     <li>",
"      Novo-Trifluzine;",
"     </li>",
"     <li>",
"      PMS-Trifluoperazine;",
"     </li>",
"     <li>",
"      Terfluzine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Outpatients: 1-2 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hospitalized or well supervised patient: Initial: 2-5 mg twice daily with optimum response in the 15-20 mg/day range; do not exceed 40 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonpsychotic anxiety:",
"     </b>",
"     Oral: 1-2 mg twice daily; maximum: 6 mg/day; therapy for anxiety should not exceed 12 weeks; do not exceed 6 mg/day for longer than 12 weeks when treating anxiety; agitation, jitteriness, or insomnia may be confused with original neurotic or psychotic symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F231064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/15/31990?source=see_link\">",
"      see \"Trifluoperazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"     Children 6-12 years: Oral: Hospitalized or well supervised patients: Initial: 1 mg 1-2 times/day, gradually increase until symptoms are controlled or adverse effects become troublesome; maximum: 15 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychoses:",
"     </b>",
"     Oral: Refer to adult dosing. Dose selection should start at the low end of the dosage range and titration must be gradual.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Behavioral symptoms associated with dementia behavior (unlabeled use):",
"     </b>",
"     Oral: Initial: 0.5-1 mg 1-2 times/day; increase dose at 4- to 7-day intervals by 0.5-1 mg/day; increase dosing intervals (bid, tid, etc) as necessary to control response or side effects. Maximum daily dose: 40 mg. Gradual increases (titration) may prevent some side effects or decrease their severity.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F231050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia; short-term treatment of generalized nonpsychotic anxiety",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F231075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of psychotic disorders; behavioral symptoms associated with dementia behavior (elderly); psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trifluoperazine may be confused with trihexyphenidyl",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Stelazine may be confused with selegiline",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypotension, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness; extrapyramidal symptoms (akathisia, dystonias, pseudoparkinsonism, tardive dyskinesia); headache, impairment of temperature regulation, lowering of seizure threshold, neuroleptic malignant syndrome (NMS)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Discoloration of skin (blue-gray), increased sensitivity to sun, photosensitivity, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, galactorrhea, gynecomastia, hyperglycemia, hypoglycemia, lactation, libido (changes in), menstrual cycle (changes in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, stomach pain, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficulty in urination, ejaculatory disturbances, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cornea and lens changes, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trifluoperazine or any component of the formulation (cross-reactivity between phenothiazines may occur); severe CNS depression; bone marrow suppression; blood dyscrasias; severe hepatic disease; coma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other antipsychotics, trifluoperazine has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Liver damage and jaundice of the cholestatic type of hepatitis have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Trifluoperazine is not approved for  the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; contraindicated in patients with pre-existing hepatic damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May also be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). Increased risk for developing tardive dyskinesia, particularly elderly women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F231040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression). Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10927364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies, except when using doses that were also maternally toxic. Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F231053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10927365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trifluoperazine is excreted into breast milk and was measurable in the serum of three nursing infants (adverse events were not reported). Milk concentrations may be higher than those found in the maternal serum. Infants should be monitored for signs of adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F231034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trifluoperazine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $58.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $85.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $108.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $163.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F231020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F231023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic response and blood levels have not been established",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trifluoperazine (PL);",
"     </li>",
"     <li>",
"      Eskazine (ES);",
"     </li>",
"     <li>",
"      Espazine (IN);",
"     </li>",
"     <li>",
"      Flupazine (MX);",
"     </li>",
"     <li>",
"      Flurazin (TW);",
"     </li>",
"     <li>",
"      Fuzine (TW);",
"     </li>",
"     <li>",
"      Jatroneural (DE);",
"     </li>",
"     <li>",
"      Jatroneural Retard (AT);",
"     </li>",
"     <li>",
"      Leptazine (VE);",
"     </li>",
"     <li>",
"      Modalina (IT);",
"     </li>",
"     <li>",
"      Modiur (CO);",
"     </li>",
"     <li>",
"      Stelazine (AE, AR, AU, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CO, CY, EG, ET, GB, GH, GM, GN, GR, GY, HK, ID, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NZ, OM, PH, PK, PL, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Stelazine Forte Solution (GB, IE);",
"     </li>",
"     <li>",
"      Stelosi (ID);",
"     </li>",
"     <li>",
"      Terflurazine (ZA);",
"     </li>",
"     <li>",
"      Terfluzine (FR, HU, PL);",
"     </li>",
"     <li>",
"      Triflumed (TH);",
"     </li>",
"     <li>",
"      Trinicalm (IN);",
"     </li>",
"     <li>",
"      Triozine (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trifluoperazine is a piperazine phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: &gt;24 hours with chronic use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beighton PH and Wilkinson DJ, &ldquo;Trifluoperazine Overdosage,&rdquo;",
"      <i>",
"       Practitioner",
"      </i>",
"      , 1967, 199(189):73-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/6044122/pubmed\" id=\"6044122\" target=\"_blank\">",
"        6044122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      FitzGerald MX and FitzGerald O, &ldquo;Reaction to Trifluoperazine Abuse,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1969, 1(7605):1100.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peabody CA, Warner MD, Whiteford HA, et al, &ldquo;Neuroleptics and the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1987, 35(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/2880887/pubmed\" id=\"2880887\" target=\"_blank\">",
"        2880887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Risse SC and Barnes R, &ldquo;Pharmacologic Treatment of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(5):368-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/2870097/pubmed\" id=\"2870097\" target=\"_blank\">",
"        2870097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz BL, Woerner MG, Kane JM, et al, &ldquo;Prospective Study of Tardive Dyskinesia Incidence in the Elderly,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(17):2402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/1681122/pubmed\" id=\"1681122\" target=\"_blank\">",
"        1681122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert RD, &ldquo;Therapeutic Drug Monitoring: Psychotropic Drugs,&rdquo;",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 1984, 6:403-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshida K, Smith B, and Kumar R, \"Psychotropic Drugs in Mothers' Milk: A Comprehensive Review of Assay Methods, Pharmacokinetics and of Safety of Breast-Feeding,\"",
"      <i>",
"       J Psychopharmacol",
"      </i>",
"      , 1999, 13(1):64-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/2/19495/abstract-text/10221361/pubmed\" id=\"10221361\" target=\"_blank\">",
"        10221361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10020 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19495=[""].join("\n");
var outline_f19_2_19495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290572\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231044\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231078\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231048\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231064\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231049\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231050\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231022\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231006\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231075\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231086\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231076\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231010\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231073\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231015\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231040\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927364\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231053\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927365\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231034\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231033\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231020\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231023\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231035\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231009\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231029\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10020|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/39/41588?source=related_link\">",
"      Trifluoperazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/15/31990?source=related_link\">",
"      Trifluoperazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19496="Persistent or recurrent Cushing’s disease: Surgical adrenalectomy";
var content_f19_2_19496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19496/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/2/19496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H362181283\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for patients with Cushing's disease (ACTH-secreting pituitary tumor) is transsphenoidal surgery and resection of the pituitary tumor. However, for patients with persistent or recurrent Cushing's disease, adrenalectomy, which can be achieved either surgically or medically (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ), is sometimes recommended for definitive cure.",
"   </p>",
"   <p>",
"    Surgical adrenalectomy for persistent or recurrent Cushing&rsquo;s disease is reviewed here. An overview of the treatment of Cushing&rsquo;s syndrome, medical therapy of hypercortisolism, and primary therapy for Cushing&rsquo;s disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1240291812\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO CUSHING'S DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's disease is caused by pituitary corticotropin-(ACTH)-secreting tumors. These corticotroph tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter). The progressive stages of treatment that may be required to cure a patient of Cushing's disease are shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef76949 \" href=\"UTD.htm?33/49/34589\">",
"     algorithm 1",
"    </a>",
"    ); this approach is consistent with a 2008 consensus statement on the treatment of ACTH-dependent Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transsphenoidal microadenomectomy is currently the treatment of choice for Cushing's disease. A neurosurgeon with expertise in transsphenoidal surgery for Cushing's patients can achieve an initial cure rate of 80 to 90 percent with microadenomas, but less than 60 percent with macroadenomas. A meta-analysis of 18 reports since 1995 showed an overall initial cure rate for micro- and macroadenomas combined of 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/2\">",
"     2",
"    </a>",
"    ]. It is important to recognize that patients who are initially &ldquo;cured&rdquo; should be considered to be in remission rather than cured, as some will recur. Overall, remission from centers with less experience may be much lower, approaching only 50 percent long-term cure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\", section on 'Transsphenoidal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with clear persistent disease after transsphenoidal surgery, there are five therapeutic options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat surgery of residual corticotroph adenoma, particularly if residual tumor is visible on MRI. However, reoperation has a lower success rate than initial surgery and many patients develop other pituitary hormone deficiencies as a result of the second procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link&amp;anchor=H13#H13\">",
"       \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\", section on 'Treatment if surgery fails'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Irradiation of the pituitary gland. This approach may also decrease the occurrence of Nelson's syndrome in patients not cured by irradiation for whom adrenalectomy becomes necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link&amp;anchor=H14#H14\">",
"       \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\", section on 'Pituitary irradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical therapy with adrenal enzyme inhibitors or other agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical adrenalectomy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , an adrenolytic agent, may be used during or after pituitary irradiation in patients with Cushing&rsquo;s disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H6330785#H6330785\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Mitotane'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical adrenalectomy. (See",
"      <a class=\"local\" href=\"#H362181869\">",
"       'Surgical adrenalectomy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice for therapy is individualized. For example, a young woman desiring fertility might choose to have adrenalectomy or repeat transsphenoidal exploration to avoid hypogonadism associated with radiotherapy and the teratogenicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    . A patient with extreme hypercortisolism might choose adrenalectomy to achieve rapid control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181869\">",
"    <span class=\"h1\">",
"     SURGICAL ADRENALECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181877\">",
"    <span class=\"h2\">",
"     Bilateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral total surgical adrenalectomy is indicated as the definitive treatment for patients in whom rapid cure of hypercortisolism is necessary or when all other therapies have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. It has also been successfully used in several pregnant women with Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome in pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There had been reluctance historically to recommend adrenalectomy in patients with refractory Cushing's disease for several reasons, all of which have become less of a concern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical morbidity with open adrenalectomy &mdash; Complication rates are now much lower as a result of laparoscopic adrenalectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20073?source=see_link&amp;anchor=H31886306#H31886306\">",
"       \"Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures\", section on 'Laparoscopic versus open adrenalectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of Nelson's syndrome (corticotroph tumor progression with increased ACTH) can now be monitored with MRI. (See",
"      <a class=\"local\" href=\"#H362181912\">",
"       'Nelson's syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Concerns about impaired quality of life related to the postoperative need for chronic glucocorticoid and mineralocorticoid replacement. However, patients who undergo bilateral adrenalectomy appear to experience an improvement in quality of life that is similar to that in patients initially cured by transsphenoidal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H362181905\">",
"       'Quality of life'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181884\">",
"    <span class=\"h2\">",
"     Unilateral/subtotal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to bilateral adrenalectomy, unilateral or subtotal adrenalectomy is virtually never successful in ACTH-dependent Cushing&rsquo;s syndrome unless the patient has improved in response to pituitary irradiation (ACTH secretion is partially inhibited) or the adrenalectomy becomes complete because of subsequent infarction of the remnant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore, we do",
"    <strong>",
"     not",
"    </strong>",
"    suggest this approach.",
"   </p>",
"   <p>",
"    The failure of incomplete adrenalectomy is related to the ability of the adrenal remnant eventually to become hyperplastic. For the same reason, total adrenalectomy with subcutaneous adrenal autotransplantation is likely to fail; three of eight patients treated with this technique developed recurrent Cushing's syndrome in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unilateral adrenalectomy for Cushing's syndrome due to an adrenal adenoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34390?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of adrenocortical adenomas\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181891\">",
"    <span class=\"h2\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic approach, which can be done via either the anterior or posterior approaches, has become standard, as hospital stays appear to be shorter (usually one to five days) and complications fewer, as compared with open surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Regardless of the approach used, the glands must be removed en bloc. Care also must be taken to ensure that the fragile capsule is not broken [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/13\">",
"     13",
"    </a>",
"    ], because cells spilled locally can become hyperplastic and cause recurrent disease; they are then not usually amenable to surgical removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20073?source=see_link&amp;anchor=H5289309#H5289309\">",
"     \"Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures\", section on 'Selection of operative approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181898\">",
"    <span class=\"h2\">",
"     Hormone replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cure should be confirmed by measuring serum or urine cortisol. Glucocorticoid coverage is similar to that for transsphenoidal surgery, except that, in addition to lifelong glucocorticoid replacement, mineralocorticoid replacement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    must also be begun soon after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The daily replacement dose of glucocorticoid is less than the excessive amount of cortisol that was secreted every day before surgery. As a result of the decreased glucocorticoid negative feedback, plasma concentrations of ACTH and other proopiomelanocortin (POMC)-derived peptides increase, potentially more in patients who have not had pituitary irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, all patients with Cushing's disease who undergo bilateral adrenalectomy should be followed with sequential MRI and plasma ACTH measured as described below to detect the development of Nelson's syndrome as early as possible.",
"   </p>",
"   <p>",
"    Many patients receive excessive doses of glucocorticoid therapy after adrenalectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As an example, in a report of 14 women receiving glucocorticoids post-adrenalectomy for Cushing's disease, bone mineral density was similar, body fat was higher, and fat-free mass was lower when compared with 14 normal women of similar age, body mass index, and menopausal status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/15\">",
"     15",
"    </a>",
"    ]. The replacement glucocorticoid doses were:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"     cortisone acetate",
"    </a>",
"    (n = 10) 15 to 50 mg per day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (n = 1) 20 mg per day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (n = 2) 5 or 7.5 mg per day, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (n = 1) 0.5 mg per day, an average of 27.3 mg hydrocortisone equivalents per day.",
"   </p>",
"   <p>",
"    The results of this and other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] suggest that a daily dose of 15 to 20 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    or its equivalent may be optimal glucocorticoid replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181905\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients show improved quality of life after bilateral adrenalectomy that is similar to that seen after transsphenoidal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in one study of 40 patients, about half had persistent fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181912\">",
"    <span class=\"h2\">",
"     Nelson's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had bilateral adrenalectomy for Cushing's disease may develop corticotroph tumor progression, defined as an enlarging pituitary tumor (&lt;2 mm) on magnetic resonance imaging. In one study, this was noted after adrenalectomy in 25 of 53 patients without prior pituitary irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18\">",
"     18",
"    </a>",
"    ]. Most changes were noted within three years of surgery. Only four of these patients developed a macroadenoma and only one presented pituitary apoplexy. Logistic regression analysis showed that patients with a shorter duration of Cushing's syndrome and higher post-operative plasma ACTH concentrations were more likely to develop tumor progression.",
"   </p>",
"   <p>",
"    Nelson's syndrome was defined in an earlier era using sellar radiograms as the association of an enlarging pituitary tumor with progressive hyperpigmentation caused by very high plasma ACTH concentrations after bilateral adrenalectomy for Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition to hyperpigmentation, other clinical manifestations due to the enlarging tumor were common, including headaches, visual field defects, and sometimes cranial nerve palsies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/20\">",
"     20",
"    </a>",
"    ]. Most patients are now diagnosed at an earlier stage by magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18\">",
"     18",
"    </a>",
"    ]. Therefore, symptoms related to the tumor itself are somewhat less common, but hyperpigmentation is still an important clinical manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181919\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nelson's syndrome occurs in 8 to 25 percent of adults and in over 50 percent of children with Cushing's disease who undergo total adrenalectomy without prior pituitary irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]. As noted above, it is less common after medical adrenalectomy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The incidence of Nelson's syndrome depends on the patient's age at the time of adrenalectomy; it is very high before age 20 years, but very low after age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/29\">",
"     29",
"    </a>",
"    ]. In one study, few patients developed corticotrope tumor progression more than seven years after adrenalectomy, suggesting that monitoring frequency could decrease at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pituitary irradiation was reported to prevent this complication in some [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/30-33\">",
"     30-33",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/5,25\">",
"     5,25",
"    </a>",
"    ], studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, as an example, it occurred in 5 of 20 patients (25 percent); this was well below the 50 percent incidence in 36 patients who were not treated with pituitary irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The protection is not complete, as some adrenalectomized patients do develop Nelson's syndrome despite prior pituitary irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/5,25,31,32\">",
"       5,25,31,32",
"      </a>",
"      ]. Nonetheless, we suggest pituitary irradiation before adrenalectomy in patients with Cushing's disease with radiologically detectable residual corticotroph tumor. In patients without visible residual tumor, we suggest close monitoring with sequential MRI at one year intervals initially and regular ACTH levels for at least seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is one report of fatal Nelson&rsquo;s syndrome with accelerated tumor growth following pituitary irradiation; a P53 mutation was found in that tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181926\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticotroph progression becomes apparent several months to many years after adrenalectomy, the average being about three years. The pathogenesis of these tumors is uncertain. They presumably represent the accelerated growth of ACTH-secreting cells in preexisting microadenomas when the effect of glucocorticoid negative feedback inhibition is reduced.",
"   </p>",
"   <p>",
"    Other than differences attributable to the larger tumor cell mass and lack of glucocorticoid inhibition of adenomas causing Nelson's syndrome, these tumors are similar to microadenomas causing Cushing's syndrome with regard to light microscopic structure, ultrastructure, response to CRH, and the proopiomelanocortin products they produce.",
"   </p>",
"   <p>",
"    However, it is not clear why only some and not all tumors continue to grow. One hypothesis is that these ACTH-producing cells are intrinsically more abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/29\">",
"     29",
"    </a>",
"    ]. Another possibility is that a somatic frame-shift mutation develops in the glucocorticoid receptor gene of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/30\">",
"     30",
"    </a>",
"    ]. Such a change could interfere with glucocorticoid binding, thereby allowing ACTH hypersecretion and tumor growth to occur unimpeded by normal serum cortisol concentrations.",
"   </p>",
"   <p>",
"    There are no predictive clinical or laboratory indexes for the development of Nelson's syndrome except the plasma ACTH value. Plasma ACTH concentrations increase much more in patients who subsequently develop Nelson's syndrome than in those who do not:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first year after adrenalectomy while taking equivalent glucocorticoid replacement therapy (greater than 700",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [154",
"      <span class=\"nowrap\">",
"       pmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One report suggested that the risk of Nelson's syndrome was greater in patients with suboptimal glucocorticoid replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181933\">",
"    <span class=\"h3\">",
"     Biochemical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma ACTH concentrations in patients with Nelson's syndrome range from as low as 800",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (175",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    to values that may exceed 25,000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (5500",
"    <span class=\"nowrap\">",
"     pmol/L).",
"    </span>",
"    Some investigators have used plasma ACTH values as low as 200",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    in addition to hyperpigmentation, as the criteria for diagnosing Nelson's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/31\">",
"     31",
"    </a>",
"    ]. These values are much higher than the normal 8 AM values for ACTH (20 to 50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [4.4 to 11.3",
"    <span class=\"nowrap\">",
"     pmol/L]).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=see_link\">",
"     \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362181940\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the tumor in a patient with Nelson's syndrome becomes large enough to expand the sella, it is locally invasive, difficult to cure, and may develop into a pituitary carcinoma. As a result, adrenalectomized patients should be followed indefinitely with MRI of the pituitary and measurements of basal and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -suppressed plasma ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18,21,35-38\">",
"     18,21,35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transsphenoidal surgery should be performed before the tumor becomes a macroadenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/18,37,38\">",
"     18,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With careful follow-up, extrasellar extension should be prevented by early intervention. In older series that did not use this approach, a transcranial approach was sometimes necessary for tumors with extrasellar extension (14 of 43 patients in one series, 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/39\">",
"     39",
"    </a>",
"    ]. Success rates vary from 10 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/20,39,40\">",
"     20,39,40",
"    </a>",
"    ]. Surgical morbidity is significant with up to 70 percent developing panhypopituitarism, 15 percent a cerebrospinal fluid leak, and 8 percent develop meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/20,40\">",
"     20,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression of very large Nelson&rsquo;s syndrome tumors may occur even after surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/40\">",
"     40",
"    </a>",
"    ]. Therefore, postoperative radiation is suggested for patients with any evidence of residual tumor. This type of radiation chosen is typically dictated by availability, cost, and patient preference regarding treatment time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal type of radiation therapy has not been determined. In one report of conventional radiation in 15 patients with Nelson&rsquo;s syndrome, satisfactory results, including regression of hyperpigmentation and tumor shrinkage, were reported in 14 of the 15 patients followed for a median of 9.6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stereotactic gamma knife radiosurgery has been used [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. In one report of 10 patients, gamma knife stereotactic radiosurgery stopped tumor growth [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 22 patients, tumor volume decreased in 12, had no change in eight, and increased in two [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"       \"Stereotactic cranial radiosurgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical therapy of Nelson&rsquo;s syndrome is relatively ineffective and, therefore, we do not suggest its use. Although there is a case report of sustained remission with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/45\">",
"     45",
"    </a>",
"    ], neither this drug nor valproic acid had a significant acute effect on ACTH secretion in six women with Nelson's syndrome in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, bromocriptine lowered plasma ACTH concentrations acutely by 52 percent in these women. Long-term cabergoline administration decreased ACTH levels and tumor size in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Rosiglitazone was effective in only 1 of 19 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    are not effective. The somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    reduced ACTH secretion and tumor size in a few patients with Nelson's syndrome for as long as two years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/29\">",
"     29",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    One report showed regression of tumor size after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    treatment in two of four patients with aggressive corticotrope tumors or carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19496/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362183267\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for patients with Cushing's disease (ACTH-secreting pituitary tumor) is transsphenoidal surgery and resection of the pituitary tumor. The progressive stages of treatment that may be required to cure a patient of Cushing's disease are shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef76949 \" href=\"UTD.htm?33/49/34589\">",
"     algorithm 1",
"    </a>",
"    ). However, for patients with persistent or recurrent Cushing's disease, adrenalectomy, which can be achieved either surgically or medically (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ), is sometimes recommended for definitive cure. (See",
"    <a class=\"local\" href=\"#H1240291812\">",
"     'General approach to Cushing's disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral total surgical adrenalectomy is indicated as the definitive treatment for patients in whom rapid cure of hypercortisolism is necessary or when all other therapies have failed. (See",
"      <a class=\"local\" href=\"#H362181869\">",
"       'Surgical adrenalectomy'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laparoscopic approach, which can be done via either the anterior or posterior approaches, has become standard, as hospital stays appear to be shorter (usually one to five days) and complications fewer, as compared with open surgery. (See",
"      <a class=\"local\" href=\"#H362181891\">",
"       'Surgical approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20073?source=see_link&amp;anchor=H5289309#H5289309\">",
"       \"Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures\", section on 'Selection of operative approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cure should be confirmed by measuring serum or urine cortisol. Glucocorticoid coverage is similar to that for transsphenoidal surgery, except that, in addition to lifelong glucocorticoid replacement, mineralocorticoid replacement with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      must also be begun soon after surgery. (See",
"      <a class=\"local\" href=\"#H362181898\">",
"       'Hormone replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A daily dose of 15 to 20 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (or its equivalent) may be optimal glucocorticoid replacement. (See",
"      <a class=\"local\" href=\"#H362181898\">",
"       'Hormone replacement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who have had bilateral adrenalectomy for Cushing&rsquo;s disease may develop corticotroph tumor progression (Nelson&rsquo;s syndrome). Nelson's syndrome was defined in an earlier era using sellar radiograms as the association of an enlarging pituitary tumor with progressive hyperpigmentation caused by very high plasma ACTH concentrations after bilateral adrenalectomy for Cushing's syndrome. In addition to hyperpigmentation, other clinical manifestations due to the enlarging tumor were common, including headaches, visual field defects, and sometimes cranial nerve palsies. Most patients are now diagnosed at an earlier stage by magnetic resonance imaging with smaller increases in tumor size (&gt;2 mm). Therefore, symptoms related to the tumor itself are somewhat less common, but increased ACTH levels and hyperpigmentation is still an important clinical manifestation. (See",
"      <a class=\"local\" href=\"#H362181912\">",
"       'Nelson's syndrome'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticotroph tumor progression occurs in 8 to 49 percent of adults and in over 50 percent of children with Cushing's disease who undergo total surgical adrenalectomy without prior pituitary irradiation. (See",
"      <a class=\"local\" href=\"#H362181919\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the tumor in a patient with Nelson's syndrome becomes large enough to expand the sella, it is locally invasive, difficult to cure, and exhibits characteristics of a pituitary carcinoma. As a result, adrenalectomized patients should be followed indefinitely with MRI of the pituitary and measurements of basal and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      -suppressed plasma ACTH. (See",
"      <a class=\"local\" href=\"#H362181940\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop Nelson&rsquo;s syndrome, we suggest early transsphenoidal surgery (before the tumor becomes a macroadenoma) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H362181940\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progression of Nelson&rsquo;s syndrome tumors may occur even after pituitary surgery. Therefore, for patients with persistent Cushing&rsquo;s disease who have clear evidence of residual tumor after pituitary surgery, we suggest postoperative irradiation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The type of radiation chosen is typically dictated by availability, cost, and patient preference regarding treatment time. (See",
"      <a class=\"local\" href=\"#H362181940\">",
"       'Treatment'",
"      </a>",
"      above.) For patients without visible residual tumor, we do not recommend preventive radiotherapy, but perform regular MRI and ACTH measurements.",
"     </li>",
"     <li>",
"      In general, medical therapy is ineffective for the treatment of Nelson&rsquo;s syndrome, with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      , an alkylating agent, that was reported to be effective in cases of aggressive macroadenomas. Further data on temozolomide are required before this drug can be recommended in this setting. (See",
"      <a class=\"local\" href=\"#H362181940\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/1\">",
"      Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008; 93:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/2\">",
"      Kelly DF. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus 2007; 23:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/3\">",
"      Alwani RA, de Herder WW, van Aken MO, et al. Biochemical predictors of outcome of pituitary surgery for Cushing's disease. Neuroendocrinology 2010; 91:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/4\">",
"      Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/5\">",
"      Moore TJ, Dluhy RG, Williams GH, Cain JP. Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 1976; 85:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/6\">",
"      Kelly WF, MacFarlane IA, Longson D, et al. Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients. Q J Med 1983; 52:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/7\">",
"      Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/8\">",
"      Thompson SK, Hayman AV, Ludlam WH, et al. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg 2007; 245:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/9\">",
"      Hardy JD. Surgical management of Cushing's syndrome with emphasis on adrenal autotransplantation. Ann Surg 1978; 188:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/10\">",
"      Young WF Jr, Thompson GB. Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/11\">",
"      Smith PW, Turza KC, Carter CO, et al. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 2009; 208:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/12\">",
"      Vella A, Thompson GB, Grant CS, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/13\">",
"      Chalmers RA, Mashiter K, Joplin GF. Residual adrenocortical function after bilateral \"total\" adrenalectomy for Cushing's disease. Lancet 1981; 2:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/14\">",
"      Ray DW, Gibson S, Crosby SR, et al. Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids. J Clin Endocrinol Metab 1995; 80:2430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/15\">",
"      Kemink SA, Frijns JT, Hermus AR, et al. Body composition determined by six different methods in women bilaterally adrenalectomized for treatment of Cushing's disease. J Clin Endocrinol Metab 1999; 84:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/16\">",
"      Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/17\">",
"      Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 1997; 46:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/18\">",
"      Assi&eacute; G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 2007; 92:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/19\">",
"      Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become \"super-sensitive\" to melanocortin peptides. Mol Cell Endocrinol 1994; 102:R7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/20\">",
"      Barber TM, Adams E, Ansorge O, et al. Nelson's syndrome. Eur J Endocrinol 2010; 163:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/21\">",
"      Hopwood NJ, Kenny FM. Incidence of Nelson's syndrome after adrenalectomy for Cushing's disease in children: results of a nationwide survey. Am J Dis Child 1977; 131:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/22\">",
"      Cohen KL, Noth RH, Pechinski T. Incidence of pituitary tumors following adrenalectomy. A long-term follow-up study of patients treated for Cushing's disease. Arch Intern Med 1978; 138:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/23\">",
"      McArthur RG, Hayles AB, Salassa RM. Childhood Cushing disease: results of bilateral adrenalectomy. J Pediatr 1979; 95:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/24\">",
"      Wilson CB, Tyrrell JB, Fitzgerald PA, Pitts LH. Cushing's disease and Nelson's syndrome. Clin Neurosurg 1980; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/25\">",
"      Pereira MA, Halpern A, Salgado LR, et al. A study of patients with Nelson's syndrome. Clin Endocrinol (Oxf) 1998; 49:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/26\">",
"      Assi&eacute; G, Bahurel H, Bertherat J, et al. The Nelson's syndrome... revisited. Pituitary 2004; 7:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/27\">",
"      Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 1979; 300:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/28\">",
"      Schteingart DE, Tsao HS, Taylor CI, et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980; 92:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/29\">",
"      Kemink, SA, Smals, AG, Hermus, AR, et al. Nelson's syndrome: a review. Endocrinologist 1997; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/30\">",
"      Karl M, Von Wichert G, Kempter E, et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996; 81:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/31\">",
"      Jenkins PJ, Trainer PJ, Plowman PN, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/32\">",
"      Nagesser SK, van Seters AP, Kievit J, et al. Long-term results of total adrenalectomy for Cushing's disease. World J Surg 2000; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/33\">",
"      Gil-C&aacute;rdenas A, Herrera MF, D&iacute;az-Polanco A, et al. Nelson's syndrome after bilateral adrenalectomy for Cushing's disease. Surgery 2007; 141:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/34\">",
"      Pinto EM, Siqueira SA, Cukier P, et al. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome. Pituitary 2011; 14:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/35\">",
"      Kasperlik-Za��uska AA, Nielubowicz J, Wis��awski J, et al. Nelson's syndrome: incidence and prognosis. Clin Endocrinol (Oxf) 1983; 19:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/36\">",
"      Kasperlik-Zaluska A, Walecki J, Brzezi��ski J, et al. MRI versus CT in the diagnosis of Nelson's syndrome. Eur Radiol 1997; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/37\">",
"      Kemink SA, Grotenhuis JA, De Vries J, et al. Management of Nelson's syndrome: observations in fifteen patients. Clin Endocrinol (Oxf) 2001; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/38\">",
"      Kasperlik-Za��uska AA, Bonicki W, Jeske W, et al. Nelson's syndrome -- 46 years later: clinical experience with 37 patients. Zentralbl Neurochir 2006; 67:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/39\">",
"      De Tommasi C, Vance ML, Okonkwo DO, et al. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J Neurosurg 2005; 103:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/40\">",
"      Kelly PA, Samandouras G, Grossman AB, et al. Neurosurgical treatment of Nelson's syndrome. J Clin Endocrinol Metab 2002; 87:5465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/41\">",
"      Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 1989; 31:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/42\">",
"      Jane JA Jr, Vance ML, Woodburn CJ, Laws ER Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus 2003; 14:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/43\">",
"      Vik-Mo EO, &Oslash;ksnes M, Pedersen PH, et al. Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur J Endocrinol 2009; 160:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/44\">",
"      Mauermann WJ, Sheehan JP, Chernavvsky DR, et al. Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 2007; 106:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/45\">",
"      Aronin N, Krieger DT. Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment. N Engl J Med 1980; 302:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/46\">",
"      Mercado-Asis LB, Yanovski JA, Tracer HL, et al. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome. J Clin Endocrinol Metab 1997; 82:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/47\">",
"      Casulari LA, Naves LA, Mello PA, et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/48\">",
"      Pivonello R, Faggiano A, Di Salle F, et al. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999; 22:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/49\">",
"      Andreassen M, Kristensen L&Oslash;. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur J Endocrinol 2005; 153:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/50\">",
"      Munir A, Song F, Ince P, et al. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 2007; 92:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/51\">",
"      Mullan KR, Leslie H, McCance DR, et al. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 2006; 64:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/52\">",
"      Kreutzer J, Jeske I, Hofmann B, et al. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. Clin Neuropathol 2009; 28:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19496/abstract/53\">",
"      Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95:4592.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16322 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-6DA085BC69-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19496=[""].join("\n");
var outline_f19_2_19496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H362183267\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362181283\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1240291812\">",
"      GENERAL APPROACH TO CUSHING'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362181869\">",
"      SURGICAL ADRENALECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181877\">",
"      Bilateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181884\">",
"      Unilateral/subtotal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181891\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181898\">",
"      Hormone replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181905\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362181912\">",
"      Nelson's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362181919\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362181926\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362181933\">",
"      - Biochemical criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362181940\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H362183267\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/16322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/16322|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/49/34589\" title=\"algorithm 1\">",
"      Treatment Cushings disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20073?source=related_link\">",
"      Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=related_link\">",
"      Cushing's syndrome in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19497="Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis";
var content_f19_2_19497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19497/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19497/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19497/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19497/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/2/19497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic, cardiac, abdominal, and retroperitoneal injuries typically occur in the setting of high-impact trauma (ie, a fall from significant height or a motor vehicle accident [MVA]). When the injuries discussed below occur in the absence of such history, inflicted injury must be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the types of thoracic, cardiac, abdominal, and retroperitoneal injuries that can occur in the setting of child abuse will be presented here. The medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical management of these injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THORACIC INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Esophageal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal perforation is rare in children; most cases are iatrogenic and occur during procedures in children with underlying disease (eg, atresia, gastroesophageal reflux) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/1\">",
"     1",
"    </a>",
"    ]. Inflicted injury should be considered in children who have esophageal perforation and no underlying esophageal disease.",
"   </p>",
"   <p>",
"    Inflicted esophageal perforation can result from forced foreign body ingestion, forced caustic ingestion, blunt external trauma, and penetrating external trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .) In one review of 21 reported cases of inflicted esophageal perforation in children, 17 involved the hypopharynx or cervical esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/2\">",
"     2",
"    </a>",
"    ]. The mean age at presentation was 19 months, with a range of three weeks to six years.",
"   </p>",
"   <p>",
"    Early diagnosis of esophageal perforation is important to prevent the increased mortality associated with mediastinal contamination by esophageal microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. However, the initial symptoms of esophageal perforation, which are subtle and nonspecific (particularly in young children who may not be able to complain of pain), may be overshadowed by associated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/2\">",
"     2",
"    </a>",
"    ]. Early symptoms of esophageal perforation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substernal pleuritic pain that radiates to the neck or shoulders",
"     </li>",
"     <li>",
"      Neck pain or stiffness",
"     </li>",
"     <li>",
"      Retrosternal pain",
"     </li>",
"     <li>",
"      Shortness of breath",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early signs of esophageal perforation include tachycardia, dyspnea, abdominal guarding, pneumothorax, mediastinal air, and subcutaneous emphysema in the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Late findings include fever and mediastinitis caused by inflammation from contaminated spillage.",
"   </p>",
"   <p>",
"    The diagnosis and management of esophageal rupture are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H7#H7\">",
"     \"Intrathoracic injuries in children\", section on 'Esophageal injury'",
"    </a>",
"    .) Plain radiographs of the neck, chest, and abdomen may demonstrate extraluminal air or pleural effusion. Computed tomography (CT) may reveal extraluminal air, fluid, and esophageal thickening. However, contrast esophagogram",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    esophagoscopy may be necessary to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflicted blunt chest trauma can result in pulmonary laceration, pulmonary contusion, or diffuse alveolar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These problems are discussed in detail separately; their clinical manifestations are presented briefly below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=see_link\">",
"     \"Pulmonary contusion in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary lacerations are tears in the parenchyma of the lung that may cause bleeding or, less commonly, an air leak, with associated pneumothorax or pneumomediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Pulmonary lacerations are caused by penetrating trauma, displaced rib fractures, deceleration forces, or sudden compression from a crush injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with pulmonary lacerations typically present with hemoptysis and signs of respiratory distress and hypotension because of the associated hemopneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=see_link&amp;anchor=H3#H3\">",
"     \"Intrathoracic injuries in children\", section on 'Pulmonary laceration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary contusion is defined as pulmonary parenchymal damage with edema and hemorrhage in the absence of an associated pulmonary laceration. Pulmonary contusions generally present with hypoxia, tachypnea, hemoptysis, and a localized opacification on chest radiograph that develops immediately or within hours of trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=see_link\">",
"     \"Pulmonary contusion in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diffuse alveolar damage (DAD) is a nonspecific reaction seen in a variety of disease processes or trauma. A characteristic feature is the evolution from an acute phase to organizing and healing phases that vary in histologic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Acute respiratory distress syndrome (ARDS) may develop due to release of mediators of inflammation from damaged lung tissue and endothelium.",
"   </p>",
"   <p>",
"    The clinical features of ARDS include rapidly worsening tachypnea, dyspnea, and hypoxemia requiring high concentrations of supplemental oxygen; dry cough and chest pain may also be present. The physical examination usually reveals cyanosis, tachycardia, tachypnea, and diffuse rales in the chest. Mechanical ventilation is almost universally required. The chest radiograph typically shows diffuse, fluffy alveolar infiltrates in multiple lung zones with prominent air bronchograms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chylothorax that occurs without a clear etiology is suggestive of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/14\">",
"     14",
"    </a>",
"    ], particularly if the child has other suspicious injuries (eg, retinal hemorrhages, subdural hematoma). Abuse-related chylothorax results from the rupture of the thoracic duct from blunt chest trauma or anteroposterior",
"    <span class=\"nowrap\">",
"     acceleration/deceleration",
"    </span>",
"    forces (as in the shaken infant) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .) Coexisting first rib and vertebral body",
"    <span class=\"nowrap\">",
"     fracture/dislocations",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/14,17\">",
"     14,17",
"    </a>",
"    ], but it is unclear whether these are directly responsible for rupture of the thoracic duct.",
"   </p>",
"   <p>",
"    Presenting signs of chylothorax may include: respiratory distress from lung compression; nutritional deficiency or electrolyte abnormalities from loss of these components of chyle; or immunosuppression from T-cell depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chylothorax is visualized on chest radiograph as unilateral (commonly left-sided) or bilateral pleural fluid collections. Thoracentesis differentiates chylous fluid from hemothorax or infectious effusion by its white, milky appearance and by the presence of triglycerides and lipid-laden lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chylothorax secondary to child abuse may be accompanied by rib fractures; detailed rib films should be obtained and a complete skeletal survey performed. Acceleration-deceleration may be the mechanism of injury. Therefore, children with chylothorax without a clear etiology should be evaluated for features of inflicted head injury (such as subdural hematoma and retinal hemorrhages) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CARDIAC INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child abuse-related cardiac injuries include trauma-induced dysrhythmias and direct cardiac trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dysrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commotio cordis, also called myocardial concussion, results from a blow to the precordial chest, usually of low impact, that causes dysrhythmia and sudden cardiac arrest. Studies in pigs have shown that the type of dysrhythmia depends upon the stage of the cardiac cycle during which the impact occurs. Blows during the upstroke of the T wave are associated with ventricular fibrillation, whereas blows struck at the peak of the QRS complex result in asystole. Commotio cordis occurs most frequently in sports-related situations (baseball, softball, lacrosse), but child deaths due to direct and intentional precordial blows have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H10#H10\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Commotio cordis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Direct trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries from direct cardiac trauma include cardiac contusion, ventricular septal defect, and cardiac aneurysm, laceration, or rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cardiac contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac contusion is the most common cardiac injury resulting from blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. There are two mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impact of the heart against the sternum due to abrupt deceleration (as in an MVA or if the child is thrown)",
"     </li>",
"     <li>",
"      Crushing of the heart due to blunt trauma to the anterior chest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The signs of cardiac contusion are nonspecific, making premortem diagnosis difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/21,23,25,26\">",
"     21,23,25,26",
"    </a>",
"    ]. Clinical indicators of cardiac contusion include elevation of the MB fraction of serum creatine kinase (CK-MB, which may also be elevated after blunt trauma to the pancreas, skeletal muscle, and bowel) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/26\">",
"     26",
"    </a>",
"    ];",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrocardiographic abnormalities including atrial arrhythmias, bundle branch blocks, and atrioventricular conduction disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. Cardiac troponin I (cTnI) and T (cTnT) are cardiac regulatory proteins that are highly sensitive for myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .) Echocardiography may reveal abnormalities of wall motion, valvular damage, or pericardial effusion in 20 to 47 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic ventricular septal defect (VSD) occurs rarely in children and is usually secondary to an MVA, a fall from a significant height, or a thoracic crush injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/31\">",
"     31",
"    </a>",
"    ]. However, it can occur in child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One case is described in which a child developed a traumatic VSD and left ventricular wall aneurysm after his father had \"punched him three or four times in the chest and stomach area\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to other cardiac injuries, a traumatic cardiac aneurysm, laceration, or rupture usually results from a significant impact such as a blast or an MVA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In the absence of the history of such an event, these injuries must be considered to be nonaccidental [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/35\">",
"     35",
"    </a>",
"    ]. These injuries result from compression of the heart between the sternum and vertebral column, or, in the case of laceration or rupture, puncture by a fractured rib or rupture through a healing contusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/35\">",
"     35",
"    </a>",
"    ]. In one report of six cases of inflicted cardiac lacerations, confessions were elicited in three cases; the mechanism of injury included a punch to the chest wall, stomping on the chest wall, and kicking the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ABDOMINAL INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal injury is the second most common cause of death in abused children after head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/37\">",
"     37",
"    </a>",
"    ]. Approximately 1 percent of abused children sustain intraabdominal injuries, which have a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Mortality is usually due to internal hemorrhage or septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar to nonaccidental head injury, inflicted abdominal injury usually occurs in children who are younger than two years of age and in the absence of a history of trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflicted abdominal trauma is caused by direct blows or kicks to the abdomen, or by direct pressure (eg, standing or kneeling on the abdomen) which cause injury or rupture of the hollow organs (eg, duodenal hematoma, traumatic pancreatitis) or contusion or laceration of the solid organs (eg, liver, spleen, kidneys) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/37,38,42,43\">",
"     37,38,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and management of children with nonaccidental abdominal injuries is often similar to that of children injured with an accidental mechanism. with the exception of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is often no history of trauma for children with inflicted injury, injuries are often multiple and more severe, and there may delay in seeking care for nonaccidental injury [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one retrospective series describing blunt abdominal trauma in children, a nonaccidental mechanism was significantly associated with young age, severe pancreatic or hollow viscus injury, undernourishment, traumatic brain injury, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms include abdominal tenderness, distension, enlargement of the liver or spleen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bruising of the abdominal wall (the last is not reliably present) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/42\">",
"     42",
"    </a>",
"    ]. A detailed overview of blunt abdominal trauma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the intraabdominal organ most frequently injured in child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/46\">",
"     46",
"    </a>",
"    ]. Inflicted hepatic injuries are usually caused by blunt trauma and include contusion, subcapsular hematoma, laceration, rupture, or disruption of the ductal system. Liver lacerations typically involve the right lobe because of its proximity to, and potential for impact against, the ribs and spine. Left lobe injuries are associated with pancreatic and duodenal injuries and are highly suspicious of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Victims of inflicted hepatic injury can have massive bleeding, either intracapsular or into the peritoneal cavity. They may present acutely with shock, anemia, tachycardia, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/41\">",
"     41",
"    </a>",
"    ], or up to several days after the injury with vomiting, abdominal distension, abdominal tenderness or rigidity, and absence of bowel sounds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/42\">",
"     42",
"    </a>",
"    ]. Laboratory findings include elevation of hepatic enzymes (alanine aminotransferase and aspartate aminotransferase), hematuria, and a falling hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/42,47\">",
"     42,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal CT is diagnostic; however, immediate fluid and blood product resuscitation, and the need for surgical exploration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repair, may supersede CT in the unstable patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Splenic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflicted injuries to the spleen are less common than those of the liver. Inflicted splenic injuries include contusion, subcapsular hematoma, laceration, and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/48\">",
"     48",
"    </a>",
"    ]. Splenic injury may compromise splenic function, leading to secondary immune deficiency and susceptibility to infection with polysaccharide-encapsulated bacteria such as S. pneumoniae, H. influenzae, and N. meningitidis. A case of pneumococcal sepsis in a four-month-old infant who had splenic and left renal infarction and multiple fractures has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with hepatic injury, abdominal CT is diagnostic; however, immediate fluid and blood product resuscitation, and the need for surgical exploration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repair, may supersede CT in the unstable patient (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Stabilization'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pancreatic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic injury is uncommon in children with blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/42\">",
"     42",
"    </a>",
"    ]. Injuries from blunt pancreatic trauma include contusion with organ edema, minor or major lacerations (usually in the body of the pancreas, where it lies over the spine) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/50\">",
"     50",
"    </a>",
"    ], ductal lacerations, pseudocyst formation, complete transection, and acute or chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the severity, symptoms and signs of pancreatic injury include vomiting, abdominal pain that radiates to the back, epigastric tenderness, peritonitis, and hypovolemia. Patients with delayed presentation may have findings suggestive of pancreatic pseudocyst.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of pancreatic injury in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     GI tract injury",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal perforation or rupture usually results from direct blunt trauma to the abdomen (such as a blow or kick) that causes a sudden increase in intraluminal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/52\">",
"     52",
"    </a>",
"    ], or the insertion of a blunt object into the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/53\">",
"     53",
"    </a>",
"    ]. Intestinal perforation also can result from acceleration-deceleration injuries that tear the bowel from its point of attachment to the posterior abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/43,52\">",
"     43,52",
"    </a>",
"    ]. Such injuries, when accidental, are associated with major trauma such as a fall from a significant height, or with lap belt injury sustained during an MVA.",
"   </p>",
"   <p>",
"    Hollow organ injury is more common in nonaccidental than accidental trauma (65 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/54\">",
"     54",
"    </a>",
"    ]. Intestinal perforation in the absence of a history of significant abdominal trauma is highly suspicious for abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/54\">",
"     54",
"    </a>",
"    ]. Children with inflicted injuries that result in intestinal perforation and other severe intraabdominal injuries are often reported by the child's caretaker to have fallen on stairs. This mechanism was evaluated in a systematic review of 312 cases of small-intestinal perforation and 677 cases of falls on stairs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/55\">",
"     55",
"    </a>",
"    ]. Falls on stairs were not reported as a cause in any of the cases of small intestine perforation; nor were there any reports of significant intraabdominal injuries, including small-intestinal perforation, among the cases of falls on stairs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whereas accidental injuries can occur anywhere in the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/52\">",
"     52",
"    </a>",
"    ], inflicted injuries most commonly involve the duodenum, jejunum, or the duodenojejunal junction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/39,56,57\">",
"     39,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation of intestinal perforation may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/58\">",
"     58",
"    </a>",
"    ]. Symptoms and signs include tachycardia, unexplained fever, abdominal pain, tenderness, diminished bowel sounds, and decreased urine output despite appropriate fluid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/59\">",
"     59",
"    </a>",
"    ]; peritoneal signs may be present. Bruising or footprint marks on the abdominal wall are helpful in diagnosis, but may be absent. The diagnosis and management of intestinal perforation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'GI tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct blunt abdominal trauma can cause compression of the intestinal wall against the vertebral column, which causes bleeding into the intestinal wall and development of intramural hematoma. Intramural hematomas occur most frequently in the duodenum, where they can cause upper intestinal obstruction. Complications of duodenal hematoma include perforation of the duodenal wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodeno-jejunal stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/41,56\">",
"     41,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms and signs of intestinal hematoma usually occur within one to five days of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/41\">",
"     41",
"    </a>",
"    ]. They include gastric distension, abdominal pain, anorexia, progressive bilious vomiting with dehydration, and other signs of proximal bowel obstruction; an upper abdominal mass may be palpable on examination. Depending upon the amount of bleeding, anemia may be present. As with other forms of abdominal injury, bruising of the abdominal wall (footprints, etc.) may be seen, but are frequently absent. The diagnosis and management of duodenal hematoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'GI tract'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     URINARY TRACT INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Renal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pediatric kidney is particularly vulnerable to blunt trauma because it is relatively larger, located lower in the abdomen, and has less protective perirenal fat than the adult kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"     60",
"    </a>",
"    ]. The severity of injury ranges from contusion or subcapsular hematoma to shattered kidney or vascular pedicle avulsion.",
"   </p>",
"   <p>",
"    Renal artery thrombosis and occlusion may result from hematomas caused by compression of the artery against the vertebral column by a direct blow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/49\">",
"     49",
"    </a>",
"    ]. Rib and spine fractures and other intraabdominal injuries are often associated.",
"   </p>",
"   <p>",
"    Hematuria is present in 41 to 68 percent of victims of renal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. However, hematuria is a nonspecific finding that is more commonly present in children with injuries to other solid organs than to the urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides incurring direct trauma, children with inflicted injuries may develop acute renal failure resulting from rhabdomyolysis and myoglobinuria secondary to muscle injury or hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .) Signs of rhabdomyolysis and myoglobinuria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Darkly pigmented urine that is positive for blood on dipstick (orthotolidine) but without significant numbers of red cells (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pigmented granular casts in the urine",
"     </li>",
"     <li>",
"      Oliguria or frank anuria",
"     </li>",
"     <li>",
"      Hyperkalemia and hypocalcemia",
"     </li>",
"     <li>",
"      Elevations of blood urea nitrogen and creatinine",
"     </li>",
"     <li>",
"      Elevations of muscle enzymes (creatine phosphokinase, serum glutamic oxaloacetic transaminate, aldolase)",
"     </li>",
"     <li>",
"      Extensive swelling and bruising over major muscle groups (often the buttocks and legs) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/65-67\">",
"       65-67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated urine or serum myoglobin levels confirm the diagnosis, but results from such tests are often not immediately available in the emergency setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/63\">",
"     63",
"    </a>",
"    ]. Prolonged dense nephrograms have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. Management is supportive and includes the avoidance of urographic contrast agents, which can initiate or worsen renal failure; aggressive hydration to promote diuresis; and management of hyperkalemia via standard protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Diuretics such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/65\">",
"     65",
"    </a>",
"    ]. However, mannitol should be avoided in patients with oliguria, because its administration may aggravate volume expansion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ureteral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteral injury is less common than renal injury, and is associated with more severe injury to other intraabdominal organs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"     60",
"    </a>",
"    ]. Mechanisms for ureteral injury include direct penetrating trauma and severe truncal hyperextension that results in partial or complete ureteral transection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder rupture has rarely been reported in the setting of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. This condition can result from a direct blow to the lower abdomen in the presence of a full bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/72\">",
"     72",
"    </a>",
"    ]. Children younger than six years are particularly vulnerable because their bladders are intraperitoneal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rupture usually occurs through the dome of the bladder, the weakest point, and the only area covered by peritoneum. Thus, rupture results in extravasation of urine and blood into the peritoneal cavity. When medical care is delayed more than 24 hours (as is common in children with inflicted injuries), extensive resorption of urea and creatinine through the peritoneum can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is that of pseudorenal failure, with elevated blood urea nitrogen (BUN) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/75\">",
"     75",
"    </a>",
"    ] and creatinine levels and acidosis, as well as peritonitis or ileus from peritoneal irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"     60",
"    </a>",
"    ]. Other symptoms include abdominal or genital pain, abdominal distension, hematuria, or anuria. Diagnosis is best made by retrograde cystography; CT is less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drainage of intraperitoneal urine results in rapid normalization of BUN and creatinine, differentiating this condition from true renal failure caused by direct injury to the kidneys or to rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADRENAL INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands are proportionately larger in children than in adults, and thus more susceptible to injury from blunt trauma. In one review of 50 cases of fatal abuse with major blunt injuries to the torso, adrenal lacerations were present in five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/76\">",
"     76",
"    </a>",
"    ]. Adrenal injuries are not fatal in and of themselves, but serve as markers of severe external force such as an MVA, a fall from a significant height, or a crush injury of the torso. When adrenal injury occurs without a history of such trauma, child abuse must be strongly suspected.",
"   </p>",
"   <p>",
"    CT findings of adrenal injury include periadrenal hematoma, perinephric edema, or hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/76\">",
"     76",
"    </a>",
"    ]. Periportal tracking (low-density blood or edema along the portal structures) is a nonspecific but highly sensitive indicator of significant hepatic or adrenal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19497/abstract/46,76,77\">",
"     46,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17111568\">",
"    <span class=\"h1\">",
"     CHILD PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a severe esophageal, pulmonary, cardiac, or abdominal injury in a child with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the medical care team should ensure that children under two years of age with suspected intentional trauma undergo funduscopic examination by an ophthalmologist to assess for retinal hemorrhages and skeletal survey to identify other injuries once the patient's clinical status is stabilized. The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17111377\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic, cardiac, abdominal, and retroperitoneal injuries typically occur in the setting of high-impact trauma (ie, a fall from significant height or a motor vehicle accident [MVA]). When these injuries occur in the absence of such history, inflicted injury must be suspected. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflicted esophageal perforation can result from forced foreign body ingestion, forced caustic ingestion, blunt external trauma, and penetrating external trauma and may result in esophageal perforation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Esophageal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflicted blunt chest trauma may cause pulmonary laceration, pulmonary contusion, chylothorax, or diffuse alveolar damage. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pulmonary injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Child abuse-related cardiac injuries include trauma-induced dysrhythmias and direct cardiac trauma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cardiac injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duodenal hematoma, intestinal perforation, and liver or splenic laceration comprise common inflicted abdominal injuries. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Abdominal injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pediatric kidney is particularly vulnerable to abusive blunt trauma because it is relatively larger, located lower in the abdomen, and has less protective perirenal fat than the adult kidney. The severity of injury ranges from contusion or subcapsular hematoma to shattered kidney or vascular pedicle avulsion. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Renal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Besides incurring direct trauma, children with inflicted injuries may develop acute renal failure resulting from rhabdomyolysis and myoglobinuria secondary to muscle injury or hypoperfusion. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Renal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of a severe esophageal, pulmonary, cardiac, or abdominal injury in a child with a questionable mechanism of injury should prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required for cases of suspected child abuse. (See",
"      <a class=\"local\" href=\"#H17111568\">",
"       'Child protection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link\">",
"       \"Child abuse: Social and medicolegal issues\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/1\">",
"      Engum SA, Grosfeld JL, West KW, et al. Improved survival in children with esophageal perforation. Arch Surg 1996; 131:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/2\">",
"      Morzaria S, Walton JM, MacMillan A. Inflicted esophageal perforation. J Pediatr Surg 1998; 33:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/3\">",
"      Friedman EM. Caustic ingestions and foreign body aspirations: an overlooked form of child abuse. Ann Otol Rhinol Laryngol 1987; 96:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/4\">",
"      Tavill MA, Trimmer WR, Austin MB. Pediatric cervical esophageal perforation secondary to abusive blunt thoracic trauma. Int J Pediatr Otorhinolaryngol 1996; 35:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/5\">",
"      Nolte KB. Esophageal foreign bodies as child abuse. Potential fatal mechanisms. Am J Forensic Med Pathol 1993; 14:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/6\">",
"      Gorenstein L, Blair GK, Shandling B. The prognosis of traumatic asphyxia in childhood. J Pediatr Surg 1986; 21:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/7\">",
"      Bliss D, Silen M. Pediatric thoracic trauma. Crit Care Med 2002; 30:S409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/8\">",
"      McEniery J, Hanson R, Grigor W, Horowitz A. Lung injury resulting from a nonaccidental crush injury to the chest. Pediatr Emerg Care 1991; 7:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/9\">",
"      Sivit CJ, Taylor GA, Eichelberger MR. Visceral injury in battered children: a changing perspective. Radiology 1989; 173:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/10\">",
"      Jackimczyk K. Blunt chest trauma. Emerg Med Clin North Am 1993; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     Kadish, H. Thoracic trauma. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1433.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/12\">",
"      Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/13\">",
"      Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/14\">",
"      Geismar SL, Tilelli JA, Campbell JB, Chiaro JJ. Chylothorax as a manifestation of child abuse. Pediatr Emerg Care 1997; 13:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/15\">",
"      Guleserian KJ, Gilchrist BF, Luks FI, et al. Child abuse as a cause of traumatic chylothorax. J Pediatr Surg 1996; 31:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/16\">",
"      Green HG. Child abuse presenting as chylothorax. Pediatrics 1980; 66:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/17\">",
"      Gartside R, Hebert JC. Chylothorax following fracture of the thoracolumbar spine. Injury 1988; 19:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/18\">",
"      Breaux JR, Marks C. Chylothorax causing reversible T-cell depletion. J Trauma 1988; 28:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/19\">",
"      Orange JS, Geha RS, Bonilla FA. Acute chylothorax in children: selective retention of memory T cells and natural killer cells. J Pediatr 2003; 143:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/20\">",
"      Denton JS, Kalelkar MB. Homicidal commotio cordis in two children. J Forensic Sci 2000; 45:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/21\">",
"      Boglioli LR, Taff ML, Harleman G. Child homicide caused by commotio cordis. Pediatr Cardiol 1998; 19:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/22\">",
"      Baker AM, Craig BR, Lonergan GJ. Homicidal commotio cordis: the final blow in a battered infant. Child Abuse Negl 2003; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/23\">",
"      Cloutier RL, Mehr MF, Lin RJ, Tanel RE. Junctional ectopic tachycardia in association with blunt abdominal trauma. Ann Emerg Med 2002; 40:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/24\">",
"      Dowd MD, Krug S. Pediatric blunt cardiac injury: epidemiology, clinical features, and diagnosis. Pediatric Emergency Medicine Collaborative Research Committee: Working Group on Blunt Cardiac Injury. J Trauma 1996; 40:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/25\">",
"      Tellez DW, Hardin WD Jr, Takahashi M, et al. Blunt cardiac injury in children. J Pediatr Surg 1987; 22:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/26\">",
"      Mayfield W, Hurley EJ. Blunt cardiac trauma. Am J Surg 1984; 148:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/27\">",
"      Sybrandy KC, Cramer MJ, Burgersdijk C. Diagnosing cardiac contusion: old wisdom and new insights. Heart 2003; 89:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/28\">",
"      Beggs CW, Helling TS, Evans LL, et al. Early evaluation of cardiac injury by two-dimensional echocardiography in patients suffering blunt chest trauma. Ann Emerg Med 1987; 16:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/29\">",
"      Hiatt JR, Yeatman LA Jr, Child JS. The value of echocardiography in blunt chest trauma. J Trauma 1988; 28:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/30\">",
"      Miller FA Jr, Seward JB, Gersh BJ, et al. Two-dimensional echocardiographic findings in cardiac trauma. Am J Cardiol 1982; 50:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/31\">",
"      Moraes CR, Victor E, Arruda M, et al. Ventricular septal defect following nonpenetrating trauma. Case report and review of the surgical literature. Angiology 1973; 24:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/32\">",
"      Karpas A, Yen K, Sell LL, Frommelt PC. Severe blunt cardiac injury in an infant: a case of child abuse. J Trauma 2002; 52:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/33\">",
"      Rees A, Symons J, Joseph M, Lincoln C. Ventricular septal defect in a battered child. Br Med J 1975; 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/34\">",
"      Bertrand S, Laquay N, El Rassi I, Vouh&eacute; P. Tricuspid insufficiency after blunt chest trauma in a nine-year-old child. Eur J Cardiothorac Surg 1999; 16:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/35\">",
"      Cohle SD, Hawley DA, Berg KK, et al. Homicidal cardiac lacerations in children. J Forensic Sci 1995; 40:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/36\">",
"      Veeragandham RS, Backer CL, Mavroudis C, Wilson AD. Traumatic left ventricular aneurysm and tricuspid insufficiency in a child. Ann Thorac Surg 1998; 66:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/37\">",
"      Ledbetter DJ, Tapper D. Injuries caused by child abuse. Compr Ther 1989; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/38\">",
"      Cooper A, Floyd T, Barlow B, et al. Major blunt abdominal trauma due to child abuse. J Trauma 1988; 28:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/39\">",
"      Touloukian RJ. Abdominal visceral injuries in battered children. Pediatrics 1968; 42:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/40\">",
"      Lane WG, Lotwin I, Dubowitz H, et al. Outcomes for children hospitalized with abusive versus noninflicted abdominal trauma. Pediatrics 2011; 127:e1400.",
"     </a>",
"    </li>",
"    <li>",
"     Wissow LS. Head and internal injuries. In: Child Advocacy for the Clinician: An Approach to Child Abuse and Neglect, Wissow LS.  (Ed), Williams and Wilkins, Baltimore 1990. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/42\">",
"      Cameron CM, Lazoritz S, Calhoun AD. Blunt abdominal injury: simultaneously occurring liver and pancreatic injury in child abuse. Pediatr Emerg Care 1997; 13:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/43\">",
"      Caniano DA, Beaver BL, Boles ET Jr. Child abuse. An update on surgical management in 256 cases. Ann Surg 1986; 203:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/44\">",
"      Wood J, Rubin DM, Nance ML, Christian CW. Distinguishing inflicted versus accidental abdominal injuries in young children. J Trauma 2005; 59:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/45\">",
"      Trokel M, Discala C, Terrin NC, Sege RD. Patient and injury characteristics in abusive abdominal injuries. Pediatr Emerg Care 2006; 22:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/46\">",
"      DiGiacomo JC, Frankel H, Haskell RM, et al. Unsuspected child abuse revealed by delayed presentation of periportal tracking and myoglobinuria. J Trauma 2000; 49:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/47\">",
"      Coant PN, Kornberg AE, Brody AS, Edwards-Holmes K. Markers for occult liver injury in cases of physical abuse in children. Pediatrics 1992; 89:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/48\">",
"      Kirks DR. Radiological evaluation of visceral injuries in the battered child syndrome. Pediatr Ann 1983; 12:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/49\">",
"      Wilson TM, Anderson BJ, Duncan D. Nonaccidental injury presenting as pneumococcal sepsis in an infant. Pediatr Emerg Care 1996; 12:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/50\">",
"      Smith SD, Nakayama DK, Gantt N, et al. Pancreatic injuries in childhood due to blunt trauma. J Pediatr Surg 1988; 23:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/51\">",
"      Van Winckel M, Robberecht E, Afschrift M, et al. Radiological case of the month. Battered child syndrome. Arch Pediatr Adolesc Med 1997; 151:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/52\">",
"      Beckmann KR, Nozicka CA. Small bowel perforation: an unusual presentation for child abuse. J Am Osteopath Assoc 2000; 100:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/53\">",
"      Press S, Grant P, Thompson VT, Milles KL. Small bowel evisceration: unusual manifestation of child abuse. Pediatrics 1991; 88:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/54\">",
"      Ledbetter DJ, Hatch EI Jr, Feldman KW, et al. Diagnostic and surgical implications of child abuse. Arch Surg 1988; 123:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/55\">",
"      Huntimer CM, Muret-Wagstaff S, Leland NL. Can falls on stairs result in small intestine perforations? Pediatrics 2000; 106:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/56\">",
"      Shah P, Applegate KE, Buonomo C. Stricture of the duodenum and jejunum in an abused child. Pediatr Radiol 1997; 27:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/57\">",
"      MCCORT J, VAUDAGNA J. VISCERAL INJURIES IN BATTERED CHILDREN. Radiology 1964; 82:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/58\">",
"      Shilyansky J, Pearl RH, Kreller M, et al. Diagnosis and management of duodenal injuries in children. J Pediatr Surg 1997; 32:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/59\">",
"      Holland AJ, Cass DT, Glasson MJ, Pitkin J. Small bowel injuries in children. J Paediatr Child Health 2000; 36:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/60\">",
"      McAleer IM, Kaplan GW. Pediatric genitourinary trauma. Urol Clin North Am 1995; 22:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/61\">",
"      Cass AS. Renal trauma in multiple-injured child. Urology 1983; 21:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/62\">",
"      McAleer IM, Kaplan GW, Scherz HC, et al. Genitourinary trauma in the pediatric patient. Urology 1993; 42:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/63\">",
"      Stalker HP, Kaufman RA, Stedje K. The significance of hematuria in children after blunt abdominal trauma. AJR Am J Roentgenol 1990; 154:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/64\">",
"      Taylor GA, Eichelberger MR, Potter BM. Hematuria. A marker of abdominal injury in children after blunt trauma. Ann Surg 1988; 208:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/65\">",
"      Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care 1985; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/66\">",
"      Mukherji SK, Siegel MJ. Rhabdomyolysis and renal failure in child abuse. AJR Am J Roentgenol 1987; 148:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/67\">",
"      Rosenberg HK, Gefter WB, Lebowitz RL, et al. Prolonged dense nephrograms in battered children. Suspect rhabdomyolysis and myoglobinuria. Urology 1983; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/68\">",
"      Beamud-Gomez A, Martinez-Verduch M, Estornell-Moragues F, et al. Rupture of the ureteropelvic junction by nonpenetrating trauma. J Pediatr Surg 1986; 21:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/69\">",
"      Reda EF, Lebowitz RL. Traumatic ureteropelvic disruption in the child. Pediatr Radiol 1986; 16:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/70\">",
"      Sirotnak AP. Intraperitoneal bladder rupture: an uncommon manifestation of child abuse. Clin Pediatr (Phila) 1994; 33:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/71\">",
"      Sawyer RW, Hartenberg MA, Benator RM. Intraperitoneal bladder rupture in a battered child. Int J Pediatr Nephrol 1987; 8:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/72\">",
"      Guerriero WG. Trauma to the kidneys, ureters, bladder, and urethra. Surg Clin North Am 1982; 62:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/73\">",
"      Yang JW, Kuppermann N, Rosas A. Child abuse presenting as pseudorenal failure with a history of a bicycle fall. Pediatr Emerg Care 2002; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/74\">",
"      Halsted CC, Shapiro SR. Child abuse: acute renal failure from ruptured bladder. Am J Dis Child 1979; 133:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/75\">",
"      Shah PM, Kim KH, Ramirez-Schon G, Reynolds BM. Elevated blood urea nitrogen: an aid to the diagnosis of intraperitoneal rupture of the bladder. J Urol 1979; 122:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/76\">",
"      deRoux SJ, Prendergast NC. Adrenal lacerations in child abuse: a marker of severe trauma. Pediatr Surg Int 2000; 16:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19497/abstract/77\">",
"      Sivit CJ, Taylor GA, Eichelberger MR, et al. Significance of periportal low-attenuation zones following blunt trauma in children. Pediatr Radiol 1993; 23:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6602 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19497=[""].join("\n");
var outline_f19_2_19497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17111377\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THORACIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Esophageal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CARDIAC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dysrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Direct trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cardiac contusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ABDOMINAL INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Splenic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pancreatic injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GI tract injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      URINARY TRACT INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Renal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ureteral injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bladder injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADRENAL INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17111568\">",
"      CHILD PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17111377\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3495?source=related_link\">",
"      Intrathoracic injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29285?source=related_link\">",
"      Pulmonary contusion in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19498="Overview of pregnancy termination";
var content_f19_2_19498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pregnancy termination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Lee P Shulman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Frank W Ling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/2/19498/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/2/19498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine evacuation is an integral part of obstetric and gynecologic care, not only for elective pregnancy termination, but also in the management of spontaneous abortion, intrauterine fetal demise, retained products of conception, and gestational trophoblastic neoplasia. The choice of technique for uterine evacuation depends more upon uterine volume and operator experience than the underlying indication for the procedure.",
"   </p>",
"   <p>",
"    Issues common to both first and second trimester pregnancy termination will be reviewed here. Techniques for first and second trimester procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"     \"Surgical termination of pregnancy: First trimester\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Centers for Disease Control (CDC), the rate of pregnancy termination in the United States (US) in 2008 was 16 per 1000 women aged 15 to 44 years, or 234 per 1000 live births; there was a 4 percent decrease in the rate of abortions from 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ]. The CDC figures are based upon data voluntarily reported to state health agencies and are incomplete. The Alan Guttmacher Institute, which surveys all known abortion providers, reported a rate of 19 abortions per 1000 women in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated worldwide rate for abortion in 2008 was 28 per 1000 women ages 15 to 44 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/3\">",
"     3",
"    </a>",
"    ]; the highest rate was in Eastern Europe (43 per 1000) and the lowest rate was in Western Europe (12 per 1000). Forty-nine percent of abortions were classified as \"unsafe\" (generally referring to illegal procedures), compared with 45 percent in 1995. Unsafe abortions occurred mostly in developing countries; the rate of unsafe abortion in Africa was 97 percent and in south central Asia was 65 percent.",
"   </p>",
"   <p>",
"    In the United States in 2008, there were 6.4 million pregnancies among 62 million women. Fifty percent of pregnancies were unintended and 19 percent of pregnancies resulted in pregnancy termination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/2\">",
"     2",
"    </a>",
"    ]. In the England in 2010, there were 225,600 unintended pregnancies and 155,500 induced abortions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abortion rates were highest in women ages 20 to 24 (30 per 1000 women) and 25 to 29 (22 per 1000) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ]. The rate of abortion in adolescents was 10.7 per 1000 women, with the highest rates for those ages 18 to 19 (21 to 26 per 1000) compared with 17 or younger (1 to 13 per 1000).",
"   </p>",
"   <p>",
"    Most terminations were performed in women who were unmarried (84 percent) and had one or more children (59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ]. The abortion rate among women living below the federal poverty level ($9570 for a single woman with no children in 2002) is more than four times that of women above 300 percent of the poverty level (44 versus 10 abortions per 1000 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most abortions in the US in 2008 were performed in non-Hispanic white (37 percent) or non-Hispanic black (36 percent) women. Abortion rates per 1000 women in a specific racial group are higher in non-Hispanic black (33.5 per 1000) and Hispanic women (20.6 per 1000) than in non-Hispanic white women (8.7).",
"   </p>",
"   <p>",
"    The vast majority of pregnancy terminations were performed in the first trimester: 63 percent at &le;8 weeks and 91 percent at &le;13 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ]. For later gestational ages, 7 percent of abortions were performed at 14 to 20 weeks of gestation and 1 percent at &ge;21 weeks. Adolescents and non-Hispanic black women were more likely than other women to undergo abortion at &ge;14 weeks. Potential barriers to early abortion include: expense, delay in recognition and confirmation of pregnancy, parental involvement laws, and lack of access to an abortion provider. Eighty-seven percent of all US counties lacked an abortion provider in 2000; 34 percent of all US women live in those counties [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat pregnancy terminations accounted for approximately 42 percent of all induced abortions in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For gestational ages &le;13 weeks, 76 percent of terminations were performed via curettage and 15 percent were medication abortions (use of medication abortions greatly increased from 3 percent in 2001) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"     1",
"    </a>",
"    ]. For gestational ages of &ge;14 weeks, 9 percent were performed via curettage and 0.1 percent via intrauterine instillation.",
"   </p>",
"   <p>",
"    The most common reasons given for choosing abortion are that having a baby would interfere with work, school, or other responsibilities; inability to afford a child; not wanting to be a single parent; and having problems with a husband or partner [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy terminations can be performed safely in freestanding clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/9\">",
"     9",
"    </a>",
"    ] and in an office setting with proper equipment for performing in-office surgical procedures. Hospitalization may be required for women with medical conditions that place them at higher risk of medical or surgical complications (eg, cardiac disease, coagulopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians performing any uterine evacuation procedure should obtain a comprehensive patient history, including any complications during previous similar procedures. A complete physical examination should be performed with special attention to the uterine size and position, and obtain confirmation of pregnancy (eg, urine or serum human chorionic gonadotropin assay, documentation of fetal cardiac activity, or sonographic visualization of an intrauterine pregnancy). The gestational age should be determined by both menstrual history and bimanual examination; ultrasound examination is useful if there is any uncertainty and at advanced gestational ages (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Imaging'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Preoperative counseling includes a thorough discussion of the various types of pregnancy termination procedures; the risks, benefits, and expected outcome of each procedure. A nondirective discussion of alternatives (eg, continuing pregnancy, adoption) is extremely important [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/10\">",
"     10",
"    </a>",
"    ]. A signed informed consent should be obtained from all patients.",
"   </p>",
"   <p>",
"    Some states have mandatory waiting times between when the patient is counseled and the actual procedure, some states require parental notification or consent for abortions in minors (minors have the right to seek a court order authorizing the procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/11\">",
"     11",
"    </a>",
"    ], while others mandate that specific topics be covered in the counseling session. Abortion providers have an obligation to be informed about local and federal laws covering their practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's hematocrit (or hemoglobin) and Rh(D) status should be determined; other tests may be warranted depending upon her medical or surgical history or indication for the procedure (eg, fibrinogen concentration if there has been an intrauterine fetal death).",
"   </p>",
"   <p>",
"    Many providers screen for sexually transmitted pathogens and treat patients with positive results prior to the pregnancy termination. Others give perioperative antibiotic prophylaxis and omit screening in low risk women or screen at the time of the procedure and subsequently treat positive results as appropriate. Screening guidelines for selecting individuals at increased risk of having sexually transmitted infections can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative ultrasonography should be considered if there is a discrepancy between uterine size and gestational age, uncertain fetal viability, or the diagnosis is in doubt (possible ectopic pregnancy or hydatidiform mole). It is also important, at advanced gestational ages, to insure that the procedure is in accordance with state and federal law. Indeed, recent laws and court rulings have led some providers to perform fetotoxic procedures prior to uterine evacuations so as to ensure that the procedures do not violate any laws concerning later-in-gestation pregnancy terminations.",
"   </p>",
"   <p>",
"    Concurrent intraoperative ultrasonography should be arranged in cases of abnormal cervicouterine architecture (eg, uterine anomaly or fibroids, cervical constriction) or abnormal intrauterine contents (eg, hydatidiform mole).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended for surgical abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/12\">",
"     12",
"    </a>",
"    ] as postabortal endometritis occurs in 5 to 20 percent of women not given antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    (100 mg orally twice per day on the day of the procedure),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    (400 mg orally twice per day on the day of the procedure), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g intravenously 30 minutes prior to the procedure) can be used to help prevent these infections. A meta-analysis found prophylactic antibiotics reduced up to one-half of periabortal endometritis in all subgroups of women undergoing therapeutic abortion, even women at low risk (ie, no history of pelvic inflammatory disease and a negative preoperative chlamydia culture) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/13\">",
"     13",
"    </a>",
"    ]. Sequelae of postabortal infection include infertility, ectopic pregnancy, and chronic pelvic pain.",
"   </p>",
"   <p>",
"    The optimal duration of post procedure therapy has not been determined. In randomized trials, three days appeared to be as effective as seven [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/14\">",
"     14",
"    </a>",
"    ] and one day was more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence regarding the use of antibiotic prophylaxis for medical abortion (ie, no invasive methods for cervical preparation or uterine evacuation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cervical preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation of the cervix to allow insertion of instruments and removal of the products of conception is usually necessary prior to surgical procedures for pregnancy termination. This can be accomplished mechanically using osmotic dilators (eg, laminaria) or rigid dilators, or by using pharmacological agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/17\">",
"     17",
"    </a>",
"    ]). A combination of methods may be needed, although any cervical preparation will likely facilitate the uterine evacuation procedure and reduce the morbidity and mortality associated with the procedure.",
"   </p>",
"   <p>",
"    Adequate cervical preparation can help minimize the occurrence of procedure-related complications, such as cervical laceration and uterine perforation. Risk factors for complications during dilation include: cervical stenosis, uterine anomalies, severe uterine flexion, adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/18\">",
"     18",
"    </a>",
"    ], advanced gestational age, provider inexperience [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and, possibly, parity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/18,20-22\">",
"     18,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rigid dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigid dilation is performed using instrument sets with progressively increasing diameters. Tapered Pratt or Denniston (a plastic equivalent of Pratt) dilators are preferred over blunt Hern or Hegar dilators, which require a greater use of force (",
"    <a class=\"graphic graphic_figure graphicRef82709 graphicRef74741 \" href=\"UTD.htm?18/27/18873\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/23\">",
"     23",
"    </a>",
"    ]. Mechanical dilation is believed to be more traumatic to the cervix than other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link&amp;anchor=H14#H14\">",
"     \"Dilation and curettage\", section on 'Cervical dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Osmotic dilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osmotic dilators (natural: seaweed Laminaria japonica; synthetic: Dilapan-S, Lamicel) absorb cervical moisture, gradually enlarging the endocervical canal and softening the cervix. Osmotic dilator-induced cervical change also results from the release of endogenous prostaglandins, which further soften the cervix and facilitate the dilation process [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of osmotic dilators helps prevent cervical injury and may also decrease the risk of uterine perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/18,19,25\">",
"     18,19,25",
"    </a>",
"    ]. A large cohort study of 15,000 first trimester abortions observed that use of laminaria significantly reduced risk of cervical injury compared to rigid dilators (RR 0.19, 95% CI 0.07-0.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/22\">",
"     22",
"    </a>",
"    ]. In a subsequent larger cohort study (67,175 first trimester abortions), the same authors noted use of laminaria also reduced the risk of uterine perforation, but the result was not statistically significant (RR 0.17, 95% CI 0.02-1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of osmotic dilators is not associated with an increased risk of postabortal infection. Randomized trials that compared use of laminaria to rigid dilation or to Dilapan did not find significant difference is postabortal infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, bacterial contamination is possible because laminaria are produced from seaweed, and sterilization techniques may not be 100 percent effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rare cases, a patient may have a hypersensitivity or anaphylactic reaction to laminaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/31\">",
"     31",
"    </a>",
"    ]. This is likely IgE-mediated due to previous exposure to laminaria during an abortion or other gynecologic procedures.",
"   </p>",
"   <p>",
"    Unlike manual dilation, which is performed immediately before evacuation, osmotic dilators must be placed several hours prior to the procedure to give them time to effect cervical change. The synthetic dilators are more expensive than laminaria, but work more quickly and therefore may be more useful for same-day procedures (",
"    <a class=\"graphic graphic_table graphicRef69543 \" href=\"UTD.htm?37/54/38764\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How to use laminaria &mdash; Proper use of laminaria tents requires that they be inserted and left in place for 12 to 18 hours to achieve optimal cervical dilation (women can be sent home following insertion of the laminaria tents), although they can be removed earlier, after six hours, often with sufficient dilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insertion of a large number of small diameter laminaria (2 or 3 mm) is preferable to using a few large ones (6 mm) because placement is easier and there is better cervical dilation. Some post-insertion cramping is common; a paracervical block or other analgesic approach may be required (",
"    <a class=\"graphic graphic_figure graphicRef64237 \" href=\"UTD.htm?16/0/16385\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The laminaria are kept in place with two 4 by 4 gauze sponges tucked into the fornices and the number of laminaria inserted recorded in the woman's chart. She should avoid intercourse and return to the office when instructed or if she develops bleeding, rupture of membranes, or fever. Failure to remove the laminaria within 48 hours of placement can result in severe infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prostaglandin E1 analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    can also be used for preoperative cervical ripening [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/32-38\">",
"     32-38",
"    </a>",
"    ]. Prostaglandin analogues are equivalent to osmotic dilators in reducing the amount of force needed for cervical dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/39\">",
"     39",
"    </a>",
"    ]; comparative studies are need to evaluate whether they decrease the incidence of major immediate complications, such as uterine perforation and cervical laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dose of 400 mcg per vagina two to three hours prior to the procedure was recommended in a study attempting to determine optimal dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/31\">",
"     31",
"    </a>",
"    ], administration only one hour before termination was not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/34\">",
"     34",
"    </a>",
"    ]. The 400 mcg dose is equivalent to placement of one medium laminaria for four hours, but causes less patient discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/41\">",
"     41",
"    </a>",
"    ]. In Europe, the PGE1 analog gemeprost (1 mg per vaginam three hours before surgery) is commonly used for cervical ripening, but this drug is not available in the United States.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was used in first trimester procedures, 97 percent of patients had cervical dilation of at least 8 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in second trimester procedures at 13 to 16 weeks of gestation, same day misoprostol was not as effective as laminaria placed the day before the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/37\">",
"     37",
"    </a>",
"    ]. A randomized trial comparing these two techniques found that use of laminaria resulted in greater mean initial dilation (43 versus 33 French [each French unit equals 0.33 mm in diameter]), less need for additional dilation (21 versus 80 percent of patients), and faster procedure times in nulliparous women (3.4 versus 9.5 minutes). Although the procedure was technically easier when laminaria were used, patients generally preferred the comfort and convenience of same day misoprostol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiprogesterone",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    promotes cervical dilation for uterine evacuation, and may facilitate manual and osmotic dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This is an off-label use and is not recommended outside of clinical investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Isosorbide dinitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     Isosorbide dinitrate",
"    </a>",
"    has also been used for cervical ripening, with mixed results compared to prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/38,39,42,43\">",
"     38,39,42,43",
"    </a>",
"    ]. The major side effect is headache.",
"   </p>",
"   <p>",
"    Regardless of the method used to dilate the cervix, preoperative cervical dilation with osmotic dilators or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is safe and effective for second-trimester uterine evacuation procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women experience pain despite use of a paracervical block, preoperative administration of analgesics, or conscious sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited evidence from histological and neurophysiological studies suggests that the fetus does not perceive pain before the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/47\">",
"     47",
"    </a>",
"    ]. There are no proven regimens for providing fetal",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    either via direct fetal injection or transplacentally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthesia (eg, paracervical or uterosacral block) with or without intravenous sedation is sufficient for most first trimester procedures. Most second trimester procedures require some sedation.",
"   </p>",
"   <p>",
"    Options for conscious sedation include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    (2 mg IV) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (100 mcg IV). Sedation administered orally medications is not as effective as intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/48\">",
"     48",
"    </a>",
"    ]. If conscious sedation is planned, the patient should fast for at least six hours prior to the procedure and have someone accompany her on the day of the procedure because she should not go home alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of a nonsteroidal antiinflammatory drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    600 to 800 mg) one hour prior to the procedure appears to diminish intraoperative and postoperative discomfort. Ibuprofen provided better analgesia than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    for first trimester surgical abortions in one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/49\">",
"     49",
"    </a>",
"    ]. Use of these agents does not appear to interfere with the actions of prostaglandins used for termination of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Paracervical block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracervical block is placed by injecting a total dose of approximately 10 to 20 mL of anesthetic agent (eg, 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) deep into the cervical stroma at the 12, 4, and 8 o'clock positions (",
"    <a class=\"graphic graphic_figure graphicRef64237 \" href=\"UTD.htm?16/0/16385\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The dose of 10 mL of 1 percent lidocaine (100 mg) [maximum dose 4.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight or 20 mL for a 50 kg woman] achieves a peak plasma level well below the toxic range and occurs 10 to 15 minutes following the injection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/52\">",
"     52",
"    </a>",
"    ]. If laminaria or synthetic dilators were inserted, the paracervical block can be deferred until after their removal.",
"   </p>",
"   <p>",
"    Before injecting, negative pressure should be placed on the syringe to ensure that the needle is not within a blood vessel. Inadvertent injection into the highly vascular gravid uterus can result in serious cardiogenic complications and convulsions. Some operators prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/17/3350?source=see_link\">",
"     chloroprocaine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    because the rapid metabolism of chloroprocaine confers a safety benefit in the event of an unintentional intravascular injection.",
"   </p>",
"   <p>",
"    Vasovagal syncope (or \"cervical shock\") can occur after administration of a paracervical block. These episodes are self-limited and can be differentiated from seizure activity by bradycardia, rapid recovery, and lack of a postictal state.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    (0.5 to 1 mg every five minutes, not to exceed a total of 3 mg or 0.04",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be used to treat such patients or can be added to the administered anesthetic agent to prevent vasovagal syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many operators add synthetic vasopressin (Pitressin) or other vasoactive substances to the injectable anesthetic to reduce intra- and post-operative blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neuraxial or general anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal, epidural, or general anesthesia may be used if the patient strongly desires or if required because extensive intrauterine manipulation is expected (eg, presence of submucosal leiomyomas, advanced gestational age). These types of anesthesia have usually been considered to be less safe than local anesthesia due to increased risk of hemorrhage and visceral injury related to uterine perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Nonetheless, more modern techniques and materials have considerably reduced the morbidity associated with such anesthesia procedures.",
"   </p>",
"   <p>",
"    The CDC reported that anesthesia related complications accounted for 35 percent of first trimester abortion related deaths, while hemorrhage, infection, and thromboembolism accounted for only 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/56\">",
"     56",
"    </a>",
"    ]. A review of the risks and benefits of the various",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    options should be included in the preoperative discussion and consent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHOICE OF TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary factors in choosing a particular surgical technique are the volume and content of intrauterine tissue and the experience of the surgeon.",
"   </p>",
"   <p>",
"    In 2003, the types and frequencies of procedures performed in the United States were: suction or sharp curettage (90.9 percent [fewer than 2 percent by sharp curettage]), intrauterine instillation (0.4 percent), medical (7.7 percent), and other (1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation and evacuation (D&amp;E) procedures involve mechanically opening the uterine cervix followed by evacuation of intrauterine contents. They can be performed in a uterus of almost any size for removal of most types of intrauterine contents (eg, placenta, molar tissue, fetal tissue). These procedures are the most common method of pregnancy termination at &le;14 weeks of gestation. Skilled physicians perform extraction procedures at later gestational ages.",
"   </p>",
"   <p>",
"    Hysterotomy and hysterectomy are now rarely performed for abortion and have been shown to be less safe than extraction procedures and nonsurgical methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonsurgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical methods may be employed in very early (&lt;7 to 9 weeks) and late pregnancy terminations (&ge;15 weeks); surgical methods are recommended for pregnancies between these gestational ages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      can also been used for termination of pregnancies under 8 weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link&amp;anchor=H33#H33\">",
"       \"Mifepristone for the medical termination of pregnancy\", section on 'Alternative medical methods'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In early pregnancy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      -alone regimens may be the treatment of choice in settings in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      are not available or are too costly. Misoprostol is commonly used as a single agent for second trimester induced abortion in the United States and many other parts of the world. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link\">",
"       \"Misoprostol as a single agent for medical termination of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For uterine evacuation &ge;15 weeks of gestation, systemic or intraamniotic abortifacients (eg, intravaginal prostaglandins, intraamniotic saline or prostaglandin F2 alpha) are administered to induce labor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"       \"Termination of pregnancy: Second trimester\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physicians who use nonsurgical methods must be prepared to employ surgical techniques of uterine evacuation when there are retained products of conception, a common occurrence following labor induction methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are observed for at least 30 minutes to monitor for vaginal hemorrhage or changes in vital signs suggestive of intraabdominal bleeding. Women who are Rh(D)-negative and unsensitized should receive 300 mcg Rh(D)-immune globulin following the procedure (50 mcg is sufficient for procedures in the first trimester).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"     Methylergonovine",
"    </a>",
"    maleate (0.2 mg orally every four hours for as many as five doses) is given by some providers to decrease postabortal bleeding resulting from uterine atony and to help prevent the development of hematometra [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women experience mild lower abdominal cramping for two to four days after the procedure, which can be treated with nonsteroidal antiinflammatory drugs.",
"   </p>",
"   <p>",
"    Women should be informed that vaginal passage of small amounts of tissue and blood can be expected following the procedure. They are instructed to expect some lower abdominal cramping and vaginal bleeding comparable to menstrual flow in volume. Severe manifestations of these signs and symptoms or fever may presage serious complications and require immediate evaluation by a physician.",
"   </p>",
"   <p>",
"    All patients should receive a 24-hour contact number in case of emergency. The physician should be called if heavy bleeding, fever, or abdominal pain develop. Most such complications occur within one week of the procedure. The physician should also be contacted if pregnancy symptoms have not resolved within one week or if menses have not returned by six weeks after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/61\">",
"     61",
"    </a>",
"    ]. Vaginal intercourse and use of tampons are restricted for two weeks postprocedure to reduce the risk of infection, especially toxic shock syndrome.",
"   </p>",
"   <p>",
"    Routine discharge instructions can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First trimester suction curettage is the safest method for surgical pregnancy termination; second-trimester techniques of extraction, intraamniotic instillation of abortifacients, and hysterotomy or hysterectomy all carry higher complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Early complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction curettage procedures performed in an outpatient setting have low rates of morbidity and mortality, comparable to procedures performed within a hospital setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/65\">",
"     65",
"    </a>",
"    ]. Immediate complications include hemorrhage, cervical laceration, and uterine perforation. These complications occurred in only 0.06 percent of 170,000 consecutive cases reported in one series from Planned Parenthood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/19\">",
"     19",
"    </a>",
"    ]. In this series, 0.07 percent of women required hospitalization because of incomplete abortion, sepsis, uterine perforation, hemorrhage, inability to complete the procedure, or combined (intrauterine and tubal) pregnancy. Minor complications, such as mild infection, incomplete abortion requiring re-suction in an ambulatory setting, cervical stenosis or laceration, or convulsive seizure due to administration of local anesthetic, occurred in 0.84 percent.",
"   </p>",
"   <p>",
"    However, two other series that may better reflect the complication rate in the average clinic reported immediate minor complication rates (infection, laceration, incomplete abortion) of 1 to 5 percent, and major complications rates of 0.1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postabortal hemorrhage may result from cervical or vaginal lacerations, uterine perforation, retained tissue, or uterine atony. Other causes of hemorrhage include infection, uterine arteriovenous malformation, placenta accreta, and coagulopathy (secondary to release of tissue thromboplastin into the maternal venous system).",
"   </p>",
"   <p>",
"    The Society of Family Planning (SFP) guidelines advise the following general approach to postabortal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment and examination",
"     </li>",
"     <li>",
"      Uterine massage and medical therapy",
"     </li>",
"     <li>",
"      Resuscitative measures with laboratory evaluation and possible re-aspiration or balloon tamponade",
"     </li>",
"     <li>",
"      Additional interventions (eg, embolization, surgery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of cervical laceration can be reduced by using cervical preparation with osmotic dilators or prostaglandins (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Cervical preparation'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/69\">",
"     69",
"    </a>",
"    ]. Atony can be treated with uterotonic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    maleate 0.2 mg intramuscularly; carboprost 250 mcg intramuscularly may repeat at 15 to 90 minute intervals to a total dose of 2 mg;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    1000 mcg per rectum). Actively bleeding lacerations and perforations must be repaired and retained tissue extracted.",
"   </p>",
"   <p>",
"    Pelvic embolization has also been successful for treatment of hemorrhage when the patient is stable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. As a temporizing measure to tamponade bleeding, a Foley catheter can be placed into the uterine cavity and the 30 mL balloon expanded with 50 to 60 mL saline or water.",
"   </p>",
"   <p>",
"    Treatment of postabortion hemorrhage is similar to postpartum hemorrhage following vaginal delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If laparoscopy or laparotomy is required, measures to control hemorrhage in gynecologic surgery are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both first and second trimester procedures, the reported rate of uterine perforation is less than 0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The specific location of a uterine perforation determines the extent of hemorrhage and expression of symptoms.",
"   </p>",
"   <p>",
"    Two factors associated with a decreased risk of perforation during pregnancy termination are (1) performance by an experienced surgeon (inexperienced physicians have a 5.5-fold increase in perforations as compared to attending staff) and (2) use of preoperative cervical dilation with osmotic dilators [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uterine perforation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hematometra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate postoperative pain without overt bleeding from the vagina may indicate development of hematometra. Hematometra (also known as uterine distension syndrome or postabortal syndrome) usually presents with complaints of dull, aching lower abdominal pain, sometimes accompanied by tachycardia, diaphoresis, or nausea. The onset is usually within the first hour after completion of the procedure. Pelvic examination reveals a large midline globular uterus that is tense and tender. Treatment requires immediate uterine evacuation, permitting the uterus to contract to a normal postprocedure size. Administration of intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    maleate (0.2 mg) is then given to ensure continued contraction of the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Maternal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimated maternal mortality by pregnancy outcome is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef63961 \" href=\"UTD.htm?5/21/5467\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    First trimester procedures are safer than second trimester procedures (0.1 to 0.4 deaths per 100,000 first trimester procedures versus 1.7 to 8.9 deaths per 100,000 second trimester procedures) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/76\">",
"     76",
"    </a>",
"    ]. Suction curettage has the lowest maternal mortality rate of any surgical pregnancy termination method. One study reported no maternal deaths in 170,000 consecutive first-trimester suction curettage procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/19\">",
"     19",
"    </a>",
"    ]. Moreover, the overall death rate from all legal abortions (0.6 per 100,000 operations) was far less than the maternal mortality rate of 8.8 per 100,000 live births in the United States from 1998 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In 2002, a total of nine women died as a result of legal induced abortions in the United States, and none died as a result of illegal induced abortions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, deaths from unsafe illegal abortion account for a significant percentage of all maternal deaths worldwide. The World Health Organization estimated that one maternal death in eight was due to abortion-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/79\">",
"     79",
"    </a>",
"    ]. In some developing countries where abortion is illegal, &ge;25 percent of all maternal deaths are abortion-related [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal mortality is lowest before 8 weeks of gestation, and increases rapidly after 18 weeks of gestation (&lt;0.3 per 100,000 induced abortions at &le;8 weeks versus 7 per 100,000 at 16 to 20 weeks and 11 per 100,000 at &ge;21 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/76\">",
"     76",
"    </a>",
"    ]. From 1988 to 1997, the distribution of causes of death was infection (27 percent), hemorrhage (24 percent), embolism (17 percent), anesthesia complications (16 percent), other (15 percent), and unknown (1 percent). The frequency of each complication varied according to the gestational age at the time of the procedure.",
"   </p>",
"   <p>",
"    Among second trimester procedures, the Joint Program for the Study of Abortion (JPSA) reported extraction to be associated with the lowest maternal",
"    <span class=\"nowrap\">",
"     death/case",
"    </span>",
"    ratio when compared to instillation techniques or",
"    <span class=\"nowrap\">",
"     hysterotomy/hysterectomy",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/55,81\">",
"     55,81",
"    </a>",
"    ]. The maternal mortality rate from extraction procedures increases with advancing gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/82\">",
"     82",
"    </a>",
"    ], and becomes similar to that of instillation procedures later in the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/55\">",
"     55",
"    </a>",
"    ]. By comparison, second-trimester extraction is as safe for the woman as having a normal pregnancy and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/83\">",
"     83",
"    </a>",
"    ]. Overall, elective abortion at any gestational age is safer for the mother than carrying a pregnancy to term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Delayed complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late complications of suction curettage are those occurring more than 72 hours after the procedure; they develop in approximately 1 percent of cases. Fever, infection, hemorrhage, and retained products of conception are the most common delayed complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/19,84\">",
"     19,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Infection/retained products of conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postabortal endometritis occurs in 5 to 20 percent of women not given prophylactic antibiotics; this rate may be reduced by about one-half if prophylactic antibiotics are given [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/13\">",
"     13",
"    </a>",
"    ]. Retained tissue is an uncommon complication of pregnancy termination. In one series with follow-up information on 80 percent of patients who underwent pregnancy termination, retained products of conception were present in 4 of 672 first trimester procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms are similar for isolated endometritis and endometritis with retained products of conception (placental tissue, fetal fragments, fetal membranes), and include fever, an enlarged tender uterus, lower abdominal pain, and uterine bleeding greater than expected postabortion. Ultrasonography can help distinguish these two groups if retained products are visualized in the uterine cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/85\">",
"     85",
"    </a>",
"    ]. Any physical or sonographic evidence of retained products of conception should prompt consideration of suction curettage to complete evacuation of the uterus. In the absence of detectable retained material, a presumptive diagnosis of endometritis may be made and treated with a trial of broad spectrum antibiotic therapy, with coverage of anaerobes (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    [2 g intravenously] plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [100 mg intravenously or orally] every 12 hours). This regimen can be completed as an outpatient oral regimen for a 14-day course. An alternative outpatient regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    250 mg intramuscularly in a single dose plus doxycycline 100 mg orally twice a day for 14 days with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg orally twice a day for 14 days.",
"   </p>",
"   <p>",
"    Generalized abdominal tenderness, guarding, tachycardia, high fever, and prostration suggest advanced sepsis. These patients require aggressive therapy with broad spectrum intravenous antibiotics, uterine re-evacuation, assessment for uterine perforation, and monitoring and support in an intensive care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Ongoing pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing pregnancy is more likely to be a complication of early rather than late abortion. All women will continue to have an elevated level of hCG for a short period following pregnancy termination. Return of the serum hCG concentration to undetectable following pregnancy termination varies widely from 7 to 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/86\">",
"     86",
"    </a>",
"    ]. The period of time depends primarily upon the hCG concentration at the time of termination. The hCG concentration peaks at 8 to 11 weeks at approximately 90,000 mIU. This is in contrast with term pregnancy, for which the hCG concentration is lower. The decline in serum hCG is rapid for the first several days (half-life 9 to 31 hours) and then proceeds more slowly (half-life 55 to 64 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=see_link&amp;anchor=H4#H4\">",
"     \"Human chorionic gonadotropin testing\", section on 'Pregnancy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    An ongoing intrauterine pregnancy may occur after an attempted pregnancy termination if the products of conception are not closely examined by an experienced clinician at the time of the procedure (and by a pathologist) to verify successful completion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link&amp;anchor=H7#H7\">",
"     \"Surgical termination of pregnancy: First trimester\", section on 'Examination of tissue'",
"    </a>",
"    .) Alternatively, ongoing pregnancy may rarely result from a multiple gestation in which only one of the sacs was aborted. In one series of 12,138 consecutive abortions with careful examination of the pathologic specimen, three continuing pregnancies were later diagnosed and attributed to physician error [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/90\">",
"     90",
"    </a>",
"    ]. Two were at 6 weeks and one was at 8 weeks of gestation. A second series reported an ongoing pregnancy rate of 1.3 per 1000 procedures for pregnancies less than 6 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and risk of possible damage to the ongoing pregnancy from an attempted abortion cannot be quantified. Direct or indirect injury to the developing embryo could occur. One preliminary report suggested there may be an increased risk of Moebius sequence with autism in children exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/92\">",
"     92",
"    </a>",
"    ]. Moebius sequence is a clinical condition characterized by ophthalmic-facial palsy and muscle or bone malformations in the limbs. It represents a cascade of events resulting from embryo trauma from varied etiologies (eg, genetic factors, environmental injuries, prolonged membrane ruptures and chorion villus sampling). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link&amp;anchor=H33#H33\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\", section on 'Teratogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Future pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting results have been reported from studies evaluating whether prior induced abortion is a risk factor for preterm delivery in a subsequent pregnancy. A review of ten studies of the long-term impact of vacuum aspiration for first trimester induced abortion found that women whose first pregnancy ended in induced abortion had no greater risk of bearing low birth weight babies, delivering prematurely, or suffering spontaneous abortions in subsequent pregnancies than women who carried their first pregnancy to term [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. Pregnancy termination did not have the same salutatory effects on the following pregnancy (eg, shorter labor, lower rate of preeclampsia) as a full term normal pregnancy. On the other hand, a meta-analysis of 37 studies reported that women with versus without a history of pregnancy termination had a significantly increased risk of low birth weight infants (OR 1.4, 95% CI 1.2-1.5) and preterm delivery (OR 1.4, 95% CI 1.2-1.5), but not infants who were small for gestational age (OR 0.87, 95% CI 0.7-1.1) in subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only two series addressing future pregnancy in women who have undergone a prior second trimester evacuation procedure using laminaria did not report any cases of spontaneous midtrimester loss nor an increased risk of spontaneous preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. However, other studies have suggested abortion may increase the risk of subsequent preterm birth. All of these retrospective studies are flawed because they are subject to recall bias and inadequate adjustment of other risk factors for adverse pregnancy outcome (eg, sexually transmitted disease, smoking). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors for preterm labor and delivery\", section on 'History of abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of a link between induced abortion and subsequent placental problems has also been studied. A report of all primigravid women delivering in Denmark from 1980 to 1982 used data from the Danish Birth, Hospital Discharge, and Induced Abortion Registries to compare the risk of placental complications in subsequent pregnancy among 15,727 women who underwent first trimester termination and 46,026 women did not have a termination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/99\">",
"     99",
"    </a>",
"    ]. There was no difference in the risk of placenta previa, but women with a previous termination had a slightly higher rate of retained placenta (OR 1.17, 95 percent CI 1.02 to 1.35).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Early Reproductive Events and Breast Cancer Workshop convened by the National Cancer Institute in 2003 concluded Induced abortion is",
"    <strong>",
"     not",
"    </strong>",
"    associated with an increase in breast cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/100\">",
"     100",
"    </a>",
"    ]. Data from studies published subsequent to this workshop have confirmed this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/101-104\">",
"     101-104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     CONTRACEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraception should be discussed prior to and reviewed immediately after the termination. Ovulation can occur two weeks after a first trimester abortion, thus immediate contraception is important (if desired) and can be initiated the day of the procedure. A full discussion of post-termination contraception can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FOLLOW UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy symptoms generally should have dissipated within one week of the pregnancy termination and normal menses should return within six weeks. The absence of these findings could suggest ongoing intrauterine or ectopic pregnancy or incomplete abortion.",
"   </p>",
"   <p>",
"    A routine follow-up visit two to four weeks after the procedure is intended to confirm that the abortion is complete and to diagnose and treat complications. In addition, general reproductive health care (eg, contraceptive plans, cervical cytology) may be performed if not initiated preoperatively or at the time of the pregnancy termination. However, there is no evidence that routine in-person follow-up after first trimester abortion is necessary to detect conditions that the women themselves could not be taught to recognize [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/61\">",
"     61",
"    </a>",
"    ]. Telephone follow-up 24 to 48 hours after the procedure and patient education about signs of incomplete abortion, ectopic pregnancy, and infection may be adequate, with more intensive follow-up of higher risk patients (eg, uterine anomaly, psychosexual issues) and those with second trimester procedures.",
"   </p>",
"   <p>",
"    Fever, pelvic pain, uterine enlargement, heavy bleeding, passage of tissue, and on-going pregnancy symptoms require further evaluation. After induced abortion, hCG is detectable for as long as 60 days, with a median of 30 days after uterine evacuation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/86,105-108\">",
"     86,105-108",
"    </a>",
"    ]; therefore, the presence of hCG is not generally useful for diagnosis of incomplete abortion and should not be ordered for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     WOMEN'S FEELINGS AFTER PREGNANCY TERMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common emotional reactions after pregnancy termination are relief, transient guilt, sadness, and a sense of loss [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/109\">",
"     109",
"    </a>",
"    ]. There is no good evidence from large surveys that choosing to terminate an unwanted first pregnancy places a woman at higher risk of subsequent depression than choosing to deliver an unwanted first pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. The frequency of psychiatric diagnoses in women who have undergone an abortion procedure is similar to that in women with no such history.",
"   </p>",
"   <p>",
"    Risk factors for postabortal psychosocial problems include previous or concurrent psychiatric illness, coercion, medical indications that force the patient to chose between possible life threatening complications and termination of a wanted pregnancy, increasing length of gestation, ambivalence, and lack of social support [",
"    <a class=\"abstract\" href=\"UTD.htm?19/2/19498/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. In 1993, the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders revised (DSM-IV-R) ceased to recognize abortion as a type of psychosocial stressor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=see_link\">",
"       \"Patient information: Abortion (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=see_link\">",
"       \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physicians performing any uterine evacuation procedure should obtain a comprehensive patient history, perform a complete physical examination with special attention to the uterine size and position, and obtain confirmation of pregnancy. The gestational age should be determined by both menstrual history and bimanual examination; ultrasound examination is useful if there is any uncertainty and at advanced gestational ages. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preoperative considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic prophylaxis is recommended because it significantly reduces the frequency of postabortal endometritis. Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice per day on the day of the procedure),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      (400 mg orally twice per day on the day of the procedure), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g intravenously 30 minutes prior to the procedure). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's hematocrit (or hemoglobin) and Rh(D) status should be determined. Rh(D)-negative patients should receive anti-D immune globulin after the procedure. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       Mifepristone",
"      </a>",
"      (RU-486), an antiprogestin, can be used for the medical termination of early pregnancies (typically up to 63 days of gestation). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Choice of technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical preparation may be performed with osmotic dilators or prostaglandins, depending on clinician and patient preference. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cervical preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physicians who use nonsurgical methods for pregnancy termination must be prepared themselves or in conjunction with another physician to employ surgical techniques for evaluation and treatment of complications such as hemorrhage and retained products of conception. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/1\">",
"      Pazol K, Zane SB, Parker WY, et al. Abortion surveillance--United States, 2008. MMWR Surveill Summ 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.guttmacher.org/datacenter/profiles/US.jsp (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/3\">",
"      Sedgh G, Singh S, Shah IH, et al. Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet 2012; 379:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/4\">",
"      Montouchet C, Trussell J. Unintended pregnancies in England in 2010: costs to the National Health Service (NHS). Contraception 2013; 87:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/5\">",
"      Jones RK, Darroch JE, Henshaw SK. Patterns in the socioeconomic characteristics of women obtaining abortions in 2000-2001. Perspect Sex Reprod Health 2002; 34:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/6\">",
"      Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/7\">",
"      Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health 2008; 40:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/8\">",
"      Finer LB, Frohwirth LF, Dauphinee LA, et al. Reasons U.S. women have abortions: quantitative and qualitative perspectives. Perspect Sex Reprod Health 2005; 37:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/9\">",
"      Grimes DA, Cates W Jr, Selik RM. Abortion facilities and the risk of death. Fam Plann Perspect 1981; 13:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/10\">",
"      Chervenak FA, McCullough LB. Ethics in fetal medicine. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13:491.",
"     </a>",
"    </li>",
"    <li>",
"     www.agi-usa.org/pubs/ib_minors/minors_table.html. (Accessed 6/6/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/12\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 74. Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2006; 108:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/13\">",
"      Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996; 87:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/14\">",
"      Lichtenberg ES, Shott S. A randomized clinical trial of prophylaxis for vacuum abortion: 3 versus 7 days of doxycycline. Obstet Gynecol 2003; 101:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/15\">",
"      Darj E, Str&aring;lin EB, Nilsson S. The prophylactic effect of doxycycline on postoperative infection rate after first-trimester abortion. Obstet Gynecol 1987; 70:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/16\">",
"      Levallois P, Rioux JE. Prophylactic antibiotics for suction curettage abortion: results of a clinical controlled trial. Am J Obstet Gynecol 1988; 158:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/17\">",
"      Khazardoost S, Hantoushzadeh S, Madani MM. A randomised trial of two regimens of vaginal misoprostol to manage termination of pregnancy of up to 16 weeks. Aust N Z J Obstet Gynaecol 2007; 47:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/18\">",
"      Cates W Jr, Schulz KF, Grimes DA. The risks associated with teenage abortion. N Engl J Med 1983; 309:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/19\">",
"      Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990; 76:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/20\">",
"      Kaunitz AM, Rovira EZ, Grimes DA, Schulz KF. Abortions that fail. Obstet Gynecol 1985; 66:533.",
"     </a>",
"    </li>",
"    <li>",
"     Ferris, LE. Can Med Assoc J; 154:1677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/22\">",
"      Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983; 1:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/23\">",
"      Hulka JF, Lefler HT Jr, Anglone A, Lachenbruch PA. A new electronic force monitor to measure factors influencing cervical dilation for vacuum curettage. Am J Obstet Gynecol 1974; 120:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/24\">",
"      Chanda M, Mackenzie P, Day JH. Hypersensitivity reactions following laminaria placement. Contraception 2000; 62:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/25\">",
"      Hale RW, Pion RJ. Laminaria: an underutilized clinical adjunct. Clin Obstet Gynecol 1972; 15:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/26\">",
"      Uldbjerg N, Ulmsten U. The physiology of cervical ripening and cervical dilatation and the effect of abortifacient drugs. Baillieres Clin Obstet Gynaecol 1990; 4:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/27\">",
"      Hern WM. Laminaria versus Dilapan osmotic cervical dilators for outpatient dilation and evacuation abortion: randomized cohort comparison of 1001 patients. Am J Obstet Gynecol 1994; 171:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/28\">",
"      Sutkin G, Capelle SD, Schlievert PM, Creinin MD. Toxic shock syndrome after laminaria insertion. Obstet Gynecol 2001; 98:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/29\">",
"      Lin SY, Cheng WF, Su YN, et al. Septic shock after intracervical laminaria insertion. Taiwan J Obstet Gynecol 2006; 45:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/30\">",
"      Acharya PS, Gluckman SJ. Bacteremia following placement of intracervical laminaria tents. Clin Infect Dis 1999; 29:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/31\">",
"      Singh K, Fong YF, Prasad RN, Dong F. Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol 1998; 92:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/32\">",
"      Ashok PW, Flett GM, Templeton A. Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. Am J Obstet Gynecol 2000; 183:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/33\">",
"      Ngai SW, Yeung KC, Lao T, Ho PC. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study. Br J Obstet Gynaecol 1996; 103:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/34\">",
"      Sharma S, Refaey H, Stafford M, et al. Oral versus vaginal misoprostol administered one hour before surgical termination of pregnancy: a randomised controlled trial. BJOG 2005; 112:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/35\">",
"      Oppegaard KS, Qvigstad E, Nesheim BI. Oral versus self-administered vaginal misoprostol at home before surgical termination of pregnancy: a randomised controlled trial. BJOG 2006; 113:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/36\">",
"      Gupta JK, Johnson N. Should we use prostaglandins, tents or progesterone antagonists for cervical ripening before first trimester abortion? Contraception 1992; 46:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/37\">",
"      Goldberg AB, Drey EA, Whitaker AK, et al. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. Obstet Gynecol 2005; 106:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/38\">",
"      Thomson AJ, Lunan CB, Ledingham M, et al. Randomised trial of nitric oxide donor versus prostaglandin for cervical ripening before first-trimester termination of pregnancy. Lancet 1998; 352:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/39\">",
"      Ledingham MA, Thomson AJ, Lunan CB, et al. A comparison of isosorbide mononitrate, misoprostol and combination therapy for first trimester pre-operative cervical ripening: a randomised controlled trial. BJOG 2001; 108:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/40\">",
"      Nucatola D, Roth N, Saulsberry V, Gatter M. Serious adverse events associated with the use of misoprostol alone for cervical preparation prior to early second trimester surgical abortion (12-16 weeks). Contraception 2008; 78:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/41\">",
"      MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 1999; 93:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/42\">",
"      Li CF, Chan CW, Ho PC. A comparison of isosorbide mononitrate and misoprostol cervical ripening before suction evacuation. Obstet Gynecol 2003; 102:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/43\">",
"      Arteaga-Troncoso G, Villegas-Alvarado A, Belmont-Gomez A, et al. Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conception. BJOG 2005; 112:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/44\">",
"      Newmann SJ, Dalve-Endres A, Diedrich JT, et al. Cervical preparation for second trimester dilation and evacuation. Cochrane Database Syst Rev 2010; :CD007310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/45\">",
"      Keder LM. Best practices in surgical abortion. Am J Obstet Gynecol 2003; 189:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/46\">",
"      Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004; 104:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/47\">",
"      Lee SJ, Ralston HJ, Drey EA, et al. Fetal pain: a systematic multidisciplinary review of the evidence. JAMA 2005; 294:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/48\">",
"      Allen RH, Fitzmaurice G, Lifford KL, et al. Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol 2009; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/49\">",
"      Romero I, Turok D, Gilliam M. A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. Contraception 2008; 77:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/50\">",
"      Glantz JC, Shomento S. Comparison of paracervical block techniques during first trimester pregnancy termination. Int J Gynaecol Obstet 2001; 72:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/51\">",
"      Wiebe ER. Comparison of the efficacy of different local anesthetics and techniques of local anesthesia in therapeutic abortions. Am J Obstet Gynecol 1992; 167:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/52\">",
"      Blanco LJ, Reid PR, King TM. Plasma lidocaine levels following paracervical infiltration for aspiration abortion. Obstet Gynecol 1982; 60:506.",
"     </a>",
"    </li>",
"    <li>",
"     Stubblefield, PG. Pregnancy termination. p. 1303. In Gabbe SG, Niebyl JR, Simpson JL (eds): Obstetrics: Normal and Problem Pregnancies. 2nd Ed. Churchill Livingstone, New York, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/54\">",
"      Peterson HB, Grimes DA, Cates W Jr, Rubin GL. Comparative risk of death from induced abortion at less than or equal to 12 weeks' gestation performed with local versus general anesthesia. Am J Obstet Gynecol 1981; 141:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/55\">",
"      Grimes DA, Schulz KF. Morbidity and mortality from second-trimester abortions. J Reprod Med 1985; 30:505.",
"     </a>",
"    </li>",
"    <li>",
"     Hopkins, E, Green, C, Berg, C, et al. Abortion mortality, United States 1972-1991: Gestational age and cause of death. In: Proceedings of National Abortion Federation Annual Meeting; Boston: May 4-6, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/57\">",
"      Gamble SB, Strauss LT, Parker WY, et al. Abortion surveillance--United States, 2005. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     Shulman, LP, Elias, S, Simpson, JL. Induced abortion for genetic indications: techniques and complications. p. 721. In Milunsky A (ed): Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment. Johns Hopkins University Press, Baltimore, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/59\">",
"      Sands RX, Burnhill MS, Hakim-Elahi E. Postabortal uterine atony. Obstet Gynecol 1974; 43:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/60\">",
"      de Groot AN, van Dongen PW, Vree TB, et al. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs 1998; 56:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/61\">",
"      Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first-trimester induced abortion. Obstet Gynecol 2004; 103:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/62\">",
"      Hodgson JE. Major complications of 20,248 consecutive first trimester abortions: problems of fragmented care. Adv Plan Parent 1975; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/63\">",
"      Nathanson BN. Ambulatory abortion: experience with 26,000 cases (July 1, 1970, to August 1, 1971). N Engl J Med 1972; 286:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/64\">",
"      Hodgson JE, Portmann KC. Complications of 10,453 consecutive first-trimester abortions: a prospective study. Am J Obstet Gynecol 1974; 120:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/65\">",
"      Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril 1986; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/66\">",
"      Thonneau P, Fougeyrollas B, Ducot B, et al. Complications of abortion performed under local anesthesia. Eur J Obstet Gynecol Reprod Biol 1998; 81:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/67\">",
"      Westfall JM, Sophocles A, Burggraf H, Ellis S. Manual vacuum aspiration for first-trimester abortion. Arch Fam Med 1998; 7:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/68\">",
"      Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131. Contraception 2013; 87:331.",
"     </a>",
"    </li>",
"    <li>",
"     Atienza, MF, Burkman, RT, King, TM. Forces associated with cervical dilatation at suction abortion: qualitative and quantitative data in studies completed with a force-sensing instrument. p. 343. In Naftolin F, Stubblefield PG (eds): Dilatation of the Uterine Cervix. Raven Press, New York, 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/70\">",
"      Borgatta L, Chen AY, Reid SK, et al. Pelvic embolization for treatment of hemorrhage related to spontaneous and induced abortion. Am J Obstet Gynecol 2001; 185:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/71\">",
"      Steinauer, JE. Uterine Artery Embolization in Postabortion Hemorrhage, Obstet Gynecol 2008; 111:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/72\">",
"      Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters 2008; 16:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/73\">",
"      Amarin ZO, Badria LF. A survey of uterine perforation following dilatation and curettage or evacuation of retained products of conception. Arch Gynecol Obstet 2005; 271:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/74\">",
"      Ben-Baruch G, Menczer J, Shalev J, et al. Uterine perforation during curettage: perforation rates and postperforation management. Isr J Med Sci 1980; 16:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/75\">",
"      Grimes DA, Schulz KF, Cates WJ Jr. Prevention of uterine perforation during curettage abortion. JAMA 1984; 251:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/76\">",
"      Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 2004; 103:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/77\">",
"      Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol 2012; 119:215.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/mmwr/preview/mmwrhtml/ss5511a1.htm?s_cid=ss5511a1_e (Accessed November 27, 2006).",
"    </li>",
"    <li>",
"     Abortion: A Tabulation of Available Information, 3rd edition. World Health Organization, Geneva, 1997.",
"    </li>",
"    <li>",
"     www.who.int/docstore/world-health-day/en/pages1998/whd98_10.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/81\">",
"      Atrash HK, MacKay HT, Binkin NJ, Hogue CJ. Legal abortion mortality in the United States: 1972 to 1982. Am J Obstet Gynecol 1987; 156:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/82\">",
"      Lawson HW, Frye A, Atrash HK, et al. Abortion mortality, United States, 1972 through 1987. Am J Obstet Gynecol 1994; 171:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/83\">",
"      Rovinsky JJ. Abortion on demand. Mt Sinai J Med 1984; 51:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/84\">",
"      Tietze C. Report of the Swedish Abortion Committee. Stud Fam Plann 1972; 3:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/85\">",
"      Wolman I, Gordon D, Yaron Y, et al. Transvaginal sonohysterography for the evaluation and treatment of retained products of conception. Gynecol Obstet Invest 2000; 50:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/86\">",
"      Steier JA, Bergsj&oslash; P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984; 64:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/87\">",
"      Billieux MH, Petignat P, Anguenot JL, et al. Early and late half-life of human chorionic gonadotropin as a predictor of persistent trophoblast after laparoscopic conservative surgery for tubal pregnancy. Acta Obstet Gynecol Scand 2003; 82:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/88\">",
"      Mock P, Chardonnens D, Stamm P, et al. The apparent late half-life of human chorionic gonadotropin (hCG) after surgical treatment for ectopic pregnancy. A new approach to diagnose persistent trophoblastic activity. Eur J Obstet Gynecol Reprod Biol 1998; 78:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/89\">",
"      Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab 1968; 28:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/90\">",
"      Fielding WL, Lee SY, Borten M, Friedman EA. Continued pregnancy after failed first-trimester abortion. Obstet Gynecol 1984; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/91\">",
"      Edwards, J, Creinin, MD. Surgical abortion for gestations of less than 6 weeks. Curr Probl Obstet Gynecol Fertil 1997; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/92\">",
"      Bandim JM, Ventura LO, Miller MT, et al. Autism and M&ouml;bius sequence: an exploratory study of children in northeastern Brazil. Arq Neuropsiquiatr 2003; 61:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/93\">",
"      Hogue CJ, Cates W Jr, Tietze C. Impact of vacuum aspiration abortion on future childbearing: a review. Fam Plann Perspect 1983; 15:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/94\">",
"      Hogue CJ, Cates W Jr, Tietze C. The effects of induced abortion on subsequent reproduction. Epidemiol Rev 1982; 4:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/95\">",
"      Atrash HK, Hogue CJ. The effect of pregnancy termination on future reproduction. Baillieres Clin Obstet Gynaecol 1990; 4:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/96\">",
"      Shah PS, Zao J, Knowledge Synthesis Group of Determinants of preterm/LBW births. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. BJOG 2009; 116:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/97\">",
"      Kalish RB, Chasen ST, Rosenzweig LB, et al. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol 2002; 187:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/98\">",
"      Schneider D, Halperin R, Langer R, et al. Abortion at 18-22 weeks by laminaria dilation and evacuation. Obstet Gynecol 1996; 88:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/99\">",
"      Zhou W, Nielsen GL, Larsen H, Olsen J. Induced abortion and placenta complications in the subsequent pregnancy. Acta Obstet Gynecol Scand 2001; 80:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/100\">",
"      Beral V, Bull D, Doll R, et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries. Lancet 2004; 363:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/101\">",
"      Michels KB, Xue F, Colditz GA, Willett WC. Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med 2007; 167:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/102\">",
"      Reeves GK, Kan SW, Key T, et al. Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer 2006; 119:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/103\">",
"      Friedman E, Kotsopoulos J, Lubinski J, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006; 8:R15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/104\">",
"      Committee on Gynecologic Practice. ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol 2009; 113:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/105\">",
"      Aral K, G&uuml;rkan Zorlu C, G&ouml;kmen O. Plasma human chorionic gonadotropin levels after induced abortion. Adv Contracept 1996; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/106\">",
"      Korhonen J, Alfthan H, Yl&ouml;stalo P, et al. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem 1997; 43:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/107\">",
"      Marrs RP, Kletzky OA, Howard WF, Mishell DR Jr. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol 1979; 135:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/108\">",
"      Barnhart KT, Sammel MD, Rinaudo PF, et al. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined. Obstet Gynecol 2004; 104:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/109\">",
"      Stotland NL. The myth of the abortion trauma syndrome. JAMA 1992; 268:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/110\">",
"      Schmiege S, Russo NF. Depression and unwanted first pregnancy: longitudinal cohort study. BMJ 2005; 331:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/111\">",
"      Sit D, Rothschild AJ, Creinin MD, et al. Psychiatric outcomes following medical and surgical abortion. Hum Reprod 2007; 22:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/112\">",
"      Stotland NL. Psychosocial aspects of induced abortion. Clin Obstet Gynecol 1997; 40:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/2/19498/abstract/113\">",
"      Korenromp MJ, Christiaens GC, van den Bout J, et al. Long-term psychological consequences of pregnancy termination for fetal abnormality: a cross-sectional study. Prenat Diagn 2005; 25:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3313 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19498=[""].join("\n");
var outline_f19_2_19498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cervical preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rigid dilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Osmotic dilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prostaglandin E1 analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Isosorbide dinitrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Paracervical block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neuraxial or general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHOICE OF TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonsurgical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Early complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hematometra",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Delayed complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Infection/retained products of conception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Ongoing pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Future pregnancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      CONTRACEPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FOLLOW UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      WOMEN'S FEELINGS AFTER PREGNANCY TERMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3313|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27746\" title=\"figure 1A\">",
"      Pratt cervical dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/30/24038\" title=\"figure 1B\">",
"      Hegar dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16385\" title=\"figure 2\">",
"      Paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3313|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38764\" title=\"table 1\">",
"      Osmotic cervical dilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/21/5467\" title=\"table 2\">",
"      Maternal mortality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=related_link\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39960?source=related_link\">",
"      Human chorionic gonadotropin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=related_link\">",
"      Misoprostol as a single agent for medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29874?source=related_link\">",
"      Patient information: Abortion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_2_19499="Principles of alternative remed";
var content_f19_2_19499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complementary and alternative therapies for rheumatic diseases: principles",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        If it sounds too good to be true, it is",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you have not read about it in the scientific literature, it is not validated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you first heard about it from the media, lay press, or your patients, it is not validated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There are no secrets in good science or good medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There have been no \"breakthrough\", important advances in rheumatology from \"complementary\" and \"alternative\" medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The question regarding trying \"complementary\" and \"alternative\" therapies should not be \"why not?\" but \"why?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        This is reality. Deal with it. Discuss \"complementary\" and \"alternative\" therapies with patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I do not believe in \"complementary\" and \"alternative\" medicine. I believe in science, scientific methods, and a single high standard of good evidence-based medicine for all patients.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bulletin on Rheumatic Diseases. Arthritis Foundation. Copyright &copy; 2002 The Arthritis Foundation",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19499=[""].join("\n");
var outline_f19_2_19499=null;
var title_f19_2_19500="Bisphosphonate vs pyrophosphate";
var content_f19_2_19500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of bisphosphonates and pyrophosphate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 126px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bisphosphonates share a P-C-P structure compared to the P-O-P structure of pyrophosphate. The different bisphosphonates vary at the two R groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19500=[""].join("\n");
var outline_f19_2_19500=null;
var title_f19_2_19501="Transmitral flow outcome HF";
var content_f19_2_19501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transmitral flow velocity predicts outcome in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with heart failure (HF) who had prolongation of the transmitral deceleration time (DT) on Doppler echocardiography to &gt;125 msec on therapy had a lower incidence of all cardiac events including death, transplantation, and hospitalization for worsening HF (36 versus 86 percent, p &lt;0.0001) compared with those in whom the DT was persistently short (&le;125 msec).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Temporelli PL, Corra U, Imparto A, et al. J Am Coll Cardiol 1998; 31:1591.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19501=[""].join("\n");
var outline_f19_2_19501=null;
var title_f19_2_19502="FOLFIRI regimen";
var content_f19_2_19502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFIRI chemotherapy for gastrointestinal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        180* mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over 90 minutes (can be administered concurrently with leucovorin via y-site connection).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL D5W and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Slow intravenous push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400",
"        <sup>",
"         &sect;",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen for prophylaxis of infusion reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia approximately 6 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea.",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment until absolute neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . US FDA-approved manufacturer's package insert suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Hold treatment until less than or equal to grade 1, if grade 2; hold treatment until less than or equal to grade 2, if grade 3 or 4",
"        <sup>",
"         [2]",
"        </sup>",
"        . Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution",
"        <sup>",
"         [3]",
"        </sup>",
"        . Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial. Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [4]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"     <br/>",
"     &sect; If there is no grade 1 or worse toxicity 1 in cycles 1 and 2, some clinicians increase the dose to 3000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     starting with cycle 3",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Tournigand C, et al. J Clin Oncol 2004; 22:229.",
"      </li>",
"      <li>",
"       Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on Novermber30, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on Novermber 30, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19502=[""].join("\n");
var outline_f19_2_19502=null;
var title_f19_2_19503="Construction RI strains";
var content_f19_2_19503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a set of RI strains from B6 and DBA progenitors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 488px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A single pair of chromosome homologs are followed through the process of RI strain development. Genomic intervals derived from B6 are indicated by shading and intervals derived from DBA are indicated without shading for all genotypes in all generations. The map positions of five fictitious loci, numbered 1-5, are shown in the progenitor generation. In the F2 generation, the genotypes at these five loci are indicated for six different animals with \"B\" signifying the B6 allele and \"D\" signifying the DBA allele. The two circled regions represent segments of the genome that are already fixed for one parental type within the two F2 progenitors of particular incipient RI strains. At the F20 generation, four separate animals with the same homozygous genotype are shown for each of the three newly constructed RI strains (fictitiously called BXD-101, BXD-102, and BXD-103).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Professor Lee M. Silver, Princeton University, for use of this illustration, which appeared originally in \"Mouse Genetics,\" published in hardcopy by Oxford University Press, and online by the Jackson Laboratory (file://www.jax.org).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_2_19503=[""].join("\n");
var outline_f19_2_19503=null;
